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Chapter 1
General introduction and outline of the thesis
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Surveillance of individuals at high risk to develop pancreatic cancer: 
where do we stand? 
Ingrid C.A.W. Konings, Femme Harinck, Jan-Werner Poley and Marco J. Bruno
American Oncology and Hematology Review, 2014: 70-79
and from
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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Pancreatic cancer remains one of the most fatal human malignancies. Incidence rates of 
pancreatic cancer have been stable since 1975 with 10-12 new cases per 100.000 persons 
per year 1-3. Despite improvements in surgical techniques and (neo)adjuvant therapies, 
survival rates have not improved during the last decades 2, 4. The median survival of patients 
diagnosed with pancreatic cancer is less than 6 months; the 5-year survival rate is approxi-
mately 6% 2, 4. Survival rates are strongly dependent on stage of pancreatic cancer and 
therefore these poor survival rates are at least partly due to the late onset of symptoms, 
leading to only 8-27% of all patients to present with localized, curable disease 4. The 5-year 
survival rate for stage IA disease after surgery is 31%, but this rate decreases dramatically 
with increasing stage 5. 
Well recognized risk factors for the development of pancreatic cancer are tobacco smoking 
(including second-hand tobacco exposure), African American or Ashkenazi Jewish descent, 
chronic pancreatitis and familial predisposition (discussed below). Probable risk factors are 
obesity, heavy alcohol drinking, and dietary factors (saturated fats increase the risk of pan-
creatic cancer, fruit and vegetable consumption decreases the risk of pancreatic cancer) 6. 
The only treatment for pancreatic cancer with a curative intention is surgery 4. Despite 
advances in surgical techniques and supportive care, the median 5-year survival rate 
after surgical resection remains well below 20% 7, 8. For this reason, both adjuvant and 
neoadjuvant therapies have been investigated. Widely used chemotherapeutic agents are 
5-fluorouracil (5-FU) and gemcitabine. However, based on available data, adjuvant treat-
ment with gemcitabine or 5-FU results in a gain of median survival of only a few months 
9. The role of adjuvant radiotherapy is subject of investigation. Recent data show a benefit 
of maximal 2 months of chemoradiation versus chemotherapy alone for locally advanced 
pancreatic cancer; however, other studies reported a decreased survival because of toxicity 
10. For metastatic pancreatic cancer, gemcitabine-based therapy is most commonly used. 
For patients in good clinical condition, a combination chemotherapy regimen consisting 
of oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) provides better survival 
benefits at the cost of increased toxicity 11.
Because of the poor prognosis once pancreatic cancer has become symptomatic, there is 
great interest in the prevention of this dreadful disease. Primary prevention strategies, such 
as lifestyle changes to reduce the number of risk factors (e.g. smoking, excessive alcohol 
consumption, obesity and dietary factors), are difficult for most people to implement and 
adhere to. People with many family members affected with pancreatic cancer might be 
better motivated to adhere to lifestyle changes, however, their risk of developing pancre-
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atic cancer remains substantially increased. Secondary prevention strategies (the diagnosis 
and treatment of advanced precursor lesions or early stage of pancreatic cancer before it 
causes significant morbidity) might contribute to the prevention of pancreatic cancer in 
these patients. Currently, several studies are being performed to assess the feasibility of 
a pancreatic cancer surveillance program. This introduction provides an overview of these 
surveillance strategies. 
Whom should we offer surveillance to?
The incidence of pancreatic cancer is relatively low with 10-12 new cases per 100.000 
persons per year 1-3. Pancreatic cancer is the tenth leading cancer type for new cancer cases 
in the United States, but, in contrast, it is the fourth leading cancer type for cancer deaths 
4. This underlines the burden of pancreatic cancer, from a patients’ but also from a societal 
perspective. A non-invasive and reliable surveillance tool for pancreatic cancer is currently 
lacking. This is an important reason why it is not feasible to offer surveillance to the general 
population. However, there may be opportunities for secondary prevention by surveillance 
of selected individuals who are at high risk for the development of pancreatic cancer. 
Well-known risk factors for pancreatic cancer are older age and cigarette smoking. Smok-
ing doubles the risk and as many as one in four cases of pancreatic cancer might be 
attributable to smoking 12, 13. Heavy alcohol consumption (i.e. 3 or more drinks per day) 
also increases the risk of pancreatic cancer by approximately 20% 14. Furthermore, an 
increased risk was demonstrated for long-standing type-1 and 2 diabetes 15-17, as well as 
for obesity 18. 
A family history of pancreatic cancer is a strong risk factor for developing pancreatic can-
cer. For decades, case reports have been suggesting that pancreatic cancer aggregates in 
families and multiple studies have shown inheritance in an autosomal dominant pattern 
19-23. Although most cases of pancreatic cancer are likely to be sporadic, it is estimated that 
in 5-10% of cases, genetic factors are involved 24, 25. Several genes have been discovered 
that are responsible for the familial clustering of pancreatic cancer, which can also cause 
significant morbidity in other organs. At present, in less than 20% of the familial pancreatic 
cancers, a known genetic syndrome is identified 24, 25. With new whole genome sequencing 
technologies, discovery of additional familial pancreatic cancer genes in the near future is 
likely.
Thus far, two groups of individuals with a hereditary risk of pancreatic cancer have been 
identified. First, individuals with a well-defined cancer susceptibility syndrome, of which 
the gene mutations are listed in Table 1. Germline mutations in the BRCA1 or BRCA2 
gene increase the risk of pancreatic cancer, independently from the risk for breast and 
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ovarian cancer, the predominant cancer types in the Hereditary Breast and Ovarian Cancer 
(HBOC) susceptibility syndrome. The risk of pancreatic cancer in patients with a BRCA2 
mutation is 3-10 fold increased, as compared to the general population 26, 27. Male BRCA2 
mutation carriers are at higher risk for pancreatic cancer than females, and the relative risk 
for pancreatic cancer increases with age 27. It is important to realize that the absence of 
breast cancer in a family with aggregation of pancreatic cancer does not exclude a BRCA2 
mutation, since pancreatic cancer can run in BRCA2 mutation-carrying families, without 
associated breast cancer 28, 29. BRCA1 mutation carriers have a slightly lower risk of pancre-
atic cancer than BRCA2 mutation carriers (relative risk 2-4 30). More recently, PALB2 gene 
mutations, a gene that codes for a protein that binds to the Brca2 protein, have also been 
proven to increase the risk for pancreatic cancer, albeit still unclear to what extent 31-33. 
Patients with familial cutaneous malignant melanoma (familial CMM, formerly known as 
familial atypical multiple mole melanoma (FAMMM)), which is caused by mutations in the 
p16/CDKN2A gene, are at an 8 to 45-fold increased risk of developing pancreatic cancer 
34, 35, which is independent from their increased risk of developing melanomas. Patients 
with hereditary chronic pancreatitis are also at high risk to develop pancreatic cancer (60 
to 90-fold increased risk 36). Hereditary pancreatitis is caused by germline mutations in the 
PRSS1 and SPINK1 genes, and is characterized by recurrent episodes of acute or chronic 
pancreatitis, starting at a young age.
At highest risk for developing pancreatic cancer, with a 75 to 135-fold increase, are indi-
viduals with the Peutz-Jeghers syndrome 37, 38. This cancer susceptibility syndrome is caused 
by mutations in the STK11 or LKB1 genes that also increase the risk for gastrointestinal, 
lung, ovarian, and breast cancer. Patients with familial adenomatous polyposis (FAP) and 
Table 1. Cancer susceptibility syndromes or inherited disease with a known elevated risk of developing 
pancreatic cancer
Syndrome Gene(s) Risk of pancreatic cancer
Hereditary breast and ovarian cancer 
(HBOC)
BRCA 1
BRCA 2
PALB2
RR 2-3
RR 3-10
RR unknown
Familial cutaneous malignant melanoma 
(familial CMM) 
CDKN2A (p16) RR 8-45
Chronic (hereditary) pancreatitis PRSS1 / SPINK 1 RR 60-90
Hereditary nonpolyposis colorectal cancer 
(Lynch syndrome)
MLH1 / MSH2 / MSH6 RR 9
Peutz-Jeghers syndrome STK11 / LKB1 RR 75-135
Familial adenomatous polyposis (FAP) APC RR 4.5
Li-Fraumeni syndrome p53 RR 7.5
RR, relative risk; SIR, standardized incidence ratio
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Li-Fraumeni syndrome also have a slightly increased risk of developing pancreatic cancer 
(4.5 and 7.5-fold, respectively 39, 40). The risk is comparable to that of patients with Lynch 
syndrome, caused by mutations in one of the DNA mismatch repair genes, including 
MLH1, MSH2 and MSH6, and who are at a 9-fold increased risk for developing pancreatic 
cancer 41. 
The second and largest hereditary high-risk group consists of individuals with a strong fam-
ily history of pancreatic cancer, but in whom no mutation was found in any of the known 
cancer susceptibility genes. This condition is referred to as familial pancreatic cancer (FPC). 
Depending on the number of affected relatives, the risk increases dramatically: individu-
als with one first-degree relative with pancreatic cancer have a 4.5 to 7-fold increased 
risk; those with two, a 4 to 6-fold increased risk, and those with three or more an up to 
32-fold increased risk, as compared to the general population 42, 43. When at least one 
family member was diagnosed below the age of 50, the relative risk increases even further 
(hazard ratio of 1.6 per year of decreased age of the family member) 43.
For FPC families, it is important to realize that at least half of the members are not affected, 
assuming a dominant inheritance pattern. Unfortunately, because the causative mutation 
is unknown, it is not possible to test carriership and hence increased risk of developing 
pancreatic cancer. Furthermore, in FPC families, the phenomenon of genetic anticipation 
has been observed: compared to sporadic cases, pancreatic cancer seems to occur at an 
earlier age (mean 72 versus 62, respectively) and within affected families, subsequent 
generations seem to die at an earlier age, compared to the preceding generations 44. 
Besides these high-risk individuals from families in which pancreatic cancer aggregates, 
individuals with the incidental finding of a pancreatic cyst and suspected intraductal papil-
lary mucinous neoplasm (IPMN) are also at high risk of developing pancreatic cancer 45. 
These patients therefore qualify for surveillance too, however, there is a clear recommen-
dation for the surveillance policy for these incidental findings (revised Sendai Consensus 
Guidelines 46), as discussed below. 
The International Cancer of the Pancreas Screening (CAPS) Consortium provided recom-
mendations concerning screening and surveillance of the pancreas for pancreatic cancer 
in 2011 47. It was recommended that only individuals with an excess risk greater than 10 
times that of the general population and who are eligible for surgery should be screened 
for pancreatic cancer (see Table 2). There was no consensus recommendation about the 
age when to initiate and end screening. The screening principles of colorectal cancer are 
mostly used, which implies to initiate surveillance of high-risk individuals from the age of 
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50 or 10 years earlier than the youngest affected member in the family, whichever occurs 
first, and end surveillance at the age of 75 48. 
Table 2. Candidates for pancreatic cancer surveillance due to a >10-fold increased risk of developing 
pancreatic cancer
Individuals with ≥ 2 relatives affected with pancreatic cancer, of which at least one in the first-
degree
Individuals with ≥ 2 first-degree relatives affected with pancreatic cancer
Individuals with Peutz-Jeghers syndrome
BRCA2 mutation carriers with at least one first-degree relative affected with pancreatic cancer or ≥ 
2 affected family members with pancreatic cancer
PALB2 or CDKN2A mutation carriers and individuals with Lynch syndrome with at least one first-
degree relative affected with pancreatic cancer
What do we want to detect during surveillance? 
Surveillance of asymptomatic individuals is aimed to detect an early stage of pancreatic 
cancer or, even more preferable, an advanced precursor lesion. Similar to the adenoma-
carcinoma sequence in colorectal cancer, pancreatic cancer evolves through non-invasive 
precursor lesions. Known precursor lesions for pancreatic cancer are pancreatic intraepi-
thelial neoplasias (PanINs), IPMNs and mucinous cystic neoplasms (MCNs) 49. These precur-
sor lesions are more common in patients with a strong family history of pancreatic cancer 
than in patients with sporadic disease, and precursor lesions are of a higher grade in 
those patients with a strong family history of pancreatic cancer 50. In sporadic cases, it 
is estimated that a precursor neoplastic clone will take approximately 11 to 12 years to 
evolve into a malignant clone and an additional 7 years to develop metastatic subclones 
51. Although the pace of progression of pancreatic cancer in hereditary cases is not known, 
at least potentially, these findings provide a window of opportunity to perform a timely 
intervention before an advanced precursor lesion evolves into cancer. Obviously, the prem-
ise of this strategy is that these precursor lesions can reliably be identified and stratified 
according to their risk of malignant transformation (i.e. degree of dysplasia) by a suitable 
surveillance technique. 
The most common precursor lesion of invasive pancreatic cancer are PanINs. PanINs arise in 
the smaller pancreatic ducts, are microscopic (<5 mm in diameter) and are often multifocal. 
They are reasonably common, particularly in the elderly (incidence of 0.1 per 100.000 at 
age 30; incidence of 50 per 100.000 at age 80) 52. Based on the degree of architectural 
and nuclear atypia, they are classified into three grades: PanIN-1 (low-grade dysplasia), 
PanIN-2 (moderate-grade dysplasia) and PanIN-3 (high-grade dysplasia or carcinoma in 
situ). PanINs are difficult to identify on imaging, however, recent data show that PanIN 
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lesions are possibly associated with lobular parenchymal atrophy which correlated directly 
with preoperative endoscopic ultrasound changes of chronic pancreatitis 53. 
IPMNs are a less frequent precursor to invasive pancreatic cancer, although they are more 
frequently recognized with the increasing use of abdominal imaging. De Jong et al. 54 reas-
sessed results of 2803 MRI-scans which were performed as part of a preventive medical 
examination and the prevalence of pancreatic cysts was found to be 2.4% which increased 
with age to >10% in those aged above 70. IPMNs are cystic epithelial neoplasms (≥ 5 mm 
in diameter) that arise from the main pancreatic duct or its side branches and produce 
mucin. They are divided into three subtypes: those that involve the main duct (main-duct 
IPMNs), those involving side ducts (branch-duct IPMNs), and those involving both (mixed-, 
or combined-type IPMNs). IPMNs are also classified into low-, intermediate-, and high-
grade dysplasia, based on the degree of atypia. Branch-duct IPMNs have lower malignant 
potential than main-duct IPMNs; the prevalence of malignancy (in situ and invasive) is much 
higher in main-duct IPMNs (70%) than in branch-duct IMPNs (25%) 55, 56. Predictive signs 
of an invasive carcinoma in an IPMN are involvement of the main pancreatic duct, diffuse 
or multifocal involvement, the presence of a large mural nodule, the size of the tumor, and 
obstruction of the common bile duct 57. Some IPMNs are multifocal and, importantly, up to 
one-third of IPMNs have an invasive component 58, 59. The molecular alterations in IPMNs 
are heterogeneous and include loss of SMAD4, loss of STK11 gene expression, activating 
mutations in the PIK3CA gene, and KRAS gene mutations 60-62. 
MCNs are also mucin-producing cystic lesions, but, in contrast to IPMNs, they do not involve 
the ductal system and have a distinctive ovarian-type stroma on pathological examination. 
MCNs arise almost exclusively in women and are mostly located in the distal pancreas 
63. MCNs are also classified according to degree of dysplasia, and up to one-third show 
an invasive component 63. At DNA level, activating mutations in the KRAS2 gene occur 
early, and inactivation of TP53 and MADH4 occur in invasive MCNs 64, 65. Unraveling the 
molecular pathology of MCNs, however, poses a challenge, partly due to their rare nature.
The International CAPS Consortium defined which findings should be considered a success 
of surveillance: detection and treatment of early invasive cancer (T1N0M0) at baseline 
or follow-up, detection and treatment of multifocal PanIN 3 (no consensus was reached 
concerning the detection and treatment of unifocal PanIN 3) and detection and treatment 
of IPMN with high-grade dysplasia 66.
15
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Which surveillance modalities should we use?
Biomarkers
Numerous efforts have been undertaken in the last years to identify new markers that 
are reliable and specific for pancreatic cancer. However, they currently have a limited role 
in diagnosing pancreatic cancer at an early stage. This is due to the low specificity and 
sensitivity of the current markers. 
The most well-known serum marker for pancreatic cancer is the carbohydrate antigen 
CA 19-9. It was discovered in 1981 and has since been used for monitoring response to 
therapy in pancreatic cancer patients. Although CA 19-9 might be useful  to detect malig-
nancy in patients with cystic lesions 67, 68 and an increase in CA 19-9 over time may predict 
malignancy in patients with chronic pancreatitis 69, CA 19-9 is not suitable for screening 
purposes because of its poor sensitivity (41-86%) and specificity (33-100%) 70, 71. Other 
serum markers that have been tested for the detection of pancreatic cancer, including CA 
50, CA 72-4, CA 125 and CA 242, proved to be inferior to CA 19-9 70. Recent studies show 
promising results for MIC-1 with a sensitivity for pancreatic cancer of 90% and a specificity 
of 94% 47. Other promising markers which are currently being investigated in serum or 
plasma, include SNAIL, osteropontin, CEACAM 1, ICAM 1, DJ 1, APRIL, HSP 70 and ULBP 2 
5. Also, panels of biomarkers (more than two biomarkers combined) are being researched 
with promising first results 71, 72. 
Stool markers as a detection tool for pancreatic cancer or its precursor lesions is in its 
infancy. Data from Kisiel et al. 73 show methylated BMP3 in stool to be a promising detector 
of pancreatic cancer with a sensitivity of 51% and a specificity of 90%. Combined with 
KRAS, results are slightly better with a possible increase of sensitivity to 64%. Currently, 
this group of researchers is conducting investigations in patients enrolled in screening 
programmes to validate this stool test as a screening tool for pancreatic cancer and its 
precursor lesions. 
Another specimen currently being researched for biomarkers is pancreatic juice. Pancreatic 
juice has a higher concentration of proteins and DNA released from pancreatic cancer 
cells than serum or stool. It can be obtained by endoscopic retrograde cholangiopan-
creaticography (ERCP), or, more preferably, from duodenal collections during endoscopy 
after secretin-infusion 74. Different studies have identified potential biomarkers (i.e. PAP-2, 
REG1α, GNAS and TP53) 74-77, however, further studies are needed to determine the clinical 
implications of these potential markers.  
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Imaging modalities
Endoscopic ultrasonography (EUS) is a well-established modality for the detection of small 
pancreatic neoplasms and it is currently the most promising surveillance tool. EUS yields a 
detection rate of pancreatic cancer of 94-100% and is accurate in determining the T-stage 
(82% accuracy), N-stage (64-72% accuracy) and vascular invasion (92-95%) 78-80. Advan-
tages of EUS are that it can visualize the entire pancreas and that, because of the close 
approximation of the EUS transducer to the pancreas, detailed images of the pancreas 
can be produced which surpass those of either computed tomography (CT) or magnetic 
resonance imaging (MRI)79. Another advantage of EUS is that, whenever a pancreatic lesion 
is detected, a EUS-guided fine needle aspiration (EUS-FNA) can be performed during the 
same procedure. EUS-FNA is 75-80% sensitive for the diagnosis of pancreatic cancer 78, 81. 
Limitations of EUS are that accuracy is highly skills- and experience-dependent and that in 
case of chronic pancreatitis small suspicious lesions may  be difficult to detect. 
Spiral computed tomography (CT) is almost always obtained during the diagnostic work-
up of a patient with a suspicious pancreatic lesion. However, its resolution is limited for 
small lesions (<1 cm), even with a multi detector computed tomography (MDCT) in which 
slice thickness is reduced from 10 to 2-5 millimetres. The sensitivity and specificity of 
conventional CT is low with 69% and 64% consecutively. MDCT has a higher sensitivity 
and specificity than the conventional CT, but comparable rates with different imaging 
modalities (see Table 3) 82-84. However, the risk of radiation-related cancers makes CT an 
inferior approach for screening or surveillance.  
Sensitivity and specificity of magnetic resonance imaging (MRI) combined with magnetic 
resonance cholangiopancreatography (MRCP) for the detection of pancreatic cancer is 
similar to CT (see Table 3) 83, 84. However, MRI/MRCP is better at characterizing cystic lesions 
of the pancreas and is better for defining the pancreatic duct and biliary tree, neither 
does it use radiation. Therefore, MRI/MRCP appears suitable for routine surveillance and 
is widely used and tested in research surveillance programmes. Limitations of MRI/MRCP 
are that it is contraindicated in patients with metal parts in their body and in patients with 
gadolinium-allergy.    
Integrated positron emission tomography/computed tomography (PET/CT) has similar sen-
sitivity and specificity to other imaging modalities (see Table 3). Compared to MDCT, it does 
not provide additional information, except for a better detection of distant metastases 84. 
Its usefulness in diagnosing pancreatic carcinomas of diameters <2 cm remains unclear 85. 
Major disadvantage of PET/CT is the increase in false negative results when serum blood 
glucose levels are elevated as seen in diabetes mellitus, which is often associated with 
pancreatic cancer. Chronic pancreatitis may also result in false-positive PET/CT results. 
17
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Another disadvantage is the risk of radiation-related cancers when PET is combined with 
CT, however, without CT sensitivity drops dramatically. 
Given the low sensitivity for the detection of malignant and premalignant lesions and the 
substantial complication risk, endoscopic retrograde cholangiopancreaticography (ERCP) 
should not be used for screening purposes. 
Recommendations
An ideal screening or surveillance tool should be widely accessible, simple to administer, 
inexpensive, associated with minimal discomfort and/or morbidity, reproducible, and able 
to detect the preclinical phase of the disease 86. EUS and MRI/MRCP are currently regarded 
as the most promising surveillance tools, since they are relatively widely accessible, have 
low morbidity rates, and, in particular, are best at revealing early pancreatic cancer and its 
precursors, since these modalities have the highest sensitivity for small lesions (see Table 
3). Canto et al. 82 showed that EUS and MRI are better than CT for the detection of small 
pancreatic lesions during screening, with good concordance of lesion size, number and 
location between EUS and MRI/MRCP.  The CAPS Consortium therefore recommended 
that for both initial screening and follow-up surveillance, EUS and MRI/MRCP should be 
performed 66. A 12-month interval in the absence of pancreatic abnormalities was sug-
gested but not agreed upon. Patients with a non-suspicious cyst should have an imaging 
interval of 6-12 months. Patients with a newly detected indeterminate solid lesion or an 
indeterminate main pancreatic duct stricture should have follow-up every 3 months. 
Table 3. Sensitivity and specificity of imaging modalities for detecting pancreatic cancer
Imaging modality Sensitivity Specificity Sensitivity for the detection of lesions <3 cm
EUS 94-100% 100% 93%
Conventional CT 69% 64% 53%
MDCT 76-92% 67% >60%
MRI/MRCP 82-85% 72-100% 67%
FDG-PET/CT 73-94% 68-94% Unclear
EUS, endoscopic ultrasonography; CT, computed tomography; MDCT, multidetector row computed tomogra-
phy; MRI, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography; FDG-PET/CT, 
18F-fluorodeoxyglucose positron emission tomography/computed tomography
Whom should we offer treatment to?
The key issue is to rightfully identify lesions that have a high risk to progress into a ma-
lignancy. Individuals with benign lesions should not receive unwarranted surgery while 
patients with (pre)malignant lesions should not be withheld curative surgery.
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The revised Sendai Consensus Guidelines recommend resection in the following cases: (i) 
all main-duct IPMNs; (ii) all branch-duct IPMNs with a main pancreatic duct diameter of 
≥ 10 mm, with a solid component within the cyst or causing obstructive jaundice; (iii) a 
branch-duct IPMN with ‘worrisome features’ (main pancreatic duct diameter of 5-9 mm, 
cyst size of ≥ 30 mm, thickened or enhancing cyst walls, associated pancreatitis, presence 
of non-enhancing mural nodule, or an abrupt change in the calibre of the pancreatic duct 
with distal pancreatic atrophy); (iv) all MCNs 46. The International Cancer of the Pancreas 
Screening (CAPS) Consortium agreed that these thresholds for resection should be either 
the same or lower in subjects with a strong family history of pancreatic cancer. For example, 
it was agreed upon that surgery should be considered for suspected branch-duct IPMNs 
from a cyst size of  ≥ 20 mm (instead of ≥ 30 mm). For all other pancreatic abnormalities, 
no evidence-based or consensus policy exists. In these particular instances findings should 
be discussed in an experienced multidisciplinary pancreatic team to reach a decision for 
each patient individually while balancing risk versus benefit of surgery versus continued 
surveillance.
A variety of operations for pancreatic lesions are available, including total pancreatectomy, 
pancreaticoduodenectomy, distal pancreatectomy and segmental resection of the tumor. 
In the majority of patients, the choice of surgery will be determined by location and size of 
the lesion. However, IPMNs might represent, especially in these high-risk patients, a pan-
creatic ‘field defect’, i.e. all pancreatic ductal epithelial cells are at risk of dysplastic change 
87. Also, branch-duct IPMNs in the setting of FPC, may indicate the presence of high-grade 
PanIN lesions elsewhere in the pancreas 88. Therefore, it has been suggested that a total 
pancreatectomy should be performed in these patients. However, the risk of malignancy 
needs to be carefully weighed against the issues that arise in apancreatic patients (endo- 
and exocrine insufficiency). The CAPS Consortium therefore recommended to start with 
minimal surgery and that further pancreatectomy should be performed intraoperatively to 
achieve R0 resection of cancer or PanIN 3 at the margin. 
What are the outcomes of surveillance programmes so far?
Over the past decade, multiple centers have initiated surveillance programs for pancreatic 
cancer, to evaluate the diagnostic yield and ultimately improve survival. Results of these 
studies are summarized in Table 4. In the 15 studies listed in Table 4, a total of 1085 high-
risk individuals underwent annual surveillance of the pancreas. Diagnostic yield differed 
greatly and ranged from 1 to 67%, mostly due to differences in surveillance modalities, 
study populations and outcome measures. EUS is used in almost all research protocols and 
MRI/MRCP and CT are also very commonly used. All studies combined, 94 relevant high-
grade dysplastic lesions were diagnosed; an overall diagnostic yield of 9%. Seventy-one of 
these individuals underwent resection.   
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Histopathology of the resected pancreatic specimens revealed pancreatic cancer in 15 of 
the 71 specimens (21%), of which 9 had been detected at the first screening visit and six 
during follow-up (of which one patient missed the 1-year surveillance visit). Only one of 
the cancers had arisen from an IPMN. IPMNs were found in 25 of 71 specimens (35%), of 
which nine were detected at the first screening visit and four during follow-up (three of 
these had been present at baseline, but showed growth after 1 year). Two IPMNs showed 
high-grade dysplasia, 6 moderate-grade, and 8 low-grade dysplasia. Serous cystadenomas 
were identified in 3 of the 71 specimens (4%) and a neuroendocrine tumor was discovered 
in one (1%). Six of  the 1085 individuals (0.6%) already had metastatic disease at diagnosis 
(two were detected at baseline, two after 1 year, and one after 4 years of surveillance). 
Table 4. Overview of results of pancreatic cancer surveillance programs for high-risk individuals
Study N High risk individuals Imaging modalities Diagnostic 
yield*, N (%)
Brentnall 1999 89 14 FPC EUS + CT +  ERCP 7 (50)
Rulyak 2001# 90 35 FPC EUS; ERCP$ 12 (34)
Kimmey 2002# 91 46 FPC EUS; ERCP$ 12 (26)
Canto 2004 92 38 FPC, PJS EUS ; CT$, EUS-FNA$, ERCP$ 2 (5)
Canto 2006 93 78 FPC, PJS EUS + CT; EUS-FNA$, ERCP$ 8 (10)
Kluijt 2009 94 3 CDKN2A EUS + MRI; CT$ 2 (67)
Poley 2009 95@ 44 FPC, PJS, CDKN2A, HP, 
BRCA, p53
EUS; CT$, MRI$ 10 (23)
Langer 2009 96 76 FPC, CDKN2A, BRCA EUS + MRI; EUS-FNA$ 1 (1)
Verna 2010 97 51 FPC, PJS, CDKN2A, HP, 
BRCA, Lynch
EUS and/or MRI; EUS-FNA$, 
ERCP$
6 (12)
Ludwig 2011 98 109 FPC, BRCA MRI; EUS$, EUS-FNA$ 9 (8)
Vasen 2011 99 79 CDKN2A MRI 16 (20)
Scheider 2011¥ 100 72 FPC, BRCA, PALB2 EUS + MRI 9 (13)
Al-Sukhni 2012 101 262 FPC, PJS, CKDN2A, HP, 
BRCA
MRI; CT$, EUS$, ERCP$ 19 (7)
Canto 2012 82 216 FPC, PJS, BRCA EUS + CT + MRI; EUS-FNA$ 5-92 (2-43)
Potjer 2012∞ 102 241 FPC, CDKN2A MRI; EUS$ 15 (6)
* Yield is defined as the detection of (pre)malignant lesions (early invasive cancer T1N0M0, PanIN ≥2 or IPMN) 
# Continuation of Brentnall 1999
@ Continuation of Kluijt 2009
$ Test performed only as an additional test for detected abnormalities
¥ Continuation of Langer 2009
∞ Continuation and combination of both data from Langer 2009 and Vasen 2011
FPC, familial pancreatic cancer; PJS, Peutz-Jeghers syndrome; HP, hereditary pancreatitis; EUS, endoscopic ul-
trasonography; CT, computed tomography; MRI, magnetic resonance imaging; ERCP, endoscopic retrograde 
cholangiopancreaticography; EUS-FNA, endoscopic ultrasonography-guided fine needle aspiration
Bartsch et al. 88 recently published histopathological results of surgical specimens of five 
patients at risk who underwent pancreatic resection because of patient preference al-
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though formal criteria for surgery were not strictly met. Importantly, multifocal moderate 
to high-grade PanIN lesions were found in all 5 cases independently of the IPMN for which 
the patient was operated on. If larger series suggest that branch-duct IPMNs, even if they 
do not yet meet the formal criteria for resection, are an indicator for the presence of 
multifocal high-grade PanIN lesions, one has to reconsider the indication for pancreatic 
resection. According to current guidelines, these 5 patients would not have undergone sur-
gery and in that regard their surveillance outcomes could be considered as false-negative. 
How should we manage cystic tumors in high-risk individuals?
At present, there is no evidence to suggest that the natural behavior of pancreatic cystic 
neoplasms in individuals with a hereditary pancreatic cancer risk differs from the general 
population. Therefore, the revised Sendai criteria for cyst management (see Table 5 46) can 
be applied in this group, but with some modification: the Sendai criteria suggest a longer 
than 1-year interval for cysts smaller than 2 cm, but in patients with a hereditary risk, 
annual follow-up is always recommended, according to the CAPS guidelines 66. 
In the general population, EUS-guided fine needle aspiration (EUS-FNA) is widely used. Al-
though cyst fluid cytology has a high specificity for malignancy (almost 100%), the sensitiv-
ity is low 103. Cytology, combined with tumor marker analysis (amylase, CEA and CA 19-9) 
can be helpful in differentiating mucinous from non-mucinous pancreatic cysts 104, but is 
still non-accurate in predicting malignancy. In high-risk individuals, the role of EUS-FNA is 
limited, as the pre-test likelihood of malignancy is so high, that clinical decision-making is 
less dependent on cyst fluid analysis. A lesion with morphological features suspicious for 
malignancy will be resected, regardless of normal FNA-results. Clearly, EUS-FNA should be 
reserved for those individuals in whom the results will have a direct impact on the decision 
to operate. 
Every pancreatic cyst, suspect of advanced dysplasia or malignancy, should be resected. 
Limited resections or focal non-anatomic resections (excision, enucleation) may be consid-
ered for MCN or branch-duct IPMN without suspicion of malignancy. Resection should aim 
to achieve complete removal of the tumor, with negative margins. Per-operative frozen 
sections can help to achieve negative margins. In case of low-grade or moderate-grade 
dysplasia on the resection margin, further resection is controversial. However, when 
positive margins for high-grade dysplasia are present, re-operation and additional resection 
should be performed. 
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For multifocal side branch IPMNs, the same surgical approach holds as for unifocal disease: 
a segmental pancreatectomy to remove the IPMNs at highest oncological risk and close 
monitoring of the remaining lesions. According to the revised Sendai criteria, however, 
in patients with a strong family history of pancreatic cancer, one should consider a total 
pancreatectomy, because of the increased prevalence of high-grade dysplasia elsewhere in 
the pancreas 88. 
It is important to realize that, after partial pancreatectomy, the pancreatic remnant is still 
prone to develop dysplastic lesions. Therefore, continued surveillance should be performed 
in these patients at least annually, regardless of pathologic findings in the surgical speci-
men, as is continued surveillance after IPMN resection. 
The true challenge in pancreatic cancer surveillance is to adequately identify both cystic 
(IPMN) and solid (PanIN) pre-neoplastic lesions. This means to avoid resection of early stage 
lesions (i.e. low or medium grade dysplastic IPMN, PanIN1 or PanIN2 lesions), and to timely 
resect advanced lesions, before cancer develops.
Where do we stand?
In 2010, Harinck et al. 105 applied the principles of screening for disease, as proposed by 
Wilson and Jungner 106, to appraise the validity of surveillance of individuals at high risk for 
developing pancreatic cancer. Principles and updated considerations are listed in Table 6. 
The majority of principles is met. Cost-effectiveness is unknown and the application of a 
test that is able to reliably detect relevant high-grade dysplastic lesions is under investiga-
tion and development.  
The ultimate question is whether screening and surveillance programmes ultimately im-
prove the overall survival rate of individuals at high risk for the development of pancreatic 
cancer. Based on present studies, it is not possible to draw a definite conclusion about 
the (potential) merits of surveillance to prevent pancreatic cancer death. To definitely an-
swer this question more research is required with careful long-term follow-up of affected 
individuals within well-defined research programmes. Pooling of data from various (inter-
national) cohorts will be needed to acquire sufficient numbers for meaningful statistical 
analysis and accurate estimates of risk reduction and survival benefit. There is no doubt 
that it will take ample time to come up with meaningful answers regarding the potential 
benefit of screening high risk individuals to prevent pancreatic cancer. In that regard we 
should not be impatient and remember that it took twenty years to prove that screening 
for colorectal cancer improves survival. 
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Conclusions
Pancreatic cancer is one of the most fatal human malignancies. Overall, the incidence of 
pancreatic cancer is low, but a well-defined group of individuals are at high risk of develop-
ing pancreatic cancer. In the last decade, surveillance programmes have been initiated in 
order to detect precursor lesions or early pancreatic cancer in these high-risk individuals. 
Results are promising, but the true impact and optimal strategy for surveillance remains 
to be determined. Annual surveillance of individuals with a >10-fold increased risk of 
pancreatic cancer with EUS and/or MRI/MRCP should only be performed in a research 
setting in expert centers. 
Outline of the thesis
This thesis starts with an overview of what is currently known about surveillance for pan-
creatic cancer (chapter 1). Many aspects of surveillance still remain to be investigated. This 
thesis assessed a few of these matters. The studies documented in this thesis consist of two 
major parts. The first part of the thesis (chapters 2, 3, 4 and 5) includes 3 studies on the 
clinical aspects of pancreatic cancer surveillance. The second part or this thesis (chapters 
6 and 7) includes 2 studies on the psychosocial aspects of participating in surveillance. 
The most optimal screening test for pancreatic cancer surveillance is not known. Many 
research protocols use EUS and MRI. In chapter 2, the yield of EUS and MRI for screening 
for pancreatic cancer was studied in high-risk individuals. We conducted a prospective 
multicenter comparative prospective blinded study comparing EUS and MRI for the detec-
tion of clinically relevant pancreatic lesions at first-time screening. In chapter 3, we studied 
the prevalence and progression of cystic pancreatic lesions in two distinct high-risk groups 
for developing pancreatic cancer (carriers of a mutation that predisposes to pancreatic 
cancer and individuals without a known gene mutation but with a strong family history of 
pancreatic cancer (FPC)), as differences between these two distinct high-risk groups might 
exist. Features of chronic pancreatitis and their progression were studied in chapter 4. 
These features are frequently detected in asymptomatic individuals participating in pan-
creatic cancer surveillance, but their significance is still unclear. In chapter 5, we describe 
the unique outcomes of surgery performed in individuals participating in pancreatic cancer 
surveillance programs worldwide. Few studies have described surgical pathology findings 
of high-risk individuals who have underwent surgery while participating in surveillance, 
and most of these studies included only a few cases. We created a worldwide registry to 
gather data more readily and reliably. We evaluated the diagnostic yield and outcomes of 
individuals  who underwent surgical resection or progressed to invasive cancer.
In the second part of this thesis, psychosocial aspects of participating in pancreatic cancer 
surveillance were studied. Importantly, when assessing the effectiveness of a surveillance 
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program, one should also take into account the psychological aspects of repeated partici-
pation in such a surveillance program. Therefore, in chapter 6, the psychological burden 
of repeated participation in surveillance was studied by using repetitive annual question-
naires. In chapter 7, cancer worries were studied in more detail to study if factors could 
be found to timely identify individuals ‘at risk’ for high levels of cancer worries who would 
likely benefit from psychosocial support.
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Clinical aspects of surveillance
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ABSTRACT 
Objective
Endoscopic ultrasonography (EUS) and MRI are promising tests to detect precursors and 
early-stage pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals (HRIs). It is 
unclear which screening technique is to be preferred. We aimed to compare the efficacy of 
EUS and MRI in their ability to detect clinically relevant lesions in HRI. 
Design
Multicenter prospective study. The results of 139 asymptomatic HRI (>10-fold increased 
risk) undergoing first-time screening by EUS and MRI are described. Clinically relevant le-
sions were defined as solid lesions, main duct intraductal papillary mucinous neoplasms 
and cysts ≥10mm. Results were compared in a blinded, independent fashion.
Results
Two solid lesions (mean size 9mm) and nine cysts ≥10mm (mean size 17mm) were detected 
in nine HRI (6%). Both solid lesions were detected by EUS only and proved to be a stage 
I PDAC and a multifocal pancreatic intraepithelial neoplasia 2. Of the nine cysts ≥10 mm, 
six were detected by both imaging techniques and three were detected by MRI only. The 
agreement between EUS and MRI for the detection of clinically relevant lesions was 55%. 
Of these clinically relevant lesions detected by both techniques, there was a good agree-
ment for location and size.
Conclusion
EUS and/or MRI detected clinically relevant pancreatic lesions in 6% of HRI. Both imaging 
techniques were complementary rather than interchangeable: contrary to EUS, MRI was 
found to be very sensitive for the detection of cystic lesions of any size, MRI however might 
have some important limitations with regard to the timely detection of solid lesions. 
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INTRODUCTION
Despite all efforts in past decades, the prognosis of pancreatic ductal adenocarcinoma 
(PDAC) is still dismal. With a mean survival of <6 months and a 5-year survival of <5%, 
PDAC ranks among the top 5 causes of cancer-related deaths in the Western world despite 
its relatively low incidence [1]. Survival rates are strongly dependent on the stage at which 
PDAC is detected. Therefore, there is great interest in pancreatic screening to detect PDAC 
at an earlier and potentially curable stage or, even more preferable, to detect high-grade 
precursor lesions. 
Screening of the general population is not feasible as we currently lack a simple, reliable 
and inexpensive screening tool. However, evidence is starting to accumulate that screen-
ing might be worthwhile when offered to individuals at high risk of developing PDAC 
[2]. High-risk individuals include mutation carriers of PDAC-prone gene mutations (eg, 
CDKN2A, BRCA1, BRCA 2, STK11/LKB1) and relatives of patients with familial PDAC. The 
risk of developing PDAC within these well-defined populations of high-risk individuals is 
estimated to be at least 10-fold increased compared to the general population and exceeds 
76-fold in selected cases [2 3]. Previous studies have shown that screening these high-risk 
individuals leads to the detection of early stage PDAC and premalignant lesions [4-13]. 
At present, endoscopic ultrasound (EUS) and MRI are considered the most accurate tech-
niques for pancreatic imaging within a screening setting [2 8]. Only one study [8] has 
prospectively compared the diagnostic yields of EUS and MRI in a blinded fashion. In this 
study [8], good concordance for lesion size, number and location between EUS and MRI 
was seen. 
We conducted a prospective head-to-head blinded comparison between EUS and MRI for 
the detection of clinically relevant pancreatic lesions at first time screening in individuals at 
high risk for developing PDAC. 
METHODS
Study design and sites
We conducted a multicenter prospective blinded cohort study. Participating centers were 
Erasmus MC-University Medical Center Rotterdam, Academic Medical Center Amsterdam, 
University Medical Center Groningen and the Netherlands Cancer Institute-Antoni van 
Leeuwenhoek Hospital.
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Objective
A prospective head-to-head blinded comparison between EUS and MRI for the detection 
of pancreatic lesions at first time screening in individuals at high risk for developing PDAC.
Participants 
Data were collected within the framework of our ongoing Familial Pancreatic Cancer 
Surveillance Study. Eligible for inclusion are asymptomatic individuals with an estimated 
≥10-fold increased familial or inherited PDAC-risk compared to the general population (see 
inclusion criteria below). The minimal age for inclusion is 45 years or 10 years younger than 
the age of the youngest relative with PDAC, whichever occurred first. For patients with 
Peutz Jeghers syndrome the minimal age for inclusion is 30 years or 10 years younger than 
the age of the youngest relative with PDAC, whichever occurred first. Potential candidates 
are evaluated and recruited by a clinical geneticist to check whether inclusion criteria are 
fulfilled. This evaluation includes (1) obtaining a detailed personal and family medical his-
tory, (2) verification of clinical diagnoses reported by patients and family members by review 
of medical and pathologic records and revision of histological slides whenever available, 
and (3) based on the medical information genetic testing for suspected gene mutation(s).
Inclusion criteria 
1. Carriers of CDKN2A gene mutations, regardless of the family history of PDAC [14]
2. Peutz-Jeghers Syndrome patients (diagnosis based on a proven LKB1/STK11 gene muta-
tion [3]
3. Carriers of gene mutations in BRCA1, BRCA2, p53, or Mismatch Repair Gene with a 
family history of PDAC in at least two family members [15-18]
4. First degree relatives (FDRs) of patients with familial pancreatic cancer (FPC). FPC families 
were defined as families affected by PDAC in at least (1) two FDRs, (2) three relatives in 
which the affected cases are FDR or second-degree relatives (SDRs) of each other, or (3) 
two SDR of whom at least one relative was aged <50 years at the time of diagnosis [8 
19]. Eligible for inclusion in our study were all family members with at least one FDR with 
PDAC.
Exclusion criteria
Individuals with a history of PDAC, age <18, upper GI tract obstruction, severe medical 
illness (ASA score ≥3), or who were unable to provide informed consent due to mental 
retardation or language barrier were excluded. 
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Experimental methods
Screening techniques
Endoscopic ultrasonography
All EUS procedures were carried out by five experienced endosonographers (JWP, PF, MJB, 
HMvD and JEvH). Both electronic radial (Olympus UC-160 AE, Olympus Europe, Hamburg, 
Germany with Aloka α 5 ultrasoundprocessor, Zug, Switzerland or Pentax EG-3670 URK, 
Pentax Medical Europe Headquarters, Hamburg, Germany with Hitachi ultrasoundproces-
sor, Hitachi Medical Systems Europe, Zug, Switzerland) and curvilinear (Olympus UCT/UCP 
160, Olympus Europe, Hamburg Germany with Philips HDI 5000 ultrasoundprocessor, 
Philips Healthcare Medical Systems, Best, The Netherlands or Aloka α 10 ultrasoundproces-
sor, Zug, Switzerland) instruments were used according to the personal preference of the 
endosonographer. Procedures were performed under conscious sedation with midazolam/
fentanyl or propofol. Imaging of the pancreas was carried out from the duodenum and 
stomach and was digitally recorded with lossy compression (Endobase, Olympus, Ham-
burg). In case a relevant clinical lesion or a lesion of unknown significance was detected, 
both a case description and video recordings were distributed amongst all participating 
endosonographists for independent review. The outcome of this independent review was 
then presented to the local multidisciplinary hepato-pancreato-biliary team consisting of 
gastroenterologists, surgeons and radiologists for final decision-making regarding further 
management. 
MRI
MRI was performed at a 1.5 or 3.0 Tesla machine (Signa HDxt, Discovery 450 or 750, 
GE Healthcare, Milwaukee, Wisconsin, USA; Siemens Avanto or Philips). The following 
sequences were obtained: coronal balanced steady state free precession imaging with 6 
mm slices, coronal and axial T2-weighted single-shot fast spin echo series with 6 mm 
slices, axial respiratory triggered (RT) fat suppressed T2-weighted fast spin echo series with 
6 mm slices, 3-D heavily T2-weighted coronal MR cholangio-pancreatography with 1.4 
mm slices (with subsequent axial reconstructions) and breath-hold axial diffusion weighted 
imaging series including apparent diffusion coefficient mapping with 6 mm slices, using 
three different b-values (b=50, 400, and 800 s/mm2). The dynamic sequence involved fat 
suppressed 3-D T1-weighted spoiled gradient-echo series using 2 or 3 mm slices before 
and after intravenous administration of gadobutrol (Gadovist 1.0 mmol/mL, Bayer Scher-
ing Pharma, Berlin, Germany) at a dose of  0.1 mmol/kg body weight using automated 
infusion with a power injector at a flow rate of 2 mL/s. Series were timed in the arterial, 
pancreatic and portal phase using bolus tracking. MRIs were scored by three highly experi-
enced radiologists (CYN, NCK and JJH).
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Image Interpretation and Reporting
Participating gastroenterologists and radiologists were blinded to the baseline results of 
either EUS or MRI. Reporting of imaging findings was standardized across EUS and MRI us-
ing a Case Record Form. We specifically looked for clinically relevant abnormalities defined 
as solid lesions of any size and cystic lesions larger than 10 mm, see also below [20]. 
The imaging diagnosis used for the present analysis was based on the initial description/
diagnosis provided by either the attending radiologist or gastroenterologist. Whenever 
there was a discrepancy between the findings of EUS and MRI with respect to clinically 
relevant lesions, the EUS video and MR images were reviewed to determine whether the 
lesion(s) was (were) indeed not detectable by the other technique.
Clinically relevant lesions
In this article, we mainly focus on the detection of clinically relevant lesions. These include 
all solid lesions suspicious for a malignancy as well as all lesions that fulfil the revised Sendai 
criteria for surgery or close follow-up [20]: cysts ≥3 cm, cysts with thickened/enhancing cyst 
walls and/or mural nodules and/or a solid component, main branch intraductal papillary 
mucinous neoplasms (IPMNs) with main pancreatic duct ≥10 mm in size, and side branch 
IPMNs with side duct dilations/cysts >10mm. 
Surgical outcomes considered ‘a success’
Detection and surgical treatment of (1) invasive cancer ≥T1N0M0 with negative margins, 
(2) multifocal pancreatic intraepithelial neoplasia (PanIN) 3 lesions and (3) high-grade 
IPMNs were defined as a successful outcome of surveillance [2].
Follow-up policy
The follow-up policy was based on the agreement of an expert panel consisting of expe-
rienced endosonographists, surgeons, radiologists and pathologists and was as follows: 
1. Annually, when EUS and/or MRI detected no pancreatic abnormalities or cystic lesions 
<10 mm. 
2. Three months in case EUS and/or MRI detected a lesion for which a morphological diag-
nosis could not be readily made, hereinafter referred to as lesions with unknown clinical 
significance.
3. Six months in case of a detected cyst or side branch IPMN with a diameter >10mm and 
<30mm without malignant features (see below).
4. Surgical resection in case of the detection of a solid lesion morphologically suspicious 
for a malignancy, cystic lesion >30mm, cystic lesions with malignant features (thickened/
enhancing cyst walls and/or mural nodules) or main branch IPMN with main pancreatic 
duct ≥10 mm [20].
41
2
Statistical methods
Descriptive statistics were generated to describe patient and lesion characteristics. To com-
pare both imaging test results, a percentage agreement was calculated for the detection 
and location of lesions, and a Spearman’s rho correlation coefficient was calculated for the 
size of lesions. We considered an agreement of 0.00 as poor, 0.01-0.20 as slight, 0.21-0.40 
as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial and 0.81-1.00 as almost perfect 
agreement [21]. All analyses were conducted using the Statistical Package for the Social 
Sciences (V21, SPSS Institute, Chicago, Illinois, USA). 
RESULTS
Patient characteristics
At 1 September 2013, a total of 166 high-risk individuals were prospectively included in 
this study. Twenty-two individuals underwent some form of pancreatic screening prior to 
inclusion and were therefore excluded from this blinded baseline analysis. Furthermore, 
five high-risk individuals were excluded from this analysis because they either had un-
derwent only EUS or only MRI (Figure 1). Therefore, a total of 139 individuals from 81 
unique families were included in this blinded analysis of whom the baseline characteristics 
are summarized in Table 1. The mean age at inclusion was 51 years (SD 9.7, range 20-73 
years). Sixteen individuals (12%) were current smokers at time of inclusion. Forty individu-
als (29%) had a medical history affected by cancer; in 24 of these individuals (60%) the 
cancer type was melanoma. Seventy-one individuals (51%) carried a pancreatic cancer-
prone gene mutation, whereas the remaining individuals stemmed from FPC families. No 
fine needle aspiration was performed and no procedure-related adverse events occurred. 
Table 1. Characteristics of asymptomatic high risk individuals who underwent baseline screening with 
EUS and MRI (n=139)
Number 
included, 
n (%)
Mean 
age at 
inclusion, 
yrs (range)
Male 
gender, 
n (%)
Mean number 
of family 
members with 
PDAC (range)
Mean age of 
youngest family 
member with 
PDAC, yrs 
Familial pancreatic cancer 68 (49) 53 (32-74) 32 (47) 2.7 (2-5) 53 
Familial CMM (CDKN2A) 38 (27) 48 (20-66) 16 (42) 2.5 (0-7) 51 
HBOC (BRCA1) 3 (2) 48 (43-57)   1 (33) 2.7 (2-3) 39 
HBOC (BRCA2) 20 (14) 52 (39-71)   8 (40) 2.4 (2-3) 52 
Peutz-Jeghers syndrome (LKB1) 7 (5) 52 (35-65)   5 (71) 0.2 (0-1) 54 
Li-Fraumeni syndrome (p53) 3 (2) 43 (34-54)   1 (33%) 2 (2) 44 
EUS, endoscopic ultrasonography; familial CMM, familial cutaneous malignant melanoma; HBOC, hereditary 
breast and ovarian cancer; PDAC, pancreatic ductal adenocarcinoma 
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Diagnostic yield
Clinically relevant lesions, as defi ned previously, were detected by either EUS and/or MRI in 
9 out of 139 high-risk individuals (6%). Two of these nine individuals (22%) had two clini-
cally relevant lesions. Therefore, a total of 11 clinically relevant lesions were identifi ed in 
nine individuals: two solid lesions and nine cysts larger than 10 mm. Further characteristics 
are summarized in Table 2. Additionally, eight hypo-echoic areas with unknown clinical 
relevance were detected by EUS in eight individuals and two lesions with reduced signal 
intensity on TI-weighted series were detected by MRI in two individuals. Together with the 
remaining 58 cysts <10 mm (in 34 individuals) and 9 duct ectasias (in 6 individuals), a total 
of 88 lesions were identifi ed in 46 out of 139 high risk individuals (33%). Characteristics 
of these lesions are summarized in Table 3. No difference in fi ndings was seen between 
individuals that carried a PDAC-prone gene mutation and individuals that stemmed from 
an FPC family.
Of all 11 clinically relevant lesions, 6 (55%) were detected by both modalities. EUS detected 
a total of eight (73%) and MRI detected a total of nine (82%) clinically relevant lesions. 
When analysing all lesions (clinically relevant lesions, hypo-echoic areas of unknown clinical 
relevance, hypo-intense areas of unknown clinical relevance and cysts <10mm), MRI was 
very sensitive for the detection of cystic lesions (of all 67 cystic lesions, 60 (90%) were de-
tected by MRI and 26 (39%) by EUS) and in specifi c for subcentimeter cysts (of all 58 cystic 
lesions <10 mm, 51 (88%) were detected by MRI and 20 (35%) by EUS). In total, there 
were 38 cysts <10 mm (mean 5 mm, range 2-9 mm) in 23 individuals that were detected 
by MRI but not by EUS. In 16 of these 23 individuals, the EUS investigation was performed 
using the radial scope (70%). The majority of these subcentimeter cysts therefore were 
missed using the radial scope and this could not be attributed to one single center or 
endosonographer. Conversely, EUS detected two solid lesions that were not detected by 
Figure 1. Flow chart. EUS, endoscopic ultrasonography; FPC, familial pancreatic cancer
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MRI, also not after re-evaluation of the MRI: (1) a 11 mm solid lesion in the body of the 
pancreas (Table 2, lesion 1 and Figure 2A) and (2) a 7 mm solid lesion in the head of the 
pancreas (Table 2, lesion 2 and Figure 2C). For both lesions, resection was performed. The 
former lesion proved to be a 12 mm T1N0M0 moderately differentiated adenocarcinoma 
(Figure 2B). Although post-surgical staging suggested a favorable outcome (R0 resection 
of a small tumour of 12 mm) the patient developed local disease recurrence with liver and 
peritoneal metastases a few months later and died within 36 months after initial diagnosis. 
The 7 mm solid lesion in the head of the pancreas proved to be two separate 3 mm lesions 
very close to each other and was therefore classified as multifocal PanIN2 (Figure 2D). 
Characteristics of all detected lesions by EUS and MRI are summarized in Table 4.  
Table 3. Characteristics of all detected lesions at baseline screening with EUS and MRI (n=88)
Total 
number 
detected 
n (%)
Number 
detected 
by EUS and 
MRI n (%)
Number 
detected by 
EUS only
n (%)
Number 
detected by 
MRI only
n (%)
Mean size, 
mm (range)
Solid lesions 2 (2) - 2 (100) -  9.0 (7-11)
Cystic lesions 
   ≥ 10 mm
   < 10 mm
   Any size (total)
9 (10)
58 (66)
67 (76)
  6 (67)
13 (22)
19 (28)
-
7 (12)
7 (10)
  3 (33)
38 (66)
41 (61)
 
16.9 (10-36)
4.8 (2-9)
5.4 (2-36)
Hypo-echoic areas with 
unknown relevance 
8 (9) - 8 (100) -  5.1 (2-11)
Hypo-intense areas with 
unknown relevance
2 (2) - - 2 (100) 7.0 (5-9)
Duct ectasias 9 (10) 4 (44) 1 (11) 4 (44)     2.2 (2-3)
EUS, endoscopic ultrasonography.
Figure 2. 
(A)   The still endoscopic ultrasound 
image of a 11 mm solid lesion 
of the body of the pancreas.
(B)   The histological image after re-
section of the lesion shown in 
(A), which proved to be a 12 
mm T1N0M0 moderately dif-
ferentiated ductal adenocarci-
noma.
(C)   Still endoscopic ultrasound im-
age of a 7 mm solid lesion in 
the head of the pancreas. 
(D)   The histological image after 
resection of the lesion shown 
in (C), which proved to be two 
separate 3 mm lesions, within 
2 mm distance of each other, 
classified as multifocal pancre-
atic intraepithelial neoplasia 2.
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Both EUS and MRI detected areas of (yet) unknown clinical relevance; these were lesions 
that were not cystic in nature and without the distinct morphology according to the 
consensus panel to be classified as a solid lesion or hypoechoic lobule. Table 5 provides a 
detailed description of these lesions of unknown clinical relevance. None of these cases 
had a history of (acute) pancreatitis or chronic ethanol overuse; only one was a heavy 
smoker (>15 cigarettes per day for over 40 years, case no. 5, Table 5). In all cases, except 
one (case no. 8, in Table 5), follow-up showed these lesions to remain stable or being not 
detectable anymore. In case no. 8, EUS detected two 5 mm hypo-echoic lesions (lesion 
#8 and #9 in Table 5). Interval screening at 3 and 6 months showed no morphological 
changes. However, at follow-up at 12 months, both lesions had a more solid appearance 
and one of these lesions discretely increased in size (from 5 to 7 mm). Based on these 
morphological changes, it was decided to resect both lesions. A partial spleen preserv-
ing body/tail resection was performed and pathological examination showed multifocal 
PanIN2 lesions. 
A total of 41 out of 139 high-risk individuals (30%) had at least one feature of chronic pan-
creatitis: lobularity was the most frequently detected feature (19%), as well as hyperechoic 
pancreatic duct margins (17%) and hyperechoic stranding (15%). Twenty individuals (14%) 
had three or more features of chronic pancreatitis. No differences in features of chronic 
pancreatitis were seen between individuals that carried a PDAC-prone gene mutation and 
individuals that stemmed from a FPC family. Also, no correlation with the presence of cysts, 
alcohol use or tobacco use was found.
Table 4. Characteristics of lesions detected by EUS and by MRI respectively at baseline screening
n (%) Mean size of lesions, mm Location of lesions (n, %)
Head Body Tail
Detected by EUS
  Solid 
  Cystic 
     ≥ 10 mm
     < 10 mm
     any size (total)
  Unclear 
  Duct ectasia
41
 2 (5)
 6 (15)
20 (49)
26 (63)
 8 (20)
 5 (12)
 6.1
 9.0 
12.7 
 5.2 
 6.9
 5.1
 2.0
14 (34)
 1 (50)
 3 (50)
 6 (30)
 9 (35)
 2 (25)
 2 (40)
18 (44)
 1 (50)
 1 (17)
10 (50)
11 (42)
 4 (50)
 2 (40)
 9 (22)
-
 2 (33)
 4 (20)
 6 (23)
 2 (25)
 1 (20)
Detected by MRI
  Solid 
  Cystic 
     ≥ 10 mm
     < 10 mm
     any size (total)
  Unclear 
  Duct ectasia
70
-
 9 (13)
51 (73)
60 (86)
 2 (3)
 8 (11)
 6.1 
 -
16.9
 4.8
 6.6
 7.0
 2.3
26 (37)
-
 6 (67)
17 (33)
23 (38)
 2 (100)
 1 (13)
24 (34)
-
 1 (11)
19 (37)
20 (33)
-
 4 (50)
20 (29)
-
 2 (22)
15 (29)
17 (28)
-
 3 (38)
EUS, endoscopic ultrasonography. 
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Agreement between EUS and MRI at baseline screening (blinded 
analysis)
The agreement between EUS and MRI for the detection of clinically relevant lesions (n=11) 
was moderate with a 55% agreement (see Table 6). Not surprisingly, the agreement was 
only fair for detection of all lesions regardless of size (n=88, agreement 26%). However, 
there was a perfect agreement between EUS and MRI for location of both clinically relevant 
lesions (n=6) and all lesions (n=26) (agreement 100%). Also, there was a substantial to 
almost perfect agreement between EUS and MRI on the size of clinically relevant lesions 
(Spearman’s rho correlation coefficient of 0.638) and the size of all detected lesions (Spear-
man’s rho correlation coefficient of 0.859).
Follow-up 12 months 
A total of 135 out of 139 high-risk individuals underwent repeated surveillance after 12 
months; one patient developed metastatic disease (case no. 1 in Table 2) and three patients 
withdrew from the surveillance programme (one patient had emigrated and two patients 
provided no reason for withdrawal). At 12 months’ follow-up, 12 clinically relevant lesions 
were detected in 8 individuals (6%). Also, 7 of these 12 lesions were unchanged compared 
Table 6. Agreement between endoscopic ultrasonography and magnetic resonance imaging for differ-
ent variables and subsets of pancreatic lesions 
Clinically 
relevant 
lesions
Clinically 
relevant lesions 
+ lesions with 
unknown 
relevance
All lesions
Detection 
Baseline
Agreement per lesion 
Agreement per participant
Follow-up 12 months
Agreement per lesion
Agreement per participant
55% (n=11)
56% (n=9)
67% (n=12)
50% (n=8)
29% (n=21)
28% (n=18)
50% (n=16)
67% (n=9)
26% (n=88)
35% (n=46)
24% (n=106)
35% (n=49)
Fair to moderate 
agreement
Fair to substantial 
agreement
Location 
Baseline
Agreement per lesion 
Agreement per participant
Follow-up 12 months
Agreement per lesion
Agreement per participant
100% (n=6)
100% (n=9)
100% (n=8)
100% (n=8)
100% (n=6)
100% (n=18)
100% (n=8)
100% (n=9)
100% (n=26)
100% (n=46)
100% (n=24)
100% (n=48)
Perfect agreement
Perfect agreement
Size 
Baseline
Spearman’s rho per lesion
Follow-up 12 months
Spearman’s rho per lesion
0.638 (n=6)
0.270 (n=8)
0.638 (n=6)
0.518 (n=8) 
0.859 (n=26)
0.619 (n=24)
Substantial to almost 
perfect agreement 
Fair to substantial 
agreement
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to baseline screening (lesion #3, 4, 6, 7, 9, 10 and 11, Table 2). Two lesions increased in 
size: in case no. 6 (Table 2) a cyst in the pancreatic head grew from 5 to 10 mm, and in 
another case, a 9 mm large cyst in the tail of the pancreas grew to 13 mm, both without 
secondary signs of malignancy. Three newly developed clinically relevant pancreatic lesions 
were identified: (1) case no. 6 developed a cyst of 13 mm in the body of the pancreas 
which was detected by both imaging modalities; (2) case no. 2, who had underwent a pan-
creaticoduodenectomy, developed a new 10 mm large cyst in the pancreatic tail detected 
by MRI; and (3) in another case, one new 10 mm large cyst in the body of the pancreas was 
detected by MRI, all without secondary signs of malignancy.  
Agreement between EUS and MRI at follow-up 12 months (unblinded 
analysis)
The agreement between EUS and MRI for the detection of clinically relevant lesions in-
creased from 55% at baseline screening (blinded results) to 67% agreement at follow-up 
12 months (unblinded results). 
DISCUSSION
To determine the effectiveness of EUS and MRI in their ability to detect pancreatic lesions in 
high-risk individuals, we conducted a multicenter prospective study in which we compared 
baseline results in a blinded fashion. This nationwide, blinded prospective study shows that 
for detection of pancreatic lesions, in this series both tests were complementary rather than 
interchangeable. EUS and/or MRI showed a total of 11 morphologically clinically relevant 
lesions at baseline screening in 6% of participating high-risk individuals. 
To date, results of 12 screening studies for pancreatic cancer have been published [4-13 
22 23]. Based on these results, EUS and MRI are currently regarded as the most promising 
screening techniques as they are relatively widely accessible, have low morbidity rates, 
and, in particular, are superior to any other imaging modality with regard to the detection 
of small pancreatic lesions. However, data on which of these two imaging techniques is 
to be preferred for screening purposes are largely lacking since only one of these series 
was conducted in a blinded fashion [8]. In this study [8], good concordance for lesion size, 
number and location between EUS and MRI was seen. 
In our cohort, however, we found a moderate to fair agreement between EUS and MRI 
on the detection of both clinically relevant lesions and all pancreatic lesions, but a good 
to perfect agreement on size and location of detected lesions. The moderate agreement 
between EUS and MRI on the detection of pancreatic lesions is a reflection of the fact that 
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only 55% of the clinically relevant lesions (6 of 11) were detected by both EUS and MRI. 
For baseline imaging, both radiologist and endosonographists were blinded to the results 
of the competing imaging modality. Since both modalities were performed on the same 
day as much as possible, the order being dependent on availability and logistics, it was not 
possible to unblind investigators after the initial investigation. For follow-up investigations 
after 12 months however, radiologists and endosonographers were aware of the baseline 
results. The agreement per lesion between both techniques increased from 55% at base-
line screening to 67% at follow-up surveillance. The disagreement between EUS and MRI 
lies mostly in the detection of cysts by EUS, and the detection of solid lesions by MRI. As 
a result, in this series both techniques were complementary rather than interchangeable. 
A possible explanation for the discrepancy in findings between Canto et al [8] and our 
study is the use of both the radial and the linear scope for EUS investigations in all individu-
als in Canto’s cohort, whereas only one of both scopes was used in our cohort. Perform-
ing an EUS investigation with two different endoscopes likely increases the detection of 
(subcentimeter) cysts, as the authors state themselves [24]. Also, since the miss rate for 
pancreatic lesions in high-risk individuals seems lower for linear EUS than for radial EUS 
[24], the frequent use of the radial scope in our cohort might have negatively influenced 
our reported concordance between EUS and MRI. Canto’s cohort consisted of a slightly 
different subset of individuals (older mean age, difference in types of underlying gene 
mutations), however, this should not affect the comparative analysis of EUS and MRI and 
thus does not explain the discrepancy in findings. Both cohorts were screened in tertiary 
high-volume centers and by experienced endosonographers and radiologists only.  
EUS proved to be particularly sensitive for the detection of small solid lesions. Two solid 
lesions detected by EUS, including a stage I PDAC, were not detected by MRI. When MRI 
investigations in both cases were re-evaluated these lesions were indeed not detectable. 
Our results are in line with the results of previous studies which were conducted in a clinical 
setting (sporadic cases) that showed EUS has the highest sensitivity for the detection of 
<20mm pancreatic cancers when compared to other imaging modalities including MRI [25 
26]. 
MRI was particularly sensitive for the detection of (small) cystic lesions. All nine cystic 
lesions sized ≥10mm were detected by MRI, whereas EUS detected six (66%). There are 
multiple possible explanations why these lesions were missed by EUS. The 24 mm cyst in 
the head of the pancreas (Table 2, lesion #9) was composed of multiple microcysts (Figure 
3). This composition influences the penetration of the ultrasound waves with the walls of 
the microcysts reflecting the ultrasound waves causing the lesion not to appear as a cystic 
lesion on EUS. However, one still would expect the lesion to be discordant compared to the 
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surrounding pancreatic parenchyma and thus identifi ed as a potential ‘lesion’. Indeed, at 
follow-up 12 months, a different endosonographer detected both lesion #9 and #10 (Table 
2, case 8). The location of cyst #11 in the uncinate process (Table 2, case 9), could be the 
reason why this particular lesion was missed. This part of the pancreas is sometimes more 
challenging to visualise by EUS. Lastly, in both cases a radial scope was used. Although in 
this multicenter study the choice of the device was left to the discretion of the attending 
investigator, most endosonographists prefer a linear device to scan the pancreas. 
Strengths of our nationwide, multicenter, prospective study are that at baseline screening 
participating gastroenterologists and radiologists were blinded to the results of either EUS 
or MRI imaging. Moreover, as a result of the extensive genetic evaluation prior to inclusion 
in this study and rigid inclusion criteria, our cohort consists of individuals truly at high risk 
for developing PDAC. 
This study is limited by the fact that we lack a defi nitive diagnosis of the vast majority 
of cases in whom an abnormality was detected, in particular if detected by one imaging 
modality only. As a resultant of this baseline screening, only two of all cases (1.4%) were 
operated. Consequently, it is yet impossible to make a fi nal judgement with regard to 
Figure 3. A 24 mm cyst in the head of the pancreas composed of multiple microcysts.
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the clinical relevance of the different types and sizes of pancreatic lesions detected. For 
instance, the importance of the hypo-echoic areas of unknown significance that were 
detected by EUS but not by MRI remains to be determined. Only longer follow-up will learn 
whether such findings bare clinical relevance. We are currently conducting a prospective 
follow-up study to assess the clinical relevance of various lesions detected by EUS and 
MRI and whether screening high-risk individuals is truly effective in reducing PDAC-related 
morbidity and mortality. 
The true challenge in pancreatic cancer surveillance is to adequately identify pre-neoplastic 
lesions to avoid resections of early stage lesions (eg, PanIN1 and 2 lesions), but timely 
resect advanced lesions before cancer has developed. Based on the present study, it is not 
possible to draw definite conclusions about the (potential) merits of surveillance to prevent 
pancreatic cancer death. To answer this pivotal question, long-term follow-up studies are 
required in a large number of individuals. In this regard, it should be recognized that it has 
taken many years to prove that colon cancer screening saves lives.
In conclusion, for individuals at high risk for developing pancreatic cancer that undergo 
screening, EUS and MRI are rather complementary than interchangeable imaging modali-
ties in our series. For future screening therefore, we will continue to use both imaging mo-
dalities in the follow-up of our cohort of high-risk individuals. We found that, in contrast 
to EUS, MRI is very sensitive for the detection of even the smallest cysts . EUS seems to be 
most sensitive for the early detection of (small) solid lesions, which from a clinical perspec-
tive is an important property of this imaging modality. Exclusive use of linear devices is 
likely to improve the overall results of EUS. This should be taken into account at future 
revisions of recommendations regarding which imaging modality to use for surveillance. 
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ABSTRACT
OBJECTIVES  The aim of this study was to compare the prevalence of cystic lesions and 
their natural behavior in two distinct high-risk groups for developing pancreatic ductal 
adenocarcinoma (PDAC): (1) carriers of a mutation that predisposes to PDAC and (2) 
individuals without a known gene mutation but with a family history of PDAC (familial 
pancreatic cancer (FPC)). 
METHODS  Pancreatic surveillance by annual magnetic resonance imaging and endoscopic 
ultrasound was performed in individuals with an estimated lifetime risk of developing 
PDAC of 10% or greater. Progression of a lesion was defined as growth 4 mm or greater 
or the development of worrisome features. 
RESULTS  We included 186 individuals: 98 mutation carriers and 88 FPC individuals (mean 
follow-up 51 months). Individuals with FPC were significantly more likely than mutation 
carriers to have a pancreatic cyst 10 mm or greater (16% vs 5%, P = 0.045). Pancreatic 
cysts detected in mutation carriers, however, were significantly more likely to progress than 
those in FPC individuals (16% vs 2%, P = 0.050). 
CONCLUSIONS  This study provides evidence that the prevalence and growth characteris-
tics of pancreatic cysts differ between distinct high-risk groups: individuals with FPC have a 
higher prevalence of pancreatic cysts 10 mm or greater, whereas cysts in mutation carriers 
are more likely to progress. These observations may help to develop more optimally tailored 
surveillance strategies in specific high-risk populations.
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INTRODUCTION
Despite recent improvements in surgical techniques and treatment options for patients 
with pancreatic ductal adenocarcinoma (PDAC), the prognosis has not significantly im-
proved over the past decades, with a 5-year survival rate still less than 6% 1. In order to 
improve prognosis, there is a growing interest toward screening and surveillance so that 
PDAC or, more preferably, its precursor high-grade dysplastic lesions can be detected at 
an early stage. However, screening and surveillance of the entire population for PDAC 
are unlikely to be feasible because of the relatively low incidence (10-12 new cases per 
100,000 persons per year 2-4) and because of the lack of an affordable, reliable and non-
invasive surveillance tool. Nevertheless, surveillance of well-defined high-risk groups for 
PDAC might be feasible and effective. 
Two separate groups of individuals are considered to be at an inherited high risk of de-
veloping PDAC: (1) mutation carriers of hereditary syndromes that increase the risk of 
developing PDAC (ie, carriers of mutations in the CDKN2A, BRCA1, BRCA2, or TP53 gene, 
and individuals with Peutz-Jeghers or Lynch syndrome), and (2) individuals who have no 
known gene mutation but who have a strong family history of PDAC (familial pancreatic 
cancer (FPC)). In these high-risk individuals, the risk of developing PDAC can be up to 
135-fold higher than in the general population 5-12. 
Over the past decade, multiple studies into the effectiveness of surveillance for PDAC 
in high-risk individuals have been performed 13-23. These studies have revealed frequent 
detection of cystic lesions of the pancreas, which are considered possible precursor le-
sions to PDAC: up to 42% of high-risk individuals have a pancreatic cyst, predominantly 
intraductal papillary mucinous neoplasm (IPMN)-like lesions, whereas the prevalence of 
pancreatic cysts in the general population is estimated to be only 0 to 10%, depending on 
age 24 25. However, it is still unclear whether the prevalence and growth characteristics of 
cystic lesions are equal within the 2 distinct high-risk groups. 
Only 1 study 23 has compared the prevalence and natural behavior of precursor lesions 
between risk groups: significantly more individuals in a mixed group – consisting of FPC 
individuals, BRCA2 and PALB2 mutation carriers – received a diagnosis of a cystic le-
sion than did carriers of a CDKN2A mutation. However, the cystic lesions detected in the 
CDKN2A mutation carriers were more likely to become malignant. 
It is important to gain more insight into the prevalence and natural behavior, including ma-
lignant progression, of cystic lesions within the 2 high-risk groups, in order to better adjust 
surveillance strategies within specific risk populations. This not only tailors the intensity 
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and burden of surveillance according to the actual risk, but also facilitates a cost-effective 
utilization of limited and costly health care resources. Therefore, the aim of this study was 
to study the incidence, prevalence and natural course of cystic pancreatic lesions in these 
2 distinct high-risk populations participating in an annual pancreatic cancer surveillance 
program. 
MATERIALS AND METHODS
Study design and sites
We extracted data from an ongoing multicenter prospective cohort study that is being 
performed in tertiary care medical centers in the Netherlands. Participating centers are 
the Erasmus MC University Medical Center Rotterdam, Academic Medical Center Amster-
dam, University Medical Center Groningen, University Medical Center Utrecht and the 
Netherlands Cancer Institute. Detailed information on study design and methods was 
described previously 26. The study protocol was approved by the Ethical Committee of all 
participating centers, and the study was conducted in accordance with the Declaration of 
Helsinki. All participants provided written informed consent prior to the performance of 
study procedures.
Participants
Data of all individuals with at least 1 year of follow-up participating in our ongoing 
Pancreatic Cancer Surveillance study were used. Eligible for inclusion in this study are 
asymptomatic individuals with an estimated familial or inherited lifetime risk of developing 
PDAC 10% or greater (see inclusion criteria in Table 1). The minimal age for inclusion 
between 2008 and 2013 was 45 years of age (or 30 in case of Peutz-Jeghers syndrome) 
or 10 years younger than the age of the youngest relative with PDAC, whichever age 
occurred first. Since 2013, the minimal age for inclusion is 50 years or 10 years younger 
than the age of the youngest relative with PDAC. Surveillance ends at the age of 75 years. 
Potential candidates are evaluated by a clinical geneticist. A detailed personal and family 
medical history is taken, cancer diagnoses of relatives are verified by review of medical 
records, and, if indicated, genetic testing for suspected gene mutation(s) is performed.  
Surveillance strategy
Annual surveillance of the pancreas is performed using both endoscopic ultrasonography 
(EUS), carried out by experienced endosonographers, and magnetic resonance imaging 
(MRI) with intravenous administration of gadobutrol. Follow-up policy is based on the 
agreement of an expert panel consisting of endosonographists, surgeons, radiologists and 
pathologists and is as follows:
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(1) Annual surveillance when either cystic lesions less than 10 mm or no pancreatic abnor-
malities are detected; 
(2) Interval surveillance after 6 months when a novel cystic lesion is detected with a diameter 
of 10 to 30 mm without worrisome features;
(3) Interval surveillance after 3 months when a lesion of unknown significance is detected for 
which there is no unanimous opinion among members of the expert panel;
(4) Surgical resection in accordance with the study protocol and international consensus 
guideline for young, fit patients 27 in case of (1) a solid lesion that is considered suggestive 
of malignancy, (2) a cystic lesion 30 mm or greater, (3) a cystic lesion with worrisome 
features (thickened/enhanced cyst wall and/or mural nodules), or (4) a main-branch IPMN 
(main pancreatic duct ≥ 10 mm). 
Cystic lesions
Cystic lesions are defined as hypoechoic lesions detected by EUS and hypointense lesions 
or hyperintense lesions detected by MRI on T1 or T2 sequences, respectively. An individual 
was scored as having a pancreatic cyst if either EUS or MRI described such a lesion. Cystic 
lesions were subdivided into lesions less than 10 mm and lesions 10 mm or greater, and 
into (1) main-branch IPMNs, (2) side-branch IPMNs (lesions with a clear connection to the 
pancreatic duct), and (3) other cystic lesions such as lesions without a certain or unclear 
connection to the pancreatic duct.   
Progression of cystic lesions
Prior to our analysis and after elaborate discussion, we defined progression of cystic lesions 
as either (1) the development of worrisome features (solid component, mural nodule(s), or 
thickened/enhancing cyst walls) or (2) growth of 4 mm or greater during follow-up. 
Table 1. Inclusion criteria 
Carriers of CDKN2A gene mutations, regardless of the family history of PDAC
Peutz-Jeghers syndrome patients (diagnosis based on a proven LKB1/STK11 gene mutation or 
clinical signs), regardless of the family history of PDAC
Carriers of gene mutations in BRCA1, BRCA2, TP53, or DNA Mismatch Repair genes with a family 
history of PDAC* in ≥ 2 family members
Individuals with ≥ 2 relatives affected by PDAC* who were related in the first degree to each 
other, of which at least one was related in the first degree to the eligible individual
Individuals with ≥ 3 relatives affected by PDAC* who were related in the first or second degree to 
each other, of which at least one was related in the first degree to the eligible individual
Individuals with ≥ 2 relatives affected by PDAC* who were related in the second degree to each 
other, of which at least one was related in the first degree to the eligible individual and was aged 
under 50 years at time of diagnosis
PDAC, pancreatic ductal adenocarcinoma
* at least one case of PDAC must have been histologically confirmed
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Statistical analysis
Descriptive statistics were used to illustrate patient and lesion characteristics. Categorical 
variables were compared using a χ2 test or, when indicated, a Fisher exact test. Continuous 
variables were compared using the independent-samples t test. Adjusting for difference 
in baseline age was done using multivariate regression analysis. P ≤ 0.05 was considered 
statistically significant. All analyses were conducted using the Statistical Package for the 
Social Sciences (version 21; SPSS Institute, Chicago, Ill). 
RESULTS
Patient characteristics
On May 6, 2015, 215 high-risk individuals were included in this study, of which 186 
individuals (87%) from 105 unique families had had at least 1 year of follow-up. A total 
of 98 (53%) of these 186 individuals were carrier of a gene mutation, and  a total of 88 
individuals (47%) had a strong family history of pancreatic cancer, but no gene mutation 
could be detected in these individuals (FPC individuals). Baseline characteristics of these 2 
groups of high-risk individuals as well as for all 215 individuals are summarized in Table 2. 
Individuals with FPC were significantly older than mutation carriers (54 vs 49 years of age, 
P = 0.002) and had more relatives who were affected by PDAC (2.6 vs 2.1, P = 0.004). 
Mutation carriers were more likely to have been treated for any type of cancer (44% of 
mutation carriers vs 9% of FPC individuals, P < 0.001), mainly for melanoma. The mean 
follow-up time was 51 months, 49 months for the mutation carriers and 53 months for 
the FPC individuals (P = 0.286). 
Cystic lesions
A total of 100 out of the 186 individuals (54%) had at least 1 pancreatic cystic lesion 
detected on EUS and/or MRI: 46 (47%) of 98 proven mutation carriers and 54 (61%) of 
88 FPC individuals (P = 0.049). Nineteen individuals (10%) had a cystic lesion 10 mm or 
greater, 5 (5%) of 98 mutation carriers and 14 (16%) of 88 FPC individuals (P = 0.015). A 
total of 34 (18%) out of 186 individuals had a cystic lesion with a clear visible connection 
to the pancreatic duct (presumed side-branch IPMN), 16 mutation carriers (16%) and 18 
FPC individuals (21%) (P = 0.467). No main-branch IPMNs were detected by EUS and/or 
MRI. There were no differences between the 2 groups in the mean number of cystic lesions 
per individual (2 in mutation carriers vs 3 in FPC individuals), in the mean largest size of 
cystic lesions per individual (7 mm in mutation carriers vs 8 mm in FPC individuals), or in 
the mean age at first diagnosis of a cystic lesion (55 years of age in mutation carriers vs 56 
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years of age in FPC individuals). Details are also summarized in Table 3. A total of 250 cystic 
lesions were identified in these 100 individuals.  
Because FPC individuals were statistically significantly older than the mutation carriers at 
study inclusion, we adjusted for this difference to exclude an age effect. The higher preva-
lence of cystic lesions of any size in FPC individuals was no longer statistically significant 
after adjusting for baseline age (P = 0.207). However, cystic lesions 10 mm or greater were 
still significantly more prevalent in FPC individuals than in proven mutation carriers (16% 
vs 5%, respectively, P = 0.045).  
Progression of lesions
Of the 100 individuals with a cystic lesion, 85 had had follow-up of their cystic lesion 
(37 mutation carriers and 48 FPC individuals). In 7 or these 85 individuals (8%), a lesion 
progressed during follow-up, 6 of which were detected in mutation carriers (6/37 (16%)) 
versus only 1 in an FPC individual (1/48 (2%); P = 0.040, P = 0.050 after adjusting for 
baseline age). All 7 progressed cases underwent surveillance with both EUS and MRI.  
Characteristics of the 7 lesions that progressed during follow-up are shown in Table 4. In 
4 individuals, a lesion had grown 4 mm or greater (patients 1, 2, 4 and 7 in Table 4). In 2 
individuals, gradual growth of a lesion was observed, which did not yet require a change in 
management policy (patients 1 and 2). Also in patient 4, in whom we saw slight growth of 
Table 3. Cystic lesions detected in the 2 groups of high-risk individuals 
Mutation carriers
(n=98), n (%)
FPC individuals
(n=88), n (%)
P-value 
(univariate 
analysis)
P-value 
(after adjusting 
for difference 
in baseline age, 
multivariate 
analysis)
Cystic lesions detected
   All cystic lesions
   Cystic lesion < 10 mm
   Cystic lesion ≥ 10 mm
   Presumed side-branch IPMNs
46 (47)
45 (46)
5 (5)
16 (16)
54 (61)
50 (57
14 (16
18 (21
0.049
0.138
0.015
0.467
0.207
0.434
0.045
0.169
Number of cystic lesions per 
individual, mean (range, SD)
2.2 (1-5, 1.4) 2.7 (1-6, 1.4) 0.088 0.111
Largest size of cystic lesions 
per individual, mean (range, 
SD), mm
6.8 (2-24, 4.8) 7.7 (2-36, 6.2) 0.465 0.524
Age at first diagnosis of a cystic 
lesion, mean (range, SD), y
55 (34-72, 8.6) 56 (38-73, 8.9) 0.507 0.493
P values (≤ 0.05) in bold font were considered statistically significant.
FPC, familial pancreatic cancer; IPMN, intraductal papillary mucinous neoplasm; SD, standard deviation.
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2 cystic lesions, management policy was not yet altered. Only in patient 7, in whom a cystic 
lesion located in the tail of the pancreas grew from 7 to 14 mm within 1 year of follow-up, 
a distal pancreatectomy was performed. The pathology of the resected specimen showed 
a main-branch IPMN with moderate grade dysplasia. In 3 remaining individuals, worrisome 
features had developed during follow-up (patients 3, 5 and 6 in Table 4). In patient 3, an 
18-mm side-branch IPMN was detected in the head of the pancreas at baseline imaging, 
without the presence of a worrisome feature. At 12-month follow-up, a small nodule (4 
mm) had developed within the cyst. At 24-month follow-up, the cyst had shrunk to 9 mm 
with the solid component grown to 6 mm. Fine-needle aspiration was performed on 2 
different occasions 3 months apart and showed no malignant cells. At 36-mont follow-up, 
the lesion had grown to 24 mm, and a hypoechoic area around the cyst was visualized with 
EUS. A pancreaticoduodenectomy was performed where a pancreatic cancer was found. 
The cancer was unfortunately unresectable because of a pathologically proven distant 
lymph node metastasis during surgery (adenocarcinoma of pancreaticobiliary origin). In 
patient 5, a morphologically multifocal side-branch IPMN was detected at baseline imaging 
with unchanged characteristics at 12-month follow-up (no worrisome features). One of 
the lesions, a tail lesion, had grown from 13 to 23 mm at follow-up at 24 months and also 
developed a solid component measuring 11 mm in diameter and appearing predominantly 
hypovascular on contrast-enhanced EUS. A distal pancreatectomy was performed. Pathol-
ogy of the resected specimen showed a T3 N1 M0 PDAC. Patient 6 developed distinct solid 
components, 6 and 4 mm, and hypovascular on contrast-enhanced EUS, in 2 separate 
cystic lesions 1 year after detection of these cysts. A body-tail resection was performed. 
Pathology of the resected specimen showed multifocal pancreatic intraepithelial neoplasia 
grade 2 (the lesions were <1 cm on pathological examination, so they did not fulfill the 
pathological criteria for IPMN). In this cohort, none of the individuals without a progressed 
lesion underwent resection.  
DISCUSSION
In this multicenter prospective study, we compared the incidence, prevalence and the 
natural behavior of cystic pancreatic lesions in 2 distinct groups of individuals at high risk 
of developing pancreatic cancer. Individuals with FPC were significantly more likely than 
mutation carriers to have a pancreatic cyst 10 mm or greater. Pancreatic cysts detected in 
mutation carriers, however, were more likely to progress during follow-up. 
Over the past decade, centers in different countries around the world have initiated surveil-
lance programs for pancreatic cancer aiming to improve the survival of PDAC 13-23. One way 
of optimizing the diagnostic yield of such surveillance programs, that is, the detection of 
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early-stage PDAC or an advanced precursor lesion, is to restrict the program to high-risk 
individuals with a clear genetic or familial background. Little is known about the possible 
differences in the incidence, prevalence and natural behavior of the abnormalities detected 
between these 2 distinct high-risk groups. 
To date, there is only 1 report comparing findings between 2 high-risk groups 23. In this 
study, 1 high-risk group consisted of CDKN2A mutation carriers, namely, p16-Leiden 
mutation carriers, whereas the other high-risk group was a mixed group consisting of FPC 
individuals, BRCA2 and PALB2 gene mutation carriers. This study demonstrated a high in-
cidence of cystic lesions in the mixed group (42%), however, with a low incidence of PDAC 
(0.8%) and progression of cystic lesions in only a small fraction of these individuals during 
follow-up (8%). In contrast, the p16-Leiden mutation carriers had a lower incidence of 
cystic lesions (16%), but a higher incidence of PDAC (7%) and a substantial proportion of 
their cystic lesions (17%) were seen to grow or develop into malignancy during follow-up. 
We report a very high incidence of cystic lesions in both groups: 61% in FPC individuals 
and 47% in mutation carriers. Such high numbers of cystic lesions in the pancreas have 
been detected before in multiple studies into the effectiveness of surveillance for PDAC 
in high-risk individuals 13-23. In contrast, the estimated prevalence of cystic lesions in the 
general population is estimated to be only 3% 24 25.  
One of the notable differences that we found between the 2 high-risk groups was the 
prevalence of cystic lesions: one might have expected a lower prevalence of cystic lesions 
in FPC individuals because we can neither prove nor rule out that these individuals carry a 
yet unknown gene mutation. Because of the presumed autosomal dominant inheritance 
pattern observed in FPC families, half of these FPC individuals do not carry a gene mutation 
and will therefore also not be at increased risk of developing PDAC. This is in contract 
to our proven mutation carriers in whom an increased risk for PDAC was confirmed by 
genetic testing. 
With regard to the significantly higher prevalence of cystic lesions in the group of FPC 
individuals, it is tempting to speculate that this might be indicative of a difference in 
pathophysiology or in molecular subtypes of PDAC 28 between the 2 high-risk groups. An 
even more important observation is the fact that almost no progression of cystic lesions 
was seen in FPC individuals (no single PDAC developed within the FPC cohort), whereas 
lesions in mutation carriers did progress in a significant proportion of individuals (PDAC 
incidence 2%). In line with current guidelines where progression of a cyst in either size or 
development of worrisome features is considered a sign of increased malignant potential, 
this difference in progression between the 2 groups eventually might have important 
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implications for surveillance strategies, such as applying differential strategies with shorter 
or longer surveillance intervals between groups. 
This multicenter prospective study has several strengths. First, all individuals were counseled 
by a clinical geneticist prior to inclusion, and DNA testing was performed, if indicated. In 
FPC individuals, or their affected relatives, no mutation in one of the PDAC-related genes 
could be identified. This makes the group of FPC individuals truly distinct from the proven 
mutation carriers. Second, as we have a large group of individuals participating in our 
annual surveillance, all mutations known to increase the risk of developing PDAC are well 
represented in our cohort. 
A limitation of this study is that for the majority of individuals in whom a cystic lesion 
was detected a definitive pathological diagnosis is lacking: confirmation was in only 3 
resected lesions. Consequently, it is not yet possible to judge the true clinical relevance 
of the detected lesions. Only longer-term follow-up will provide more insight into the 
relevance of these lesions. Another limitation of this study is that the age at inclusion 
differed significantly between the 2 high-risk groups: the FPC individuals were slightly 
older than the mutation carriers. From literature, it is well known that cystic lesions become 
more prevalent with increasing age 24. Nevertheless, when comparing the 2 groups, we 
adjusted for this difference in baseline age and still found a higher prevalence of cystic 
lesions 10 mm or greater in FPC individuals. 
In conclusion, this observational cohort study provides evidence that the prevalence and 
growth characteristics of pancreatic cysts differ between distinct groups of individuals at 
high risk of developing PDAC. Individuals with FPC have a higher prevalence of pancreatic 
cysts 10 mm or greater, whereas cysts in mutation carriers are more likely to progress. 
These observations may help to develop more optimally tailored effective and cost-effective 
surveillance strategies in specific risk populations at high risk of developing PDAC.
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ABSTRACT
Background and study aims
During endoscopic ultrasound (EUS)-based pancreatic ductal adenocarcinoma (PDAC)-
surveillance in asymptomatic individuals, features of chronic pancreatitis (CP) are often 
detected. Little is known about the prevalence and progression of these features. The aim 
of this study was to quantify these features, assess the interobserver agreement, assess 
possible associated factors, and assess the natural course during 3 years of follow-up.
Patients and methods
Two experienced endosonographers reviewed anonymized sequential EUS videos of 
participants in PDAC surveillance that were obtained in 2012 and 2015 for features of 
CP. Descriptives, agreement analyses, univariate and multivariate analyses for possible risk 
factors, and repeated measures analyses to assess intra-individual changes over time were 
performed. 
Results
A total of 42 EUS videos of 21 participants were reviewed. Any feature of CP was present 
in 86% (2012) and 81% (2015) of participants, with a mean of 2.5 features per individual. 
The overall interobserver agreement was almost perfect at 83%. No baseline factors were 
significantly associated with features of CP. Features did not change over time, except for 
hyperechoic foci without shadowing, which decreased intra-individually (β=-1.6, P=0.005).
Conclusions
This blinded study shows features of CP to be highly prevalent in individuals at high risk of 
developing pancreatic cancer. No baseline factors were associated with presence of these 
features. CP features did not increase intra-individually over a 3-year period. Longer follow-
up and pathological examination of pancreatic resection specimens will be essential to 
learn whether the EUS detection and follow-up of these CP features bear clinical relevance.
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INTRODUCTION 
Over the past decades, multiple centers have initiated surveillance programs in individu-
als at high risk of developing pancreatic ductal adenocarcinoma (PDAC) to evaluate the 
diagnostic yield of such surveillance programs and to ultimately improve the poor survival 
of PDAC [1-13]. As recommended by the Cancer of the Pancreas Screening (CAPS) Consor-
tium, most surveillance programs entail annual magnetic resonance imaging (MRI) as well 
as endoscopic ultrasound (EUS) imaging of the pancreas [14]. The diagnostic yield for the 
detection of high-grade dysplastic precursor lesions (i.e., pancreatic intraductal neoplasia 
(PanIN)-3 and intraductal papillary mucinous neoplasms (IPMN) with high-grade dysplasia) 
or early stage PDAC varies between studies with an overall diagnostic yield of about 10% 
[15]. 
During EUS-based PDAC surveillance, not only cystic or solid lesions can be detected and 
features of chronic pancreatitis (CP) also are frequently observed. The clinical significance 
of these CP features in asymptomatic individuals is still unclear. Research suggests that 
these features might be related to emerging PanIN and IPMN lesions [16,17], however, 
little is known about the prevalence and progression of these CP features detected in 
asymptomatic high-risk individuals. Therefore, the aim of this study was to quantify CP 
features in individuals participating in our EUS/MRI-based surveillance program by review-
ing stored videos of sequential EUS examinations and assess their progress over a 3-year 
period. We also aimed to study interobserver agreement in our series and assess possible 
factors associated with presence of these CP features.   
PATIENTS/MATERIAL AND METHODS
Our PDAC-surveillance program has been described in detail before [13]. In summary, 
annual surveillance is performed using EUS and MRI/MRCP in individuals at inherited or 
familial increased risk of developing PDAC (≥ 10% life-time risk, i.e. all carriers of CDKN2A 
gene mutations, all Peutz-Jeghers syndrome patients, carriers of gene mutations in BRCA1, 
BRCA2, TP53 or mismatch repair genes with a family history of PDAC in at least two fam-
ily members, and first-degree relatives of patients with familial pancreatic cancer (FPC)). 
All EUS-investigations are performed under conscious sedation with midazolam/fentanyl 
by experienced endosonographers using a curvilinear device. Images of the pancreas are 
obtained from the duodenum and stomach and are digitally recorded in real time with 
lossy compression. 
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For this study, all participants in PDAC surveillance at the Erasmus University Medical Cen-
ter Rotterdam, The Netherlands, were included for whom two EUS videos were available 
3 years apart (2012 and 2015). The images were anonymized for patient ID and date of 
investigation. Two highly experienced endosonographers (MB and JWP, each over 3500 ca-
reer EUS investigations) individually reassessed the videos for features of CP: parenchymal 
features [18] were scored in the head, body and tail of the pancreas and ductal features 
features [18] were scored in the body and tail, using a standardized Case Record Form. The 
EUS videos were randomly assigned a video number and were thus assessed in an order 
for which no correlation could be made between patient ID or date of investigation. Both 
endosonographers scored the videos separately, after which a consensus meeting was held 
to discuss individuals in whom there was a difference in scored features.  
The study was approved by the local Ethical Committee and was conducted in accordance 
with the Declaration of Helsinki. All participants provided written informed consent prior 
to the performance of any study procedures.
Statistical methods
Descriptive statistics were used to describe participants’ characteristics. A proportion of 
agreement was calculated to assess interobserver agreement for each feature of CP. We 
considered an agreement of 0.00 as poor, 0.01-0.20 as slight, 0.21-0.40 as fair, 0.41-0.60 
as moderate, 0.61-0.80 as substantial and 0.81-0.99 as almost perfect agreement and 
1.00 as perfect agreement [19].
Data after consensus agreement were analyzed using descriptive statistics and univariate 
(Chi-square test, Fisher’s exact test and independent t-test where appropriate) and mul-
tivariate analyses, to detect participants’ characteristics associated with a mean of ≥ 4 
CP features on EUS assessments. Intra-individual changes over time were assessed with 
repeated measures, generalized estimated equations for ordinal outcomes, and with 
mixed-effect models (growth curve models) with maximum likelihood estimator and un-
structured covariance matrix for longitudinal data (non-proportional analyses). To correct 
for multiple testing, we only report P-values of <0.01 as statistically significant. For all 
statistical analyses, the Statistical Package for the Social Sciences was used (version 23.0, 
SPSS Institute, Chicago, IL).
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RESULTS
Participant characteristics
In 2012, EUS videos of 26 individuals participating in surveillance were stored, of which 21 
individuals had a follow-up EUS video available in 2015. These 21 individuals were included 
in the study, whose characteristics are summarized in Table 1. The mean age of the 21 
included individuals was 52, they were predominantly female and there were no excessive 
alcohol consumers or diabetic participants.
Review of the first EUS video showed any feature of chronic pancreatitis in 18 of 21 (86%) 
participants, and in 17 (81%) at review of the second video, 3 years later (as specified in 
Table 2). The mean number of CP features per participant was 2.5 (range 0-7). When the 
Table 1. Baseline characteristics of included individuals
All individuals included in the 
study (n=21)
N (%)
Sex, male 4 (19%)
Age at inclusion (years), mean (range, SD) 52 (41-68, 7.1)
Body Mass Index, mean (range, SD) 26 (16-40, 5.4)
Underlying gene mutation
   CDKN2A mutation
   BRCA2 mutation
   LKB1/STK11 mutation
   Unknown (FPC)
6 (29%)
1 (5%)
1 (5%)
13 (62%)
No. of relatives affected by PDAC, mean (range, SD) 2 (0-6, 1.5)
Age of youngest relative affected by PDAC, mean (range, SD) 50 (42-72, 9.1)
Diabetes 0 (0%)
Smoking
   Current smoker
   Past smoker
   Never smoker
   ≥ 20 pack years of smoking
3 (14%)
3 (14%)
15 (71%)
3 (14%)
Alcohol consuming
   Current alcohol consumer
      Current excessive alcohol consumer (≥ 3 units/day)
   Past alcohol consumer
      Past excessive alcohol consumer (≥ 3 units/day)
   Never alcohol consumer
16 (76%)
0 (0%)
1 (5%)
0 (0%)
4 (19%)
Features of chronic pancreatitis
   Individuals with features present at first available EUS video
    Individuals with features present at second available EUS 
video
18 (86%)
17 (81%)
SD, standard deviation; FPC, familial pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; EUS, endo-
scopic ultrasound. 
Chapter 4  |  Evolution of features of chronic pancreatitis
78
Rosemont classification [18] was applied, only 52% of screened individuals had a normal 
EUS examination and three (7%) fulfilled criteria for CP.   
Table 2. Overview of detected features of chronic pancreatitis 
Table 2. (continued) Overview of detected features of chronic pancreatitis
Features of chronic pancreatitis All available 
EUS videos 
(n=42)
First available 
EUS video 
(2012, n=21)
Second available
 EUS video 
(2015, n=21)
Intra-individual 
change 
(2012 vs 2015)
Β SE P
Hyperechoic foci with 
shadowing
   Head
   Body
   Tail
3 (7%)
1 (2%)
3 (7%)
2 (5%)
2 (10%)
0 (0%)
2 (10%)
1 (5%)
1 (5%)
1 (5%)
1 (5%)
1 (5%)
-0.74
-
-0.74
-
1.3
-
1.3
-
0.570
-
0.570
1.000
Hyperechoic foci without 
shadowing
   Head
   Body
   Tail
20 (48%)
15 (36%)
10 (24%)
8 (19%)
14 (67%)
12 (57%)
8 (38%)
5 (24%)
6 (29%)
3 (14%)
2 (10%)
3 (14%)
-1.61
-2.08
-1.77
-0.63
0.6
0.7
0.8
0.8
0.006
0.005
0.035
0.414
Lobularity with honeycombing
   Head
   Body
   Tail
5 (12%)
1 (2%)
5 (12%)
4 (10%)
3 (14%)
1 (5%)
3 (14%)
2 (10%)
2 (10%)
0 (0%)
2 (10%)
2 (10%)
-0.46
-
-0.46
-
0.8
-
0.8
-
0.564
-
0.564
1.000
Lobularity without 
honeycombing
   Head
   Body
   Tail
13 (31%)
6 (14%)
7 (17%)
6 (14%)
8 (38%)
4 (19%)
5 (24%)
2 (10%)
5 (24%)
2 (10%)
2 (10%)
4 (19%)
-0.68
-0.80
-1.09
0.80
0.6
0.8
1.0
0.8
0.251
0.318
0.265
0.318
Cysts
   Head
   Body
   Tail
9 (21%)
5 (12%)
5 (12%)
5 (12%)
5 (24%)
2 (10%)
3 (14%)
3 (14%)
4 (19%)
3 (14%)
2 (10%)
2 (10%)
-0.28
0.46
-0.46
-0.46
0.8
1.0
0.8
0.8
0.705
0.656
0.564
0.564
Stranding
   Head
   Body
   Tail
30 (71%)
26 (61%)
15 (36%)
12 (29%)
14 (67%)
12 (57%)
6 (29%)
5 (24%)
16 (76%)
14 (67%)
9 (43%)
7 (33%)
0.47
0.41
0.63
0.47
0.6
0.6
0.5
0.6
0.411
0.477
0.167
0.411
MPD calculi
   Head
   Body
   Tail
1 (2%)
1 (2%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
1 (5%)
1 (5%)
0 (0%)
0 (0%)
-
-
-
-
-
-
-
-
-
-
-
-
Irregular MPD contour
   Body
   Tail
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
-
-
-
-
-
-
-
-
-
Dilated side branches
   Body
   Tail
5 (12%)
2 (5%)
5 (12%)
2 (10%)
1 (5%)
2 (10%)
3 (14%)
1 (5%)
3 (14%)
0.46
-
0.46
0.8
-
0.8
0.564
1.000
0.564
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Interobserver agreement
Results of the interobserver agreement analyses are shown in Table 3. On almost all CP 
features, there was an almost perfect to perfect agreement between the two reviewers. 
Substantial agreement was reached for hyperechoic foci without shadowing overall (69% 
agreement), in the head (69% agreement) and in the tail of the pancreas (79% agree-
ment), for lobularity without honeycombing overall (71% agreement) and in the body of 
the pancreas (71% agreement), and for hyperechoic main pancreatic duct margins overall 
(71% agreement), and in the body of the pancreas (79% agreement). Only moderate 
agreement was reached for stranding overall, and in the head of the pancreas (59.5 and 
52.4% agreement, respectively). Agreement for all CP features (taken together, all possible 
CP features in any location of the pancreas, i.e. the 29 items from Table 3) rated as almost 
perfect at 83%. 
Characteristics associated with features of chronic pancreatitis 
Table 4 shows the results of univariate and multivariate analyses regarding possible risk 
factors associated with detection of a mean of ≥ 4 features of CP on EUS. On univariate 
analysis, ‘age of the youngest relative affected by PDAC’ was the only identified risk factor 
(P  = 0.002), but it was not sustained after multivariate analysis. 
Intra-individual change in detected features of chronic pancreatitis
Results of the repeated measures generalized estimated equations analyses of intra-
individual change in CP features are shown in Table 2. Except for hyperechoic foci without 
Table 2. (continued) Overview of detected features of chronic pancreatitis
Features of chronic pancreatitis All available 
EUS videos 
(n=42)
First available 
EUS video 
(2012, n=21)
Second available
 EUS video 
(2015, n=21)
Intra-individual 
change 
(2012 vs 2015)
Β SE P
MPD dilatation
   Body
   Tail
1 (2%)
0 (0%)
1 (2%)
0 (0%)
0 (0%)
0 (0%)
1 (5%)
0 (0%)
1 (5%)
-
-
-
-
-
-
-
-
-
Hyperechoic MPD margin
   Body
   Tail
15 (36%)
14 (33%)
8 (19%)
8 (38%)
7 (33%)
4 (19%)
7 (33%)
7 (33%)
4 (19%)
-0.21
-
-
0.6
-
-
0.739
1.000
1.000
Mean number of features of CP 
(range, SD)
2.5 (0-7, 1.5) 2.7 (0-5, 1.4) 2.2 (0-7, 2.2) -0.43 0.4 0.328
Rosemont classification 
   Normal
   Indeterminate for CP
   Suggestive of CP
   Consistent with CP
22 (52%)
13 (31%)
4 (10%)
3 (7%)
9 (43%)
7 (33%)
3 (14%)
2 (10%)
13 (62%)
6 (29%)
1 (5%)
1 (5%)
0.956 4.4 0.029
EUS, endoscopic ultrasound; MPD, main pancreatic duct; SE, standard error. 
Bold P-values (< 0.01) were considered statistically significant.
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Table 3. Interobserver agreement per feature of chronic pancreatitis
Features of chronic pancreatitis
% agreement between 
two reviewers
Interpretation of 
% agreement
Hyperechoic foci with shadowing
   Head
   Body
   Tail
85.7
90.5
88.1
95.2
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
Hyperechoic foci without shadowing
   Head
   Body
   Tail
69.0
69.0
85.7
78.6
Substantial agreement
Substantial agreement
Almost perfect agreement
Substantial agreement
Lobularity with honeycombing
   Head
   Body
   Tail
88.1
97.6
88.1
88.1
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
Lobularity without honeycombing
   Head
   Body
   Tail
71.4
83.3
71.4
83.3
Substantial agreement
Almost perfect agreement
Substantial agreement
Almost perfect agreement
Cysts
   Head
   Body
   Tail
92.9
95.2
92.9
85.7
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
Stranding
   Head
   Body
   Tail
59.5
52.4
83.3
85.7
Moderate agreement
Moderate agreement
Almost perfect agreement
Almost perfect agreement
MPD calculi
   Head
   Body
   Tail
100.0
100.0
100.0
100.0
Perfect agreement
Perfect agreement
Perfect agreement
Perfect agreement
Irregular MPD contour
   Body
   Tail
97.6
100.0
97.6
Almost perfect agreement
Perfect agreement
Almost perfect agreement
Dilated side branches
   Body
   Tail
83.3
92.9
88.1
Almost perfect agreement
Almost perfect agreement
Almost perfect agreement
MPD dilatation
   Body
   Tail
97.6
100.0
97.6
Almost perfect agreement
Perfect agreement
Almost perfect agreement
Hyperechoic MPD margin
   Body
   Tail
71.4
78.6
83.3
Substantial agreement
Substantial agreement
Almost perfect agreement
Overall (taken together all 29 items above) 83.3 Almost perfect agreement
MPD, main pancreatic duct
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shadowing, which decreased intra-individually (overall (β = - 1.6, standard error (SE) 0.6, P 
= 0.006) and, more specifically, in the head of the pancreas (β = - 2.1, SE 0.7, P = 0.005)), 
CP features did not change in the 3 years. Also, the mean number of CP features and the 
Rosemont classification did not change. However, there was one individual, a 60-year old 
woman without a known gene mutation (FPC), in whom in 2012 only 1 feature of CP 
was present (a cyst in the head of the pancreas), while in 2015, no less than 7 features 
were detected (hyperechoic foci with and without shadowing, lobularity with and without 
honeycombing, stranding, MPD calculi, and hyperechoic MPD margins), see Figure 1. 
Unfortunately, this patient subsequently died of a trauma. 
Table 4. Univariate and multivariate analyses for factors possibly associated with a mean ≥ 4 features of 
chronic pancreatitis
Factors
Univariate analyses
P-value
Multivariate analysis
P-value
Sex 0.546 0.999
Age 0.504 0.625
Body Mass Index 0.646
Underlying gene mutation 0.890
Number of relatives affected by PDAC 0.388 0.938
Age of youngest relative affected by PDAC 0.002 0.367
Smoking 0.574
Number of pack years of smoking 0.371 0.677
Alcohol consuming 0.849
Number of alcohol units per week 0.691
PDAC, pancreatic ductal adenocarcinoma. 
Bold P-values (< 0.05) were considered statistically significant.
Figure 1. Serial still images of endosonography in a participant with marked progression of features of 
chronic pancreatitis
A. Still image of the endoscopic ultrasound examination in 2012, showing an unremarkable pancreas.
B. Still image of the endoscopic ultrasound examination in 2015 in the same individual, showing multiple 
features of chronic pancreatitis (hyperechoic foci, lobularity, stranding, and a hyperechoic main pancreatic duct 
margin).
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None of the individuals in this series underwent surgery between 2012 and 2015. One in-
dividual, a 50-year old male without a known gene mutation (FPC), had already undergone 
a distal pancreatectomy in 2011 as a consequence of two EUS-detected solid lesions. Prior 
to surgery, no features of CP were detected. The resection specimen harbored a panIN-2 
lesion and diffuse foci with panIN-1B. The EUS videos of the remnant pancreas from 2012 
and 2015 showed hyperechoic foci without shadowing and hyperechoic MPD margins in 
2012; in 2015 only stranding was detected. 
DISCUSSION
This study shows CP features to be highly prevalent in asymptomatic participants in PDAC 
surveillance, with a substantial to almost perfect interobserver agreement. Also, these 
features hardly changed over a 3-year course of follow-up. 
Since the start of our PDAC surveillance program in 2008, features of CP were often 
detected, but their clinical relevance was unclear. They have been associated with incipient 
or emerging PanIN and IPMN lesions producing lobular parenchymal atrophy resulting in 
CP-like changes [16,17]. Therefore, to assess the detection of features of CP, interobserver 
agreement for these features, factors associated with them, and above all, the natural 
course of these features over time during EUS-based surveillance for PDAC in high-risk 
individuals, we conducted this blinded single-center study in which we reviewed stored 
videos from EUS examinations in 2012 and 2015.
In our series, we showed CP features to be highly prevalent: 86% (in 2012) and 81% 
(in 2015) of individuals had an EUS feature of CP; only 52% of individuals fell into the 
category ‘normal’ when the Rosemont classification [18] was applied. This prevalence is 
much higher than described in a non-high risk cohort. Petrone et al. [20] described 16.8% 
of asymptomatic individuals undergoing EUS for an indication not related to pancreatico-
biliary disease as having at least one ductal or parenchymal abnormality present. As the 
prevalence of CP features in our cohort at high risk of developing PDAC is this high, the 
alleged association between (progression) of specific EUS features and presence of PanIN 
or IPMN lesions bears particular interest. 
Assessing the intra-individual change in CP features over our 3-year study period, the 
number of CP features, individual CP features and Rosemont classification did not change, 
except for a statistically significant intra-individual decrease in hyperechoic foci without 
shadowing. However, development and progression of precursor lesions into PDAC may 
take multiple years [21]. Continued follow-up of these individuals therefore is of pivotal 
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importance. Eventually, pathological examination of resected pancreatic specimens, not 
yet available from individuals in the current study, are needed to further clarify the associa-
tion and clinical relevance of EUS detection of CP features. 
Our study revealed no baseline factors significantly associated with the detection of a 
mean of ≥ 4 CP features. Even factors that are known to be associated with CP, includ-
ing smoking and alcohol consumption [22,23], were not associated with the detection of 
CP features in our cohort. Although speculative, this could be related to the underlying 
pathophysiologic mechanism of chronic pancreatitis-like changes in individuals at high 
risk of developing pancreatic cancer. Studies suggest that (multifocal) PanIN and IPMN 
lesions produce obstructive lobular atrophy or the pancreatic parenchyma which is likely 
the source of the CP-like changes that follow in these patients [16,17]. 
Our analyses into the interobserver agreement for detection of CP features showed an 
excellent agreement for most of the CP features. Overall agreement between the two 
expert endosonographers was 83% and rated as almost perfect. This is somewhat bet-
ter than described in previous reports where a moderate to substantial agreement was 
described [24-26] (kappa-values of 0.46, 0.65 and agreement of 68%, respectively). Our 
high interobserver agreement might be explained by the fact that our two reviewers are 
highly trained and experienced endosonographers. 
To our knowledge, this is the first study to longitudinally assess features of CP in asymp-
tomatic high-risk individuals participating in an EUS-based PDAC surveillance program. 
Another strength of this study is that two expert endosonographers reviewed the EUS 
recordings in a blinded fashion using a standardized case record form. However, this study 
also has some limitations. The number of participants was limited and the follow-up com-
prised 3 years. None of the participating individuals underwent surgery and we therefore 
lack definite diagnoses and pathological correlates. Consequently, it is not possible to de-
termine the clinical relevance of the different EUS features of CP that were detected. Also, 
the Rosement classification was applied in our cohort. This classification was not designed 
for the purpose of diagnosing CP in asymptomatic patients at high risk of developing 
PDAC. Although individual criteria can be readily applied and followed in an asymptomatic 
cohort of high-risk individuals undergoing PDAC surveillance, its clinical relevance in this 
setting remains unclear. The total score also may be less relevant than development of 
individual features over time.
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CONCLUSION
In conclusion, this blinded study, reviewing EUS videos of asymptomatic high-risk indi-
viduals participating in EUS-based PDAC surveillance, showed features of CP to be highly 
prevalent but stable over a 3-year period, with a high interobserver agreement. We could 
not associate any baseline factors with detection of these CP features. Longer follow-up 
and, if available, pathological examination of pancreatic resection specimens will be es-
sential to understanding the relationship between these CP features and development of 
malignancy, and whether detection of these features bears clinical relevance, for example, 
in setting the indication for resection or serving as a criterion of influence in determining 
the screening interval. 
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ABSTRACT
Background
Surveillance of high-risk individuals (HRI) for pancreatic ductal adenocarcinoma (PDAC) and 
its precursors is being evaluated for its ability to improve outcomes. The aim of this study 
was to determine prevalence and outcomes of PDAC and high-risk neoplastic precursor 
lesions (HRN) among HRI participating in PDAC-surveillance. 
Method
A multicenter retrospective study was conducted through the International CAPS Con-
sortium Registry to identify HRI who had undergone pancreatic resection or progressed 
to advanced PDAC while under surveillance. HRN were defined as PanIN-3, IPMN with 
high-grade dysplasia and pancreatic neuroendocrine tumors (PanNET) ≥2 cm.
Results
Seventy-six HRI were included from 11 surveillance programs; 71 had undergone surgery, 
5 were diagnosed with inoperable PDAC. Thirty-two of the 71 resected pancreata (45%) 
had PDAC or HRN: 19 PDAC, 4 MD-IPMN, 4 BD-IPMN, and 5 PanIN-3; the remainder of 
cases had lower-risk neoplasia. Age ≥65, female gender, carriage of a gene mutation and 
location of a lesion in the head/uncinate region were associated with HRN or PDAC. The 
survival between HRI with low-risk neoplastic lesions versus HRI with HRN did not differ; 
survival was worse among patients with PDAC. There was no surgery-related mortality.
Conclusion
A high proportion of HRI who undergo surgical resection for screening-detected pancreatic 
lesions have HRN or PDAC. Survival was best and equal for HRI with low-risk neoplastic 
lesions and HRI with HRN. While all screening programs carry the risk of overtreatment, 
our results suggest that surveillance of HRI leads to the treatment of an acceptable mix of 
lesions.
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INTRODUCTION
Despite improvements in treatment options for pancreatic ductal adenocarcinoma (PDAC), 
PDAC remains the third leading cause of cancer deaths in the United States (U.S.) with 
a 5-year survival of only 8% 1. By 2030, PDAC is projected to become the second lead-
ing cause of cancer-related death in the U.S. 2. Advances in screening, prevention, and 
treatment have the potential to change pancreatic cancer incidence and/or death rates, 
but significant reductions in mortality will require a concerted effort by the research and 
healthcare communities to effect a substantial change 2. Inherited susceptibility is thought 
to be a major factor in PDAC susceptibility, accounting for 5-10% of cases 3. Surveillance 
for PDAC and its precursor lesions in asymptomatic high-risk individuals (HRI) is increasingly 
being performed worldwide 4-15. HRI can be categorized into two groups: (1) carriers of 
known PDAC-associated gene mutations (especially carriers of deleterious mutations in 
CKDN2A,BRCA2, BRCA1, ATM, TP53, a Lynch syndrome gene, PRSS1 or STK11), and (2) 
first-degree relatives of familial PDAC cases (clustering of at least two first-degree blood 
relatives with PDAC) 16. The goals of pancreatic surveillance of HRI have been previously 
described by the CAncer of the Pancreas Screening (CAPS) Consortium 17. These include 
the detection and treatment of early invasive pancreatic cancer (T1N0M0) at baseline or 
follow-up; detection and treatment of any invasive resectable cancer at baseline screening; 
detection and treatment of multifocal pancreatic intraepithelial neoplasia 3 (PanIN-3); and 
the detection and treatment of intraductal papillary mucinous neoplasm (IPMN) with high-
grade dysplasia. 
Few studies have described the surgical pathology findings of HRI who have undergone 
surgery 15 18, and most of these included only a few cases. The CAPS Consortium Registry 
was created to more rapidly gather information about the experience of surveillance of 
HRI. In this study, we evaluated the diagnostic yield and outcomes of HRI who underwent 
surgical resection or progressed to invasive cancer, and examined the characteristics of HRI 
that developed high-risk neoplastic precursor lesions (HRN) or PDAC. 
METHODS
All participating centers in the CAPS Consortium (36 centers from nine countries across the 
world, see acknowledgements) were requested to enter patient information data for HRI 
participating in their PDAC-surveillance program who either underwent pancreatic surgery 
because of the detection of a suspicious pancreatic lesion, or who had progressed to 
advanced non-resectable malignant disease while participating in PDAC surveillance. Data 
were retrospectively collected through the use of web-based data collection software (Om-
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niComm Electronic Data Capture). Anonymized clinical and demographic information was 
collected (gender, age, tobacco and alcohol use, diabetes mellitus, history of pancreatitis, 
body mass index (BMI), known gene mutations, and family history of PDAC), pancreatic 
imaging modalities that detected the lesions, characteristics of the lesions detected by 
imaging, timing of detection, therapy, pathology and outcomes after surgery or diagnosis 
of advanced PDAC. Research protocols of all participating centers have been largely based 
on the consensus statements of the Cancer of the Pancreas Screening (CAPS) Consortium 
17. However, given the retrospective nature and large time span of this study, it is inevitable 
that differences between protocols of screening centers worldwide existed, in particular 
for the period before publication of the CAPS consensus statements in 2013. The index 
examinations and follow-up examinations were carried out using MRI and/or endoscopic 
ultrasonography. However, when suspect lesions were detected, other modalities, such 
as CT imaging, were often used for further characterization and staging. All individuals 
in this study provided written informed consent for their participation in the respective 
PDAC-surveillance programs as approved by the Ethical Committees of the participating 
centers and the study was conducted in accordance with the Declaration of Helsinki. 
For analyses, participants with pathologically proven high-risk neoplastic precursor lesions 
(HRN) or pathologically proven PDAC were compared to participants who underwent sur-
gery but in whom the resection specimen harbored no HRN or PDAC. HRN were defined 
as multifocal PanIN-3 lesions, main-duct IPMNs, and branch-duct IPMNs with high-grade 
dysplasia. We also classified unifocal PanIN-3 lesions and PanNETs ≥ 2 cm as HRN 19 20. 
Statistical methods
Descriptive statistics were performed to describe patient and lesion characteristics. Univari-
ate analyses (Chi square, or Fisher’s exact test where indicated) were performed on possible 
risk factors associated with PDAC or HRN in the operated cases. All variables with a P -value 
<0.200 in the univariate analyses were included in the multivariate analysis. A Kaplan-
Meier curve was plotted to compare survival for different subgroups, a hazard ratio was 
calculated using the Log Rank. All analyses were conducted using the Statistical Package 
for the Social Sciences (V.21, SPSS Institute, Chicago, Illinois, USA). 
RESULTS
Patient characteristics
A total of 76 HRI were included from 11 prospective PDAC-surveillance programs in 4 
countries (62 HRI from 7 centers in the United States, 9 HRI from 2 centers in The Nether-
lands, 3 HRI from one center in Israel, and 2 HRI from one center in Italy). In the 11 centers, 
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approximately 1700 HRI underwent surveillance, of whom approximately 70% were 
female, mean ages ranged from 53 to 75, and follow-up ranged from one to 10 years. Of 
the 76 HRI included, 5 were diagnosed with advanced disease during surveillance and 71 
underwent surgery for a suspected lesion of whom two were diagnosed with inoperable 
disease during surgery. Baseline characteristics of all 76 HRI are summarized in Table 1. 
Table 1. Baseline characteristics of all high-risk individuals who underwent surgery due to the detec-
tion of a suspicious pancreatic lesion or who were diagnosed with advanced pancreatic cancer during 
participation in PDAC surveillance.
High-risk individuals 
who underwent 
surgery
(n=71)
N (%)
High-risk individuals 
who were diagnosed 
with advanced PDAC
(n=5)
N (%)
Age at surgery or diagnosis of advanced PDAC, 
mean (median, range, SD)
60.3 (59.8, 36-80, 11.6) 70.5 (65-80, 6.6)
Gender, male 37 (52.1%) 1 (20.0%)
Race
   White
   Black
   Other
67 (94.4%)
3 (4.2%)
1 (1.4%)
5 (100.0%)
-
-
Genetic background
   Familial pancreatic cancer (FPC)
   CDKN2A (FAMMM syndrome)
   BRCA2 (HBOC)   
   Peutz-Jeghers syndrome   
   BRCA1 (HBOC)
   TP53 (Li Fraumeni syndrome)
   MMR (Lynch syndrome)
   APC 
   ATM
   PRRS1 (hereditary pancreatitis)
52 (73.2%)
7 (9.9%)
3 (4.2%)
3 (4.2%)
1 (1.4%)
1 (1.4%)
1 (1.4%)
1 (1.4%)
1 (1.4%)
1 (1.4%)
4 (80.0%)
-
-
1 (20.0%)
-
-
-
-
-
-
Number of FDR with PDAC, mean (median, 
range, SD)
Number of SDR with PDAC, mean (median, 
range, SD)
1.5 (1.0, 0-3, 0.8)
1.1 (1.0, 0-4, 1.0)
1.4 (0-2, 0.9)
0.3 (0-1, 0.6)
Youngest family member affected by PDAC,   
mean (range, SD)
55.5 (33-77, 10.8) 63.3 (52-68, 7.5)
Body mass index, mean (median, range, SD) 27.3 (26.6, 18-48, 5.1) 26.1 (23-31, 3.7)
Personal history of diabetes 11 (15.5%) 2 (40.0%)
Number of months of diabetes prior to surgery 
or diagnosis of advanced PDAC, mean (median, 
range, SD)
36.6 (45.0, 0-63, 23.7) 66 (12-120, 76.4)
Personal history of pancreatitis 9 (12.7%) 1 (20.0%)
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High-risk neoplastic precursor lesions and (advanced) pancreatic ductal 
adenocarcinoma
HRN or PDAC were present in the pancreatic specimen of 32 (45%) of the 71 HRI who 
underwent surgery: 5 (7%) cases had PanIN-3 lesions as the highest grade neoplastic le-
sion, 4 (6%) a branch-duct IPMN with high-grade dysplasia, 4 (6%) a main-duct IPMN, and 
19 (27%) PDAC. Pathology findings in all 71 HRI who underwent surgery are summarized 
in Table 2, as well as lesion characteristics and type of surgery. 
In 39 of the HRI (55%) the indication for surgery was detected at the baseline screen-
ing evaluation. Of the remaining 32 (45%) cases, the lesion was detected at follow-up 
investigation. In 9 of these 32 cases a lesion was already present at previous investigations 
a mean 9 months prior to resection. These lesions originally did not meet resection criteria. 
However, their appearance changed over time at close follow-up for which resection was 
then performed. Ten of these 32 cases were a mean 7 months overdue for their recom-
mended screening interval (recommended screening intervals ranged from 3-24 months, 
depending on the visualization of a lesion and if so, the type of lesion). EUS detected the 
vast majority of lesions (87.3%). A total of 93 suspicious lesions were detected in the 71 
HRI who underwent surgery, of which 44 (47%) were cystic and 33 (36%) solid in appear-
ance. Mean size of these 93 lesions was 14 mm, ranging between 3 to 51 mm. 
Table 1 (continued). Baseline characteristics of all high-risk individuals who underwent surgery due to 
the detection of a suspicious pancreatic lesion or who were diagnosed with advanced pancreatic cancer 
during participation in PDAC surveillance.
High-risk individuals 
who underwent 
surgery
(n=71)
N (%)
High-risk individuals 
who were diagnosed 
with advanced PDAC
(n=5)
N (%)
Smoking behavior
   Never smoker 
   Former smoker
   Current smoker
   No data
   ≥ 10 pack years in total
   ≥ 20 pack years in total
46 (64.8%)
20 (28.2%)
3 (4.2%)
2 (2.8%)
11 (15.5%)
4 (5.6%)
3 (60.0%)
2 (40.0%)
-
1 (20.0%)
-
Alcohol consumption
   Never consumer 
   Former consumer
   Current consumer
   No data
   ≥ 10 units per week (current or past)
   ≥ 20 units per week (current or past)
38 (53.5%)
12 (16.9%)
19 (26.8%)
2 (2.8%)
5 (7.0%)
2 (2.8%)
2 (40.0%)
1 (20.0%)
2 (40.0%)
-
-
-
PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; FAMMM, familial atypical multiple mole mel-
anoma syndrome; HBOC, hereditary breast and ovarian cancer; MMR, mismatch repair genes; APC, adenoma-
tous polyposis coli; ATM, ataxia telangiectasia mutated; FDR, first degree relative; SDR, second degree relative.
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Table 2. Overview of lesion characteristics, type of surgery and pathology in all high-risk individuals who 
underwent surgery (n=71) and all high-risk individuals who were diagnosed with advanced disease (n=5) 
while participating in pancreatic cancer surveillance
High-risk individuals 
who underwent 
surgery
(n=71)
N (%)
High-risk 
individuals who 
were diagnosed 
with advanced 
PDAC
(n=5)
N (%)
Lesion characteristics
   Time point of lesion detection:
        Baseline
        Follow-up 
             Present at previous investigations
              Mean months of lesion visualization prior to 
resection/diagnosis (median, range, SD)
             Case overdue for recommended screening
              Mean months overdue for recommended screening 
(median, range, SD)
   Modality that detected the lesion (≥1 option possible):
        EUS
        MRI/MRCP
        CT / PET-CT
        ERCP
    Lesion type of lesions that were reason for surgery (n=93)
        Cystic 
        Solid                
        Hypoechoic
        Dilated pancreatic duct
        Features of chronic pancreatitis
        Other
   Lesion location (n=93)
        Head/uncinate region
        Body
        Tail
        No data
   Lesion size in mm, mean (median, range, SD)
        All lesions (n=93)
        Cystic lesions (n=44)
        Solid lesions (n=33)
39 (54.9%)
32 (45.1%)
9 (12.7%)
8.7 (5.0, 1-32, 9.5)
10 (14.1%)
6.7 (6.0, 1-12, 3.4)
62 (87.3%)
29 (40.8%)
28 (39.4%)
8 (11.3%)
44 (47.3%)
33 (35.5%)
3 (3.3%)
2 (2.2%)
1 (1.1%)
10 (10.8%)
35 (37.6%)
20 (21.5%)
29 (31.2%)
9 (9.7%)
14.0 (11.9, 3-51, 8.8)
13.6 (11.6, 3-40, 8.0)
15.5 (13.0, 4-51, 10.0)
2 (40.0%)
3 (60.0%)
1 (20.0%)
41 (41, 41, -)
1 (20.0%)
3 (3, 3,-)
2 (40.0%)
3 (60.0%)
2 (40.0%)
-
Neoadjuvant therapy 4 (5.6%) N/A
Type of surgery
   Distal pancreatectomy
   Pancreaticoduodenectomy
   Total pancreatectomy
    Pancreaticoduodenectomy followed by completion 
pancreatectomy
   Central pancreatectomy
   Diagnosis of non-resectable disease during surgery
36 (50.7%)
18 (25.4%)
9 (12.7%)
4 (5.6%)
2 (2.8%)
2 (2.8%)
N/A
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Table 2 (continued). Overview of lesion characteristics, type of surgery and pathology in all high-risk 
individuals who underwent surgery (n=71) and all high-risk individuals who were diagnosed with ad-
vanced disease (n=5) while participating in pancreatic cancer surveillance
High-risk individuals 
who underwent 
surgery
(n=71)
N (%)
High-risk 
individuals who 
were diagnosed 
with advanced 
PDAC
(n=5)
N (%)
Complications of surgery (≥1 option possible)
   None
   Infectious complications
   Delayed gastric emptying
   Pancreatic fistula
   Bile leak
   Peri-pancreatic fluid collection
   Other
   No data
37 (52.1%)
10 (14.1%)
6 (8.5%)
4 (5.6%)
2 (2.8%)
1 (1.4%)
6 (8.5%)
7 (9.9%)
N/A
Pathology (≥1 could be present)
   PDAC
   Main-duct IPMN with high-grade dysplasia
   Main-duct IPMN with moderate-grade dysplasia
   Main-duct IPMN with low-grade dysplasia
   Mixed-duct IPMN with high-grade dysplasia
   Mixed-duct IPMN with moderate-grade dysplasia
   Mixed-duct IPMN with low-grade dysplasia
   Branch-duct IPMN with high-grade dysplasia
   Branch-duct IPMN with moderate-grade dysplasia
   Branch-duct IPMN with low-grade dysplasia
   PanIN-3, multifocal
   PanIN-3, unifocal
   PanIN-2, multifocal
   PanIN-2, unifocal
   PanIN-1, multifocal
   PanIN-1, unifocal
   Pancreatic neuroendocrine tumor ≥ 2 cm
   Pancreatic neuroendocrine tumor < 2 cm
   Incipient IPMN
   Serous cystadenoma
   Vascular malformation
19 (26.8%)
1 (1.4%)
4 (5.6%)
1 (1.4%)
1 (1.4%)
-
-
5 (7.0%)
9 (12.7%)
16 (22.5%)
3 (4.2%)
3 (4.2%)
35 (49.3%)
10 (14.1%)
32 (45.1%)
4 (5.6%)
-
8 (11.3%)
5 (7.0%)
2 (2.8%)
1 (1.4%)
5 (100.0%)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
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Distal pancreatectomy was performed in 36 cases (51%) and a pancreaticoduodenectomy 
in 18 (25%) cases. Thirty-four HRI (48%) had complications of surgery. The most com-
mon complications were infections (in 14% of cases), delayed gastric emptying (in 9% of 
cases) and pancreatic fistula (in 6% of cases). There were no surveillance or surgery-related 
deaths.
Of the five cases diagnosed with advanced disease during surveillance, 3 (60%) were diag-
nosed at a follow-up visit, the other two were detected at baseline evaluation; one of these 
cases was 3 months overdue for recommended screening (surveillance was performed at 
9 months after the previous surveillance, while a 6-month interval was recommended). 
Outcomes
The outcomes of both risk groups are summarized in Table 3. Of all 76 HRI who were 
included in this study, 61 (80%) are still alive, a mean 52 months after surgery or diagnosis 
of advanced PDAC. Fifty-nine of 71 HRI (83%) who underwent surgery are still alive after 
Table 2 (continued). Overview of lesion characteristics, type of surgery and pathology in all high-risk 
individuals who underwent surgery (n=71) and all high-risk individuals who were diagnosed with ad-
vanced disease (n=5) while participating in pancreatic cancer surveillance
High-risk individuals 
who underwent 
surgery
(n=71)
N (%)
High-risk 
individuals who 
were diagnosed 
with advanced 
PDAC
(n=5)
N (%)
Highest grade of neoplastic lesion per HRI
   PDAC
      Stage I/II PDAC
      Stage III/IV PDAC
   Main-duct IPMN with high-grade dysplasia
   Main-duct IPMN with moderate-grade dysplasia
   Main-duct IPMN with low-grade dysplasia
   Branch-duct IPMN with high-grade dysplasia
   Branch-duct IPMN with moderate-grade dysplasia
   Branch-duct IPMN with low-grade dysplasia
   PanIN-3, multifocal
   PanIN-3, unifocal
   PanIN-2, multifocal
   PanIN-2, unifocal
   PanIN-1, multifocal
   PanIN-1, unifocal 
   Pancreatic neuroendocrine tumor < 2 cm
   Serous cystadenoma
19 (26.8%)
16 (22.5%)
3 (4.2%)
1 (1.4%)
2 (2.8%)
1 (1.4%)
4 (5.6%)
7 (9.9%)
9 (12.7%)
3 (4.2%)
2 (2.8%)
9 (12.7%)
7 (9.9%)
1 (1.4%)
1 (1.4%)
3 (4.2%)
2 (2.8%)
5 (100%)
0 (0%)
5 (100%)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
PDAC, pancreatic ductal adenocarcinoma; EUS, endoscopic ultrasonography; MRI, magnetic resonance imag-
ing; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; IPMN, intraductal 
papillary mucinous neoplasm; PanIN, pancreatic intraepithelial neoplasia; N/A, not applicable.
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surgery (a mean 54 months); 12 HRI died, of which 8 were PDAC-related. Two of the 5 
cases with advanced PDAC are still alive (mean 10 months after diagnosis), three cases 
died a mean 11 months after diagnosis. Survival was significantly poorer for individuals 
with advanced PDAC as compared to the individuals who underwent surgery (survival 
40% vs 83%, P=0.05; mean 10 vs 54 months, P <0.001). Only 2 out of 71 HRI (3%) who 
underwent surgery died within a year (all-cause 1-year mortality), as compared to 2 out of 
5 (40%) HRI with advanced PDAC; 52% survived more than 3 years after surgery. 
Risk factors 
Univariate analyses for factors associated with HRN or PDAC in the resection specimen (see 
Table 4) included age ≥ 65 at the time of surgery (OR 4.1, P = 0.007) and female gender 
(OR 3.8, P = 0.007). In the multivariate analysis, four factors were significantly associated 
with the presence of HRN or PDAC in the pancreatic resection specimen: age ≥ 65 at the 
time of surgery (OR 7.5, P = 0.010), female gender (OR 5.8, P = 0.017),  carriage of a 
deleterious mutation in a known pancreatic cancer susceptibility gene (OR 4.9, P = 0.040) 
and location of a lesion in the head/uncinate region of the pancreas (OR 4.2, P = 0.041). 
Table 3. Outcomes in all high-risk individuals who underwent surgery (n=71) and all high-risk individuals 
who were diagnosed with advanced disease (n=5) while participating in pancreatic cancer surveillance
High-risk 
individuals who 
underwent 
surgery
(n=71)
N (%)
High-risk 
individuals who 
were diagnosed 
with advanced 
PDAC
(n=5)
N (%)
P-value
Follow-up time in mean months (median, range, 
SD)
51.6 (42.0, 0-168, 
45.1)
8.2 (3.0, 3-28, 
11.1)
< 0.001
Survival
   Alive
   Mean months after surgery/diagnosis (median, 
range, SD)
   Long-term survival (≥ 3 years)
59 (83.1%)
54.3 (44.0, 0-168, 
45.9)
37 (52.1%)
2 (40.0%)
9.5 (3.5, 3-28, 
12.3)
0
0.050
< 0.001
Mortality
   Died
   Mean months after surgery/diagnosis (median, 
range, SD)
   Short-term mortality (≤ 1 year)
   PDAC-related 
   Non-PDAC-related
   Unknown cause of death
12 (16.9%)
54.3 (28.5, 5-164, 
56.0)
2 (2.8%)
8 (11.3%)
2 (2.8%)
2 (2.8%)
3 (60.0%)
11.3 (3.0, 3-28, 
14.4)
2 (40.0%)
3 (60.0%)
0
0
0.050
0.221
0.154
0.506
PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation
Bold P-values were considered statistically significant
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We also analyzed the variable ‘surgery after 2011’ (n=23), to analyze if surgery in more 
recent years yielded more HRN or PDAC in the resection specimens as compared to prior 
years when surveillance was just being implemented (‘the learning curve’). There was a 
trend towards more HRN or PDAC in recent years, however, this difference was not statisti-
cally significant (OR 1.5, P = 0.448).
Survival analysis
The pancreatic neoplasia grade was significantly associated with overall survival in HRI. 
Figure 1 shows the Kaplan-Meier curve for different pathologic subgroups. HRI with no or 
low-risk neoplastic lesions (group A, N=39) and HRI with HRN (group B, N=13) had the best 
survival, followed by HRI with stage I or II PDAC (group C, N=16), and HRI with stage III or 
IV PDAC (group D, N=8). The hazard ratio for group B compared to group A was 4.5 (P = 
0.163), for group C 13.1 (P = <0.001) and for group D 25.3 (P = <0.001). 
DISCUSSION
In this multicenter international retrospective study, high-risk neoplastic lesions or PDAC 
were present in 45% of the HRI that underwent surgery while participating in PDAC-
surveillance. Survival between HRI with no or low-risk neoplastic lesions versus HRI with 
Figure 1. Kaplan-Meier survival curve per subgroup
A.   Low-risk neoplastic lesions including pancreatic neuroendocrine tumors (PanNETs) <2 cm (n=39)
B.   High-risk neoplastic lesions including all main-duct intraductal papillary mucinous neoplasms (IPMNs), 
branch-duct IPMNs with high-grade dysplasia and PanIN-3 lesions (n=13)
C.   Stage I and II PDACs (n=16)
D.   Stage III and IV PDACs (n=8)
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HRN did not differ significantly. However, PDAC had a significantly higher overall mortality 
and poorer survival as compared to HRI with no or low-risk neoplastic lesions. 
As surveillance has the potential to improve the poor survival of PDAC, it is increasingly 
being performed worldwide and already a sizeable number of HRI are being screened and 
surveilled. In 2010, the CAPS Consortium was formed to help organize global pancreatic 
surveillance. By pooling data from all participating centers into a worldwide registry, im-
portant research questions pertaining to pancreatic surveillance can be assessed much 
more readily and reliably. In a step-by-step approach of gathering worldwide data, we 
now report the pooled data of HRI for whom surveillance led to the detection of advanced 
disease or the detection of a lesion for which pancreatic surgery was performed.   
Goals of surveillance previously described by the CAPS Consortium 17 were early invasive 
cancers (T1N0M0), PanIN-3, MD-IPMNs and BD-IPMNs with high-grade dysplasia. We also 
defined PanNETs ≥ 2 cm as a goal of surveillance, however, no such large PanNETs were 
detected in our cohort. Timing of intervention is an important issue. In this series, 55% of 
the resection specimens harbored no HRN or PDAC, but did harbor, for example, low-risk 
PanIN lesions (PanIN-1 or 2) or small PanNETs. Although not the primary intent of the 
surgery, long-term follow-up may show that patients with resected low-risk lesions might 
have a reduced risk for developing PDAC. Obviously, all-cause mortality and morbidity 
including quality of life after surgery, should be taken into consideration to genuinely 
assess the effects of surgery in individuals with low-risk neoplasia. In other individuals, 
surgical resection was performed too late, as only 3 of the 19 PDAC-cases were T1. The 
main challenge in any surveillance program for PDAC is how to rightfully distinguish be-
tween those individuals that can be safely monitored and those who require surgery to 
resect an (early) neoplastic lesion. Based on the complexity to diagnose and differentiate 
these early lesions, we currently do not advocate expanding surveillance programs outside 
expert centers. Instead, surveillance for pancreatic cancer should only be done within the 
framework of a collaborative study consortium, in order to continuously monitor, analyze 
and optimize performance. 
In this study, 55% of lesions that prompted surgery were detected at baseline visit. This 
could raise the question whether one-time screening of HRI at a given age is also effec-
tive. Nevertheless, in some individuals in whom an advanced lesion was found at the 
index investigation, it could be argued that this lesion would have been detected at an 
earlier stage with potentially a better outcome if that subject had entered the surveillance 
protocol at an earlier age. We also observed newly developed or detected high-risk lesions 
in several patients who missed their follow-up visit by only a few months. Therefore, based 
on current observations, we believe that it is appropriate to adhere to an annual surveil-
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lance protocol, until more data are available from large prospective cohort series to define 
the optimal management strategy per risk group.
Although not all cases with main-duct IPMN progress to cancer, the overall 10-year risk 
is estimated at approximately 25% which is the rationale why these lesions are regarded 
high risk 21. Interestingly, only 2 patients in our study cohort were identified with main-duct 
IPMN (dilated pancreatic duct) prior to surgery. After pathological evaluation of the resec-
tion specimen 4 cystic lesions were re-classified as main-duct IPMN. A discrepancy between 
imaging report and pathology report is not an uncommon finding 22 and it would be very 
interesting to compare imaging characterization of a lesion and duct diameter on imaging 
to pathology reports, however this is beyond the scope of this study. 
To improve selection of HRI for surgery, we also looked for risk factors that can easily be 
assessed preoperatively for association with HRN or PDAC in the resection specimens. 
Multivariate analyses showed age ≥ 65, female gender, carriage of a gene mutation and 
location of a lesion in the head/uncinate region of the pancreas to be associated with the 
detection of HRN or PDAC in the resection specimen. Therefore, particularly in female 
carriers of a gene mutation aged above 65 with a lesion suspicious for malignancy in the 
head/uncinate region of the pancreas, one should carefully weigh the option of pancreatic 
surgery versus continuing surveillance.  
In our risk factor analyses, we examined the potential effect of time on the prevalence 
of neoplasia in resection specimen because criteria for surgery might be confounded by 
increased clinical experience and accumulating data. Surgery in more recent years (after 
2011) did not yield significantly more HRN or PDAC in the resection specimens as compared 
to prior years when surveillance was just being implemented, however, there was a trend 
towards more HRN or PDAC in recent years (‘the learning curve’). Also, when disregard-
ing index cases (detection of the indication for surgery at baseline visit, no statistically 
significant difference over the years was found.  
Our survival analysis confirmed that overall mortality and survival rates strongly depend 
on the stage of disease at diagnosis 23. Importantly, we found that the survival of HRI 
with HRN in their resection specimen was equal to the HRI with no or low-risk neoplastic 
lesions, which emphasizes the need to reliably identify these HRN lesions, more so than 
detecting early cancers. Our study results support the intent and pursuit of pancreatic 
cancer surveillance programs to detect and resect advanced neoplastic lesions before they 
have developed into PDAC.
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The strength of this study is the worldwide pooling of data on PDAC-surveillance programs. 
This yielded a unique and sizeable cohort of HRI participating in PDAC-surveillance pro-
grams in whom either a suspicious lesion was detected for which they underwent surgery, 
or in whom an inoperable pancreatic cancer developed. The main limitations of this study 
are its retrospective design and potential lead-time and length bias 24. Another limita-
tion of this retrospective study is that differences between protocols of screening centers 
worldwide existed, in particular for the period before publication of consensus statements 
of the Cancer of the Pancreas Screening (CAPS) Consortium in 2013 17. Furthermore, even 
though this is the largest cohort ever described, its sample size is still too limited to assess 
differences in survival between R0 and R1 resections. Another limitation of our study due to 
the retrospective design is the lack of detailed information of all 1700 HRI that underwent 
surveillance. We specifically focused our attention and efforts to the high selected group 
of HRI who either developed advanced neoplasia or underwent pancreatic surgery. The aim 
of this particular manuscript was not to assess the overall performance of screening, simply 
because we lack reliable (retrospective) data to do such an analysis and make any claim on 
that regard. We do believe however that with the current manuscript and methodology, 
despite its retrospective nature, we add new, interesting and valuable data to the literature 
that provides some rationale to screening individuals at high risk for pancreatic cancer. 
Furthermore, it provides a foundation to our initiative to initiate a world-wide prospective 
collaborative CAPS-registry to further analyze the merits of screening. 
In conclusion, pooling of worldwide data on HRI in whom PDAC-surveillance led to the 
detection of advanced disease or the detection of a lesion for which pancreatic surgery 
was performed, yielded the following outcomes: 45% of pancreatic resection specimens 
harbored PDAC or HRN; age ≥ 65 at time of surgery, female gender, carriership of a gene 
mutation, and location of a lesion in the head/uncinate region were significantly associ-
ated with the detection of PDAC or HRN in the resection specimen. Importantly, survival 
between HRI with non-malignant or low-risk neoplastic lesions versus HRI with HRN did 
not differ; survival was worse among patients with (advanced) PDAC. While all screen-
ing programs carry the risk of overtreatment, our results suggest that surveillance of HRI 
leads to the treatment of an acceptable mix of lesions. More research is needed to better 
understand the risk factors for individuals at high risk of developing PDAC, and importantly 
to improve selection of HRI for surgery. Collaborating internationally in large worldwide 
prospective studies is of high importance due to the small number of interventions at any 
individual center. 
101
5
ACkNOwLEDGEMENTS
On behalf of the participating centers of the CAncer of the Pancreas Screening (CAPS) 
Consortium (in alphabetical order):
Amsterdam Medical Center (The Netherlands), Beaujon Hospital (France), Columbia 
University Medical Center (USA), Creighton University Hereditary Cancer Center (USA), 
Dana Farber Cancer Institute (USA), Erasmus MC University Medical Center Rotterdam (The 
Netherlands), Icahn School of Medicine at Mount Sinai (USA), Indiana University (USA), 
Institut Paoli-Calmettes (France), Jefferson Medical Center (USA), Johns Hopkins Medical 
Institutions (USA), Mayo Clinic (USA), MD Anderson Cancer Center (USA), Medical Col-
lege of Wisconsin (USA), Karolinska Institute (Sweden), Kyoto University Hospital (Japan), 
Ohio State University (USA), Pancreatic Cancer Action Network (USA), Rambam Healthcare 
Campus (Israel), St. Vincent’s Hospital (Australia), Teikyo University Medical Center (Japan), 
University Hospital of Verona (Italy), University Hospital of Santiago de Compostela (Spain), 
University Hospitals Case Medical Center (USA), University of Alabama (USA), University 
of Arizona (USA), University of California San Diego (USA), University of Colorado Denver 
(USA), University of Michigan (USA), University of Nebraska (USA), University of Pennsyl-
vania (USA), University of Pittsburgh (USA), University of Southern California (USA), Yale 
University (USA), Vita-Salute San Raffaele University (Italy), Washington University (USA)
Chapter 5  |  Detection and outcome of pancreatic cancer surveillance
102
REFERENCES
 1.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016 doi: 10.3322/
caac.21332 [published Online First: 2016/01/09]
 2.  Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the 
unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 
2014;74(11):2913-21. doi: 0008-5472.CAN-14-0155 [pii] 10.1158/0008-5472.CAN-14-0155 
[published Online First: 2014/05/21]
 3.  Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 
1996;23(2):251-75. [published Online First: 1996/04/01]
 4.  Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic 
cancer (FaPaCa): ten years experience. Fam Cancer 2011;10(2):323-30. doi: 10.1007/s10689-
010-9414-x [published Online First: 2011/01/06]
 5.  Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymp-
tomatic high-risk individuals. Gastroenterology 2012;142(4):796-804; quiz e14-5. doi: 
10.1053/j.gastro.2012.01.005 [published Online First: 2012/01/17]
 6.  Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic 
cancer. Gastrointest Endosc 2002;56(4 Suppl):S82-6. [published Online First: 2002/09/26]
 7.  Canto MI, Goggins M, Hruban RH, et al. Screening for Early Pancreatic Neoplasia in High-Risk 
Individuals: A Prospective Controlled Study. Clin Gastroenterol Hepatol 2006;4(6):766-81.
 8.  Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in 
screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 
2009;104(9):2175-81. doi: 10.1038/ajg.2009.276 [published Online First: 2009/06/06]
 9.  Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort 
of high-risk patients: A comprehensive strategy of imaging and genetics. Clin Cancer Res 
2010;16(20):5028-37.
 10.  Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial 
pancreatic cancer families. Am J Gastroenterol 2011;106(5):946-54. doi: ajg201165 [pii] 
10.1038/ajg.2011.65 [published Online First: 2011/04/07]
 11.  Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects 
early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 
2011;140(3):850-6. doi: S0016-5085(10)01738-5 [pii] 10.1053/j.gastro.2010.11.048 [pub-
lished Online First: 2010/12/07]
 12.  Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for Pancreatic Cancer in a High-Risk 
Cohort: An Eight-Year Experience. J Gastrointest Surg 2011 doi: 10.1007/s11605-011-1781-
6 [published Online First: 2011/12/01]
 13.  Potjer TP, Schot I, Langer P, et al. Variation in precursor lesions of pancreatic cancer among 
high-risk groups. Clin Cancer Res 2013;19(2):442-9. doi: 1078-0432.CCR-12-2730 [pii] 
10.1158/1078-0432.CCR-12-2730 [published Online First: 2012/11/23]
 14.  Harinck F, Konings IC, Kluijt I, et al. A multicentre comparative prospective blinded analysis of 
EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 2016;65(9):1505-
13. doi: gutjnl-2014-308008 [pii] 10.1136/gutjnl-2014-308008 [published Online First: 
2015/05/20]
 15.  Vasen H, Ibrahim I, Ponce CG, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk 
Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert 
103
5
Centers. J Clin Oncol 2016;34(17):2010-9. doi: 10.1200/jco.2015.64.0730 [published Online 
First: 2016/04/27]
 16.  Roberts NJ, Norris AL, Petersen GM, et al. Whole Genome Sequencing Defines the Ge-
netic Heterogeneity of Familial Pancreatic Cancer. Cancer discovery 2016;6(2):166-75. doi: 
10.1158/2159-8290.cd-15-0402 [published Online First: 2015/12/15]
 17.  Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) 
Consortium summit on the management of patients with increased risk for familial pancreatic 
cancer. Gut 2013;62(3):339-47. doi: 10.1136/gutjnl-2012-303108 [published Online First: 
2012/11/09]
 18.  Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular 
atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am 
J Surg Pathol 2006;30(9):1067-76. doi: pas.0000213265.84725.0b 00000478-200609000-
00001 [pii] [published Online First: 2006/08/26]
 19.  Toste PA, Kadera BE, Tatishchev SF, et al. Nonfunctional pancreatic neuroendocrine tumors <2 
cm on preoperative imaging are associated with a low incidence of nodal metastasis and an 
excellent overall survival. J Gastrointest Surg 2013;17(12):2105-13. doi: 10.1007/s11605-
013-2360-9 [published Online First: 2013/10/09]
 20.  Fitzgerald TL, Mosquera C, Vora HS, et al. Indications for Surgical Resection in Low-Grade 
Pancreatic Neuroendocrine Tumors. Am Surg 2016;82(8):737-42. [published Online First: 
2016/09/24]
 21.  Choi SH, Park SH, Kim KW, et al. Progression of Unresected Intraductal Papillary Mucinous 
Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis. Clin Gastroen-
terol Hepatol 2017;15(10):1509-20 e4. doi: 10.1016/j.cgh.2017.03.020
 22.  de Pretis N, Mukewar S, Aryal-Khanal A, et al. Pancreatic cysts: Diagnostic accuracy and risk of 
inappropriate resections. Pancreatology 2017;17(2):267-72. doi: 10.1016/j.pan.2017.01.002
 23.  Witkowski ER, Smith JK, Tseng JF. Outcomes following resection of pancreatic cancer. J Surg 
Oncol 2013;107(1):97-103. doi: 10.1002/jso.23267 [published Online First: 2012/09/20]
 24.  Morrison AS. The effects of early treatment, lead time and length bias on the mortal-
ity experienced by cases detected by screening. International journal of epidemiology 
1982;11(3):261-7. [published Online First: 1982/09/01]

PART II
Psychosocial aspects of surveillance 

Chapter 6
Repeated participation in pancreatic cancer 
surveillance by high-risk individuals imposes low 
psychological burden 
Ingrid C.A.W. Konings1, Grace N. Sidharta2, Femme Harinck1, Cora M. Aalfs3, Jan-
Werner Poley1, Jacobien M. Kieffer2, Marianne A. Kuenen2, Ellen M.A. Smets4, 
Anja Wagner5, Jeanin E. van Hooft6, Anja van Rens7, Paul Fockens6, Marco J. 
Bruno1 and Eveline M.A. Bleiker2,7
On behalf of the Dutch research group on pancreatic cancer surveillance in high-risk individuals
1 Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center 
Rotterdam
2 Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, 
Amsterdam
3 Department of Clinical Genetics, Academic Medical Center, Amsterdam
4 Department of Medical Psychology, Academic Medical Center, Amsterdam
5 Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam
6 Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam
7 Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam
Psychooncology, 2016 Aug; 25(8): 971-8
Chapter 6  |  Psychological burden of pancreatic surveillance
108
ABSTRACT
Background  When assessing the feasibility of surveillance for pancreatic cancer (PC), it is 
important to address its psychological burden. The aim of this ongoing study is to evaluate 
the psychological burden of annual pancreatic surveillance for individuals at high risk to 
develop PC.  
Methods  This is a multicenter prospective study. High-risk individuals who undergo annual 
pancreatic surveillance with magnetic resonance imaging (MRI) and endoscopic ultrasound 
(EUS) were invited to complete questionnaires to assess motivations for participating in 
surveillance, experiences with participation, perceived PC risk, topics of concern, and 
psychological distress. Questionnaires were sent after intake for participation (T1), after 
the first MRI and EUS (T2), and after the MRI and EUS 1 (T3), 2 (T4) and 3 years (T5) after 
first surveillance.   
Results  In total, 140 out of 152 individuals returned one or more of the questionnaires 
(response 92%); 477 questionnaires were analyzed. The most frequently reported mo-
tivation for participating in surveillance was the possible early detection of (a precursor 
stage of) cancer (95-100%). Only a minority of respondents experienced MRI and EUS 
as uncomfortable (10% and 11%, respectively) and respondents dreaded their next EUS 
investigation less as surveillance progressed. Respondents’ cancer worries decreased sig-
nificantly over time, and both their anxiety and depression scores remained stable and low 
over the 3-year period of follow-up. 
Conclusions  The psychological burden of pancreatic surveillance is low at all assessments. 
Therefore, from a psychological point of view, participation of high-risk individuals in an 
annual pancreatic surveillance program is feasible. 
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BACkGROUND
Pancreatic cancer (PC) is one of the most fatal human malignancies with a 5-year survival 
of only 5% [1]. Survival rates strongly depend on the stage of PC. Therefore, there is great 
interest in surveillance to detect PC, or more preferably precursor lesions, in an earlier and 
potentially still curable stage. Screening and surveillance of the entire population for PC, 
however, seem infeasible because of the relatively low incidence [2] and the lack of a non-
invasive, reliable and affordable surveillance tool. Nevertheless, surveillance of well-defined 
high-risk groups might be effective. 
Two separate groups of individuals are considered to be at an inherited high risk to develop 
PC: (1) mutation-carriers of PC-prone hereditary syndromes and (2) individuals without a 
known gene mutation but with a strong family history of PC (familial pancreatic cancer 
(FPC)). The risk of developing PC in these high-risk individuals can be increased up to 
75-fold [3-10]. 
Multiple studies on surveillance for PC in high-risk individuals have provided results on the 
efficacy of the detection of precursor lesions and asymptomatic cancers [6, 11-20]. Impor-
tantly, when assessing the successfulness of a surveillance program, one should not only 
focus on clinical results, but also on the psychological aspects of repeated participation in 
such a program; if eligible patients do not start participation or quit prematurely because 
of perceived psychological burden, this program will not be successful.  
Only three studies have assessed the feasibility of PC surveillance from a psychological 
point of view [21-23], with a maximum follow-up of only 12 months. All three conclude 
that participation in surveillance does not lead to increased psychological distress. How-
ever, as surveillance entails long-term participation and repeated exposure to investiga-
tions, longer follow-up studies are required to clarify whether the psychological burden 
remains acceptable as surveillance progresses. The aim of this prospective, sizeable, and 
ongoing multicenter study was therefore to evaluate the long-term psychological burden 
of repeated pancreatic surveillance. 
METHODS
Patients
All participants of an ongoing Dutch PC surveillance study (FPC study) are invited to 
participate in a psychological questionnaire study. The Dutch FPC study is a multicenter 
prospective study investigating the effectiveness of PC surveillance in high-risk individuals. 
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Eligible individuals are: (1) all CDKN2A mutation carriers and all Peutz-Jeghers syndrome 
patients, (2) BRCA 1/BRCA 2 or p53 mutation carriers or Lynch syndrome patients, all 
with at least two family members affected by PC, and (3) all first-degree relatives (FDR) of 
an FPC case. FPC was defined as families affected by PC in at least (1) two FDR, (2) three 
relatives in which the affected cases are FDR or second-degree relatives of each other, or 
(3) two second-degree relatives of whom at least one relative was aged <50 years at the 
time of diagnosis. 
All participants are evaluated and counseled by a clinical geneticist prior to inclusion and 
are informed that the effectiveness of surveillance for PC in reducing morbidity and mortal-
ity is not yet proven. 
Clinical study procedures
The PC surveillance study consists of annual endoscopic ultrasonography (EUS) and mag-
netic resonance imaging (MRI). EUS is performed under conscious (midazolam/fentanyl) or 
propofol sedation. 
Questionnaire study
All participants of the ongoing PC surveillance study are invited to participate in the psy-
chological questionnaire study. Participants receive a first questionnaire on background 
data after having undergone counseling by the clinical geneticist (T0), a second question-
naire after having received the explanation of study procedures by the gastroenterolo-
gist (T1), and thereafter annually after having received their surveillance results (T2 and 
further) (Figure 1). We report the results of a 3-year period here. Participants receive their 
questionnaires 1- 4 weeks after counseling/intake or surveillance results. Because this 
questionnaire-study was added after the first inclusion period of the original clinical study 
protocol, some participants had already had their first investigations and therefore started 
their questionnaires at T2.
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Measurements
Socio-demographic and clinical data: Data were obtained on age, sex, marital status, 
children, level of education, personal and family history of cancer, genetic background, and 
surveillance results, using medical records and questionnaires. 
Motivations for participating in pancreatic cancer surveillance: Participants were 
asked to select their motive(s) from a checklist as used in our previous study [22]; for the 
items on this checklist, see Table 1. 
Attitudes towards and experiences with participation in pancreatic cancer surveil-
lance: A 16-item questionnaire comprising four subscales was used, assessing commu-
nication, reassurance, nervous anticipation and specific perceived advantages [24]. The 
Cronbach’s alpha on internal consistency of the subscales in this study was moderate to 
low (between 0.03 and 0.34), for which we do not have an obvious explanation but 
which led us to the decision of showing the results on item level and not on subscale level 
(see items in Table 2). Experiences with each of the surveillance tests (EUS and MRI) were 
assessed with questions having four response options (i.e., not uncomfortable, slightly 
uncomfortable, rather uncomfortable or very uncomfortable).
Perceived risk: Participants were asked to report their perceived risk of developing PC 
when compared with the risk of an average similar-aged person in the Dutch population 
(lower, equal, slightly elevated, moderately elevated, or strongly elevated risk - item adapted 
from Lerman et al. [25]). They were also asked to scale their perceived risk between 0 and 
100, with and without undergoing annual surveillance.  
Cancer worries: Cancer-related worries were assessed with the eight-item Cancer Worry 
Scale (CWS) [26, 27]. The total score ranges from 8 to 32, with higher scores indicating 
more frequent worries about cancer. The Cronbach’s alpha on internal consistency in this 
study was high (0.85-0.90).  
Anxiety and depression: Generalized anxiety and depression were measured with two 
seven-item subscales of the Hospital Anxiety and Depression Scale (HADS) [28, 29]: HADS-
A and HADS-D. The total score for each subscale ranges from 0 to 21; a score >10 reflects 
a high level of anxiety or depression and is considered clinically significant. The Cronbach’s 
alpha in this study was high on both the anxiety and the depression subscale (0.79-0.88, 
and 0.82-0.87, respectively). 
Topics of concern and need for additional psychosocial support: Participants were 
asked to select the importance of their level of concern on a list of 22 possible topics 
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(not important, slightly important, rather important, or very important). For each of the 
concerns, participants were asked to report their need for professional psychosocial sup-
port (developed by Bleiker and Hahn, unpublished (a copy of the Dutch questionnaire is 
available upon request by emailing the corresponding author)). 
Data analysis
Questionnaires were analyzed using descriptive statistics. Intra-individual changes over time 
were assessed, with mixed-effect models for longitudinal data (growth curve models) hav-
ing a maximum likelihood estimator and unstructured covariance matrix, and with repeated 
measures generalized estimated equations having binomial distribution for ordinal out-
comes. The numbers in the tables of this paper refer to average percentages (proportional 
analyses); the superscript lowercase letters in the tables refer to intra-individual changes 
over time (non-proportional analyses). β, P-values, standard errors (SE), and confidence 
intervals (CI) are shown in Supporting Information Table S1. To correct for multiple testing, 
we only report P-values of <0.01 as statistically significant. For all statistical analyses, the 
Statistical Package for the Social Sciences was used (version 21.0, SPSS Institute, Chicago, 
IL, USA). 
Both the clinical study procedures as well as the questionnaire study were approved by the 
Ethical Review Committees of the participating hospitals. 
RESULTS
Response
Of the 152 individuals who have been participating in the FPC study since its start in 2008, 
140 individuals (92%) returned one or multiple completed questionnaires. In total, 477 
questionnaires have been received and analyzed: 36 (out of 38 sent) T0 questionnaires, 
69 (out of 74 sent) T1 questionnaires, 127 (out of 136 sent) T2 questionnaires, 109 (out 
of 116 sent) T3 questionnaires, 85 (out of 93 sent) T4 questionnaires, and 51 (out of 54 
sent) T5 questionnaires. The mean number of questionnaires returned per respondent was 
3.4 (range 1-6). 
Sociodemographic and clinical data
Patient characteristics of both respondents (n = 140) and non-respondents (n = 12) are 
shown in Table 1; there were no differences.   
In total, 368 clinical surveillance investigations were performed. Seven participants were 
referred to surgery as a result of surveillance. Eight patients (6%) withdrew from the sur-
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Table 1. Patient characteristics 
Ever-respondents 
(returned 
at least one 
questionnaire)
(n = 140)
N (%)
Never-
respondents
(n = 12)
N (%)
P-value
Gender, male 59 (42%) 7 (58%) 0.28
Age at inclusion, mean (range, SD) 51 (19-73, 9.3) 47 (32-65, 10.0) 0.15
Genetic background of individuals
  FPC    
  Syndromic PC
71 (51%)
69 (49%)
4 (33%)
8 (67%) 0.25
Syndromic PC individuals
  CDKN2A mutation carriers
  BRCA 1 mutation carriers
  BRCA 2 mutation carriers
  LKB1 / STK 11 mutation carriers
  p53 mutation carriers
38 (27%)
2 (1%)
19 (14%)
7 (5%)
3 (2%)  
5 (42%)
2 (17%)
1 (8%)
0
0 0.07
Number of relatives with PC, mean (range, SD) 2.3 (0-7, 1.3) 2.9 (0-4, 1.1) 0.12
Marital status
  Married/cohabiting/living apart together 
     relationship
  Single/divorced/widowed
  No data
114 (81%)
15 (11%)
11 (8%) 12 (100%) N/A
Children
  Yes
  No
  No data
122 (87%)
15 (11%)
3 (2%)
7 (58%)
1 (8%)
4 (33%) 1.00
Level of education
  Primary school
  High school
  College / university
  No data
3 (2%)
39 (28%)
96 (69%)
2 (1%) 12 (100%) N/A
Ever treated for any type of cancer 42 (30%) 4 (33%) 0.76
Underwent surveillance with:
  EUS and MRI
  EUS only
  MRI only
135 (96%)
2 (1%)
3 (2%)
12 (100%)
0
0 0.80
Motivations for participating in PC surveillance  
(more than one answer could be checked on the 
checklist)
  Cancer, or a precursor stage, might be 
      detected early and might still be treatable
  I will be contributing to scientific research
  Reduces my fear of cancer
  Gives me a sense of control over my body
  A physician referred me to undergo surveillance
  A family member asked me to undergo surveillance
98%
71%
22%
22%
11%
  9%
N/A N/A
SD, standard deviation, FPC, familial pancreatic cancer; PC, pancreatic cancer; EUS, endoscopic ultrasonogra-
phy; MRI, magnetic resonance imaging; N/A, not applicable
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veillance program: one for financial reasons, one because of the psychological burden of 
repeated participation, and six did not provide a reason. The available questionnaires from 
these individuals were included in our analyses. 
Motivations for participating in pancreatic cancer surveillance
The results of the checklist for motivations for participating in PC surveillance are shown 
in Table 1. The most frequently reported motivations were that cancer might be detected 
early (checked in an average of 98% of all instances) and that by participating, they would 
be contributing to scientific research (71%). 
Attitudes towards and experiences with participation in pancreatic 
cancer surveillance
The results of the 16-item questionnaire assessing attitudes towards surveillance are shown 
in Table 2. For as much as 87% of respondents, the advantages of surveillance outweigh 
the disadvantages, and the majority of respondents (79%) feel reassured after their follow-
up visit. Only a minority of respondents are nervous before their follow-up visit or dread 
the visit (14% and 13%, respectively). Only 8% of respondents perceive the investigations 
as burdensome. Compared with the first assessment of attitudes and experiences (T2), 
respondents felt that they could ask fewer questions during follow-up at T3 (β = -1.29, SE 
0.46, CI -2.47 to -0.10, P = 0.005); that the advantages outweighed the disadvantages less 
at T3 (β = -0.99, SE 0.28, CI -1.71 to -0.27, P <0.001), T4 (β = -0.95, SE 0.34, CI -1.83 to 
-0.08, P = 0.005) and T5 (β = -1.05, SE 0.40, CI -2.09 to -0.01, P = 0.009); and that the 
follow-up visits at T4 (β = -0.82, SE 0.31, CI -1.61 to -0.03, P = 0.007) and T5 (β = -1.07, 
SE 0.33, CI -1.91 to -0.23, P = 0.001) conveyed less sense of security. 
The experiences of respondents with MRI and EUS are summarized in Supporting Informa-
tion Table S2. Both MRI and EUS are experienced as uncomfortable by only the minority 
of respondents (10% and 11%, respectively). Only 3% of respondents dread their first 
MRI versus 34% of respondents dreading their first EUS. However, once experienced, the 
percentage of respondents dreading their next EUS dropped significantly (P <0.001) to the 
same level as that of the MRI (6-9% and 0-8%, respectively). 
Perceived risk
The majority of respondents perceived the risk of their developing PC as elevated when 
compared with the risk of an average similar-aged person: 0-6% reported their perceived 
risk as ‘lower’, 6-22% as ‘equal’, 29-42% as ‘slightly elevated’, 18-31% as ‘moderately 
elevated’, and 19-28% as ‘strongly elevated’. 
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Respondents scaled their risk (scale 0-100) significantly higher when they would not 
undergo annual surveillance (mean 44.3, SD 28.1) than when they would undergo an-
nual surveillance (mean 29.4, SD 24.7, P <0.001) (Supporting Information Table S3). This 
difference in risk perception reflects respondents’ belief that the surveillance program is 
effective in early detection. 
Cancer worries
The mean CWS score of respondents was low at 13.0 (SD 3.6) (Supporting Information 
Table S3). The mean CWS score from baseline (14.4, SD 4.3) decreased significantly by 0.5 
Table 2. Attitudes towards surveillance for pancreatic cancer
% ‘rather’ / ‘very’  
To what extent… T2 
(%)
T3 
(%)
T4 
(%)
T5 
(%)
Average 
(%)
Communication
… do people in the hospital pay attention to what you say? 95 85 88 88 90%
… do the physicians have enough time for you? 67 74 75 75 79%
… can you ask about things at a follow-up visit? 77 72a 71 76 74%
… can you discuss with your doctor matters that are of concern to you 
or about which you worry at a follow-up visit? 
76 65 60 55 66%
Reassurance
… do the advantages of follow-up outweigh the disadvantages? 85 87a 91a 86a 87%
… are you reassured after the follow-up visit? 77 81 82 78 79%
… do the follow-up visits convey a sense of security to you? 63 70 67a 77a 68%
… would you worry more about your disease if there was no follow-up? 66 66 69 71 67%
Nervous anticipation
… are you nervous before a follow-up visit? 16 14 15 8 14%
… do you dread the follow-up visits? 16 13 9 14 13%
… do you sleep worse in the week before your follow-up visit? 11 5 7 4 7%
… do you postpone plans until after the follow-up visit? 4 8 6 2 5%
… would you rather have follow-up visits less often? 5 2 2 8 4%
Perceived disadvantages
… would you prefer, if possible, to have follow-up visits in a hospital 
closer by?
26 19 19 16 21%
… does the follow-up visit remind you each time of your disease, while 
you would rather think less often about it? 
20 15 16 16 17%
… do you experience the investigations at follow-up visits to be 
burdensome?
12 7 5 2 8%
a Significant intra-individual decrease over time (in comparison with first assessment (T2)), non-proportional 
analysis, P <0.01
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point each year (β = -0.53, SE 0.09, CI -0.78 to -0.28, P <0.001), indicating fewer cancer 
worries as surveillance progressed. 
Anxiety and depression
Anxiety and depression levels of respondents were low with a mean HADS-A score of 4.5 
(SD 3.7) and a mean HADS-D score of 2.8 (SD 3.2) (Supporting Information Table S3). Only 
a few respondents showed scores indicative of clinically significant anxiety or depression 
disorder (score >10; 7% and 5%, respectively). No significant intra-individual changes over 
time were noted for either anxiety or depression levels. 
Topics of concern
The results of the questionnaire on possible topics of concern are shown in Table 3. The 
most important concern was that of cancer risk in children and family (rather important or 
very important for 83% of respondents). Moreover, bereavement of family losses (67%) 
scored high on importance of concern. Interestingly, the risk of getting cancer scored lower 
on importance (rather or very important for 46% of respondents). In addition, feelings of 
guilt towards their children or family scored low on importance (for 37% of respondents 
rather or very important). The most frequent topics of concern that respondents would 
like to discuss with a psychosocial worker were ‘consequences of (preventive) resection’, 
‘dealing with cancer’, and ‘cancer-risk in children and family’ (20%, 19%, and 19% of 
respondents, respectively). 
Eleven different topics showed an intra-individual decrease over time (i.e., fewer worries 
about these topics as surveillance progressed): cancer risk in children and family, communi-
cation with the clinician, genetic testing, bereavement of family losses, informing children 
or family, consequences of (preventive) resection, choice of medical treatment, complica-
tions after medical treatment, physical complaints, body image, and sexual functioning. 
However, three topics showed an intra-individual increase over time (i.e., more worries 
on these topics as surveillance progressed): former psychological problems, fear about 
frequent medical checkups, and desire for children. 
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DISCUSSION
This study shows that PC surveillance is well feasible from a psychological point of view, as 
the repeatedly assessed psychological burden of participation in a PC surveillance program 
is low, which is also supported by a low clinical drop-out rate (6%). 
Table 3. Topics of concern and wishes to discuss with a psychosocial worker 
% ‘rather important’ / 
‘very important’  
Topics of concern
T0 
(%)
T1 
(%)
T2 
(%)
T3 
(%)
T4 
(%)
T5 
(%)
Average 
(%)
Wish to 
discuss 
topic
(%)
Cancer risk in children and family 80 83a 83 82a 78 92 83% 19%
Communication with clinician 66 67 74 69a 61a 80 70% 12%
Genetic testing 56 63a 68a 70 67a 80 69% 14%
Bereavement of family losses 65 67 66a 70a 68a 68a 67% 14%
Informing children or family 65 60 73a 67 63a 67a 67% 14%
Consequences of (preventive) resection 70 67 67a 60 64 73a 66% 20%
Choice of medical treatment 71 70 68 62 65a 80 65% 18%
Complications after medical treatment 60 60 62 59a 61 73 62% 18%
Physical complaints (such as pain) 58 63 54 57a 60 62 58% 12%
Fatigue 42 57 52 45 55 60 52% 12%
Relationship problems 52 47 47 48 52 52 49% 10%
Dealing with cancer 50 48 45 51 41 49 47% 19%
Chances of getting cancer 38 59 45 49 43 50 46% 14%
Body image 52 40a 43 44 49 42 45% 8%
Mood swings/depressive feelings 49 37 48 39 43 48 44% 14%
Questions concerning life and death 42 36 45 41 51 40 44% 11%
Consequences for work, study, and social activities 30 31 41 38 49 44 41% 10%
Sexual functioning 50 33 40a 41 41 36 40% 8%
Feelings of guilt towards children or family 44 32 34 42 33 36 37% 12%
Former psychological problems 16 14b 23b 18b 23b 22b 21% 9%
Fear about frequent medical checkups 26 17b 22b 21b 16b 18b 20% 9%
Desire for children 13 7 11b 10b 8b 9b 10% 3%
a Significant intra-individual decrease over time (in comparison with first assessment (T0)), non-proportional 
analysis, P <0.01
b Significant intra-individual increase over time (in comparison with first assessment (T0)), non-proportional 
analysis, P <0.01
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Multiple studies have assessed the clinical effectiveness of surveillance for PC in high-risk 
individuals [6, 11-20]. It is, however, important to also take into account the psychological 
aspects of ongoing participation and repeated investigations because this will have an 
important effect on adherence to surveillance. To date, there are no prospective studies 
with more than 12 months of follow-up assessing the feasibility of PC surveillance from a 
psychological point of view. Hart et al. [23] found that cancer-related distress and worries 
did not increase over the course of 1 year. From our cohort, we previously published the 
results of 69 individuals who completed a one-time questionnaire, concluding that PC 
surveillance by EUS and MRI was feasible from a psychological point of view [22]. Because 
surveillance for PC in high-risk individuals will entail a lifelong program with repetitive 
investigations, it is pivotal to investigate the psychological burden in a prospective design 
with a longer follow-up period. 
In our unique prospective and large cohort of high-risk individuals, we have now acquired 
follow-up data up to 3 years including six assessments pertaining to psychological burden 
with a high overall response rate of 92%. We found that respondents experienced annual 
EUS and MRI investigations as ‘not’ uncomfortable or only ‘slightly’ uncomfortable and 
dread their next EUS investigations less as surveillance progressed while having decreasing 
worries about cancer and having normal and stable levels of anxiety and depression. These 
results are in line with the psychological burden of surveillance for other inherited forms 
of cancer [30-39]. 
A total of 34% of respondents dreaded their first EUS in contrast to only 3% of respon-
dents dreading their first MRI. However, on follow-up questionnaires, the percentage of 
respondents dreading their next EUS dropped significantly to 6-9%, comparable with the 
percentage level of respondents dreading their next MRI (0-8%). This indicates that once 
respondents had experienced EUS, it proved to be very tolerable. This assumption is sup-
ported by our finding that only 11% of respondents experienced EUS as uncomfortable, 
which is comparable with the percentage of respondents experiencing MRI as uncomfort-
able (10%). In this regard, it is important to emphasize that all EUS investigations were 
performed under sedation. 
Interestingly, we found that the individual worries about cancer decreased significantly 
each year. One might have expected an increase in cancer worries due to the reminder 
of their increased risk at follow-up visits. However, only 17% of respondents answered 
‘rather’ or ‘very much’ to the question as to what extent the follow-up visits reminded 
them of their risk of developing PC. Because a high percentage of respondents (79%) are 
reassured after their follow-up visit, this might explain the decrease in their worries about 
developing cancer. Moreover, respondents scaled their risk of developing PC significantly 
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lower when they undergo annual surveillance than when they would not; this might also 
explain the decreasing worries. These are interesting findings because all participants were 
informed that the effectiveness of PC surveillance in reducing morbidity and mortality is 
not yet proven.
Many topics of concern showed an intra-individual change over time. These changes can-
not all readily be explained. The decrease in concerns about genetic testing and informing 
of children or family might be explained by the fact that genetic testing, and therefore 
informing children and family members, was almost always completed after questionnaire 
T0 and that, therefore, as time progressed, fewer and fewer concerns on these topics 
were present. However, the increase in concerns about the desire for children cannot be 
explained and is contra-intuitive to what one might expect because participants are mostly 
beyond child-bearing age.   
In our cohort, we found an average of 7% of respondents having clinically significant 
anxiety scores and an average of 5% with clinically significant depression scores. This 
prevalence of clinically significant scores is low, stable over our 3-year follow-up period, 
and comparable with the scores of the general European population [40].  
A particular strength of this multicenter study is its prospective design with long-term 
follow-up. In addition, a response rate of 92% is very high. Our cohort consists of true 
high-risk individuals for developing PC, based on strict inclusion criteria and extensive 
genetic evaluation prior to inclusion in this study.  
A limitation of our study is that we were only able to send questionnaires to individu-
als actively participating in the surveillance study and not to those who decided against 
participation after counseling by the geneticist. Previously, we reported that only a small 
proportion of high-risk individuals, 14%, declined participation in surveillance [22]; thus, 
we expect that our current data are not severely biased. Another limitation of our study is 
that the majority of the respondents were highly educated and that we therefore cannot 
estimate the psychological burden in a less educated population. A final limitation of this 
study is multiple testing and possible power issues. This was corrected for by only reporting 
P-values <0.01 as statistically significant and showing CIs to facilitate the determination of 
the adequacy of the sample size. 
In conclusion, the psychological burden of repeated investigations in pancreatic surveil-
lance is low with only few respondents experiencing annual MRI and EUS as uncomfort-
able. Few respondents experience worries about cancer, and the mean level of worries 
decreases even further each year of participation. For the vast majority of respondents, 
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the advantages of surveillance outweigh the disadvantages. The percentage of individuals 
with clinical relevant levels of anxiety and depression is low and stable over a 3-year period. 
Therefore, from a psychological point of view, repeated participation of high-risk individu-
als in an annual PC surveillance program is well feasible.
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Supporting Information Table S1. Results of the analyses on intra-individual change over time (as-
sessed with mixed effect models and generalized estimated equations) showing β / estimate, P-values 
and standard errors (SE) per assessed item. 
Assessed items Measurement 
in time
β / 
estimate
Standard 
error
99% 
Confidence 
interval of 
estimate
P-value
ATTITUDES TOWARDS SURVEILLANCE 
FOR PANCREATIC CANCER
Lower Upper
To what extent do people in the 
hospital pay attention to what you 
say?
T2
T3
T4
T5
0
-0.15
-0.07
-0.84
.
0.25
0.30
0.49
.
-0.79
-0.84
-2.12
.
0.50
0.70
0.43
.
0.563
0.823
0.089
To what extent do the physicians 
at follow-up in the hospital have 
enough time for you? 
T2
T3
T4
T5
0
-0.34
-0.39
-0.28
.
0.22
0.30
0.31
.
-0.92
-1.16
-1.09
.
0.23
0.39
0.53
.
0.126
0.199
0.375
To what extent can you ask about 
things at follow-up? 
T2
T3
T4
T5
0
-1.29
-1.06
-1.18
.
0.46
0.54
0.57
.
-2.47
-2.44
-2.65
.
-0.10
0.32
0.29
.
0.005
0.048
0.039
To what extent at follow-up, can you 
discuss with your doctor matters that 
are of concern to you or about which 
you worry? 
T2
T3
T4
T5
0
-0.12
-0.57
-0.34
.
0.30
0.35
0.46
.
-0.90
-1.47
-1.53
.
0.67
0.34
0.86
.
0.705
0.106
0.469
To what extent do the advantages 
of follow-up outweigh the 
disadvantages?
T2
T3
T4
T5
0
-0.99
-0.95
-1.05
.
0.28
0.34
0.40
.
-1.71
-1.83
-2.09
.
-0.27
-0.08
-0.01
.
<0.001
0.005
0.009
To what extent are you reassured 
after the follow-up visit?
T2
T3
T4
T5
0
-0.48
-1.03
-1.60
.
0.32
0.48
0.67
.
-1.29
-2.28
-3.33
.
0.34
0.21
0.13
.
0.132
0.033
0.017
To what extent do the follow-up visits 
convey you a sense of security?
T2
T3
T4
T5
0
-0.61
-0.82
-1.07
.
0.26
0.31
0.33
.
-1.28
-1.61
-1.91
.
0.06
-0.03
-0.23
.
0.020
0.007
0.001
To what extent would you worry 
more about your disease if there was 
no follow-up?
T2
T3
T4
T5
0
0.27
0.23
0.39
.
0.19
0.23
0.28
.
-0.21
-0.35
-0.32
.
0.74
0.82
1.11
.
0.149
0.309
0.156
To what extent are you nervous 
before a follow-up visit?
T2
T3
T4
T5
0
0.74
0.20
-0.55
.
0.49
0.69
0.68
.
-0.53
-1.59
-2.30
.
2.01
1.99
1.21
.
0.135
0.775
0.424
To what extent do you normally 
dread the follow-up visits?
T2
T3
T4
T5
0
0.24
0.45
0.12
.
0.28
0.31
0.39
.
-0.49
-0.35
-0.88
.
0.98
1.25
1.12
.
0.391
0.147
0.761
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Supporting Information Table S1.  (continued) Results of the analyses on intra-individual change 
over time (assessed with mixed effect models and generalized estimated equations) showing β / esti-
mate, P-values and standard errors (SE) per assessed item. 
Assessed items Measurement 
in time
β / 
estimate
Standard 
error
99% 
Confidence 
interval of 
estimate
P-value
To what extent do you sleep worse in 
the week before follow-up?
T2
T3
T4
T5
0
-0.43
0.25
-0.18
.
0.26
0.19
0.38
.
-0.72
-0.25
-1.15
.
0.63
0.75
0.79
.
0.869
0.198
0.633
To what extent do you postpone 
plans till after the follow-up visit?
T2
T3
T4
T5
0
-0.26
-0.17
-0.44
.
0.28
0.31
0.49
.
-0.97
-0.96
-1.70
.
0.46
0.62
0.83
.
0.354
0.585
0.375
To what extent would you rather 
have follow-up visits less frequently?
T2
T3
T4
T5
0
-0.31
-0.25
-0.53
.
0.23
0.28
0.37
.
-0.90
-0.98
-1.48
.
0.29
0.49
0.43
.
0.187
0.386
0.154
To what extent would you prefer, if 
possible, to have follow-up visits in a 
hospital closer by?
T2
T3
T4
T5
0
-0.02
0.07
0.18
.
0.21
0.21
0.27
.
-0.55
-0.46
-0.52
.
0.52
0.60
0.87
.
0.942
0.746
0.511
To what extent does the follow-
up remind you each time of your 
disease, while you would rather think 
less often about it? 
T2
T3
T4
T5
0
-0.92
-0.54
-1.24
.
0.45
0.38
0.64
.
-2.07
-1.53
-2.90
.
0.24
0.45
0.42
.
0.041
0.163
0.054
To what extent do you think 
the investigations at follow-up 
burdensome?
T2
T3
T4
T5
0
-1.16
-1.02
0.39
.
0.77
0.88
0.48
.
-3.13
-3.29
-0.86
.
0.82
1.24
1.64
.
0.131
0.245
0.418
EXPERIENCES OF RESPONDENTS 
WITH ENDOSCOPIC ULTRASOUND 
(EUS) AND MAGNETIC RESONANCE 
IMAGING (MRI)
How uncomfortable was your 
experience with MRI? 
T2
T3
T4
T5
0
-0.70
-0.57
-1.26
.
0.38
0.37
0.76
.
-1.68
-1.52
-3.22
.
0.28
0.38
0.70
.
0.066
0.121
0.098
To what extent do you dread your 
next MRI?
T1
T2
T3
T4
T5
0
0.45
0.06
-0.75
-0.19
.
0.77
0.79
1.01
1.12
.
-1.53
-1.99
-3.36
-3.08
.
2.42
2.10
1.86
2.70
.
0.560
0.945
0.459
0.865
How uncomfortable was your 
experience with EUS? 
T2
T3
T4
T5
0
-0.59
-1.05
-0.34
.
0.31
0.51
0.52
.
-1.38
-2.37
-1.69
.
0.21
0.27
1.02
.
0.059
0.040
0.523
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Supporting Information Table S1.  (continued) Results of the analyses on intra-individual change 
over time (assessed with mixed effect models and generalized estimated equations) showing β / esti-
mate, P-values and standard errors (SE) per assessed item. 
Assessed items Measurement 
in time
β / 
estimate
Standard 
error
99% 
Confidence 
interval of 
estimate
P-value
To what extent do you dread your 
next EUS?
T1
T2
T3
T4
T5
0
-1.37
-1.76
-2.30
-0.54
.
0.40
0.47
0.65
0.41
.
-2.39
-2.98
-3.98
-1.60
.
-0.35
-0.54
-0.63
0.52
.
0.001
<0.001
<0.001
0.192
PERCEIVED RISK
Perceived risk of developing PC 
without surveillance 
T0-T5 0.45 0.72 -1.43 2.33 0.533
Perceived risk of developing PC with 
surveillance 
T0-T5 0.97 0.70 -0.87 2.82 0.170
CANCER WORRY SCALE SCORE
Cancer Worry Scale score T0-T5 -0.53 0.09 -0.78 -0.28 <0.001
HOSPITAL ANXIETY AND DEPRESSION 
SCALE (HADS) SCORE
HADS-anxiety score T0-T5 -0.12 0.10 -0.37 0.14 0.242
HADS-depression score T0-T5 0.04 0.09 -0.19 0.26 0.667
TOPICS OF CONCERN
Cancer risk in children and family T0
T1
T2
T3
T4
T5
0
-2.25
-0.04
-1.38
-0.66
-0.24
.
0.68
0.43
0.41
0.44
0.50
.
-4.00
-1.13
-2.45
-1.78
-1.53
.
-0.50
1.06
-0.32
0.46
1.05
.
0.001
0.935
0.001
0.129
0.633
Communication with clinician T0
T1
T2
T3
T4
T5
0
-0.35
0.51
-1.51
-1.90
1.36
.
0.43
0.43
0.38
0.42
0.61
.
-1.46
-0.59
-2.50
-2.98
-0.20
.
0.76
1.61
-0.51
-0.82
2.92
.
0.415
0.233
<0.001
<0.001
0.025
Genetic testing T0
T1
T2
T3
T4
T5
0
-1.33
-1.89
0.08
-2.30
0.29
.
0.34
0.34
0.30
0.38
0.40
.
-2.21
-2.75
-0.69
-3.29
-0.75
.
-0.45
-1.02
0.85
-1.31
1.33
.
<0.001
<0.001
0.787
<0.001
0.470
Bereavement of family losses T0
T1
T2
T3
T4
T5
0
-0.12
-1.05
-1.29
-0.90
-3.18
.
0.19
0.30
0.31
0.33
0.59
.
-0.61
-1.83
-2.09
-1.75
-4.70
.
0.37
-0.26
-0.49
-0.05
-1.65
.
0.536
0.001
<0.001
0.006
<0.001
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Supporting Information Table S1.  (continued) Results of the analyses on intra-individual change 
over time (assessed with mixed effect models and generalized estimated equations) showing β / esti-
mate, P-values and standard errors (SE) per assessed item. 
Assessed items Measurement 
in time
β / 
estimate
Standard 
error
99% 
Confidence 
interval of 
estimate
P-value
Informing children or family members T0
T1
T2
T3
T4
T5
0
-0.06
-2.92
-0.01
-3.33
-2.45
.
0.39
0.42
0.35
0.54
0.49
.
-1.07
-4.01
-0.92
-4.71
-3.71
.
0.95
-1.84
0.89
-1.95
-1.19
.
0.873
<0.001
0.967
<0.001
<0.001
Consequences of (preventive) 
resection
T0
T1
T2
T3
T4
T5
0
0.10
-2.33
-0.32
0.21
-2.46
.
0.52
0.37
0.34
0.33
0.45
.
-1.24
-3.29
-1.20
-0.64
-3.63
.
1.43
-1.38
0.56
1.06
-1.30
.
0.850
<0.001
0.352
0.523
<0.001
Choice of medical treatment T0
T1
T2
T3
T4
T5
0
-1.02
-0.87
-0.63
-2.30
-0.66
.
0.43
0.37
0.36
0.41
0.43
.
-2.12
-1.83
-1.56
-3.35
-1.78
.
0.08
0.09
0.29
-1.26
0.46
.
0.017
0.020
0.076
<0.001
0.127
Complications after medical 
treatment
T0
T1
T2
T3
T4
T5
0
-0.26
-0.67
-1.92
0.04
-0.77
.
0.39
0.33
0.38
0.33
0.41
.
-1.28
-1.53
-2.89
-0.81
-1.82
.
0.76
0.19
-0.94
0.89
0.27
.
0.510
0.044
<0.001
0.901
0.056
Physical complaints (such as pain) T0
T1
T2
T3
T4
T5
0
-0.15
0.49
-1.78
0.31
-0.47
.
0.40
0.34
0.44
0.35
0.41
.
-1.18
-0.39
-2.89
-0.59
-1.52
.
0.88
1.36
-0.65
1.20
0.59
.
0.714
0.152
<0.001
0.377
0.251
Fatigue T0
T1
T2
T3
T4
T5
0
-0.22
-0.11
-0.37
-0.25
-0.11
.
0.46
0.37
0.36
0.38
0.42
.
-1.40
-1.06
-1.31
-1.24
-1.19
.
0.96
0.83
0.57
0.74
0.97
.
0.626
0.757
0.313
0.510
0.797
Relationship problems T0
T1
T2
T3
T4
T5
0
-0.67
-0.38
0.01
-0.63
-0.70
.
0.39
0.28
0.25
0.27
0.34
.
-1.68
-1.10
-0.64
-1.31
-1.58
.
0.34
0.34
0.66
0.06
0.19
.
0.088
0.173
0.960
0.019
0.043
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Supporting Information Table S1.  (continued) Results of the analyses on intra-individual change 
over time (assessed with mixed effect models and generalized estimated equations) showing β / esti-
mate, P-values and standard errors (SE) per assessed item. 
Assessed items Measurement 
in time
β / 
estimate
Standard 
error
99% 
Confidence 
interval of 
estimate
P-value
Dealing with cancer T0
T1
T2
T3
T4
T5
0
0.45
-0.30
0.30
0.16
-0.12
.
0.44
0.29
0.33
0.29
0.37
.
-0.67
-1.03
-0.57
-0.60
-1.06
.
1.57
0.44
1.16
0.92
0.83
.
0.303
0.302
0.378
0.580
0.754
Chance on getting cancer (again) T0
T1
T2
T3
T4
T5
0
-0.19
0.32
0.60
-0.11
0.46
.
0.45
0.33
0.36
0.37
0.38
.
-1.35
-0.54
-0.31
-1.06
-0.50
.
0.96
1.18
1.51
0.84
1.43
.
0.666
0.334
0.089
0.772
0.217
Body image T0
T1
T2
T3
T4
T5
0
-2.48
0.26
-0.61
-0.48
0.05
.
0.57
0.34
0.30
0.36
0.36
.
-3.94
-0.63
-1.38
-1.40
-0.88
.
-1.02
1.14
0.15
0.44
0.97
.
<0.001
0.459
0.039
0.182
0.892
Mood swings / depressive feelings T0
T1
T2
T3
T4
T5
0
0.25
0.31
0.66
0.21
-0.16
.
0.46
0.36
0.36
0.37
0.40
.
-0.93
-0.62
-0.26
-0.75
-1.20
.
1.43
1.24
1.58
1.17
0.89
.
0.583
0.387
0.063
0.567
0.697
Questions concerning life and death T0
T1
T2
T3
T4
T5
0
-0.65
-0.13
0.10
0.17
-0.51
.
0.50
0.39
0.40
0.39
0.44
.
-1.95
-1.12
-0.92
-0.84
-1.64
.
0.65
0.86
1.13
1.18
0.63
.
0.198
0.732
0.797
0.671
0.247
Consequences for work, study, social 
activities
T0
T1
T2
T3
T4
T5
0
0.25
0.46
0.75
0.99
0.36
.
0.48
0.37
0.38
0.39
0.46
.
-0.99
-0.50
-0.23
-0.02
-0.82
.
1.49
1.43
1.72
1.99
1.53
.
0.607
0.215
0.048
0.011
0.436
Sexual functioning T0
T1
T2
T3
T4
T5
0
0.39
-0.97
-0.49
-0.31
-0.91
.
0.46
0.34
0.34
0.36
0.43
.
-0.80
-1.86
-1.65
-1.22
-2.03
.
1.57
-0.08
0.38
0.61
0.21
.
0.401
0.005
0.148
0.387
0.036
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Supporting Information Table S1.  (continued) Results of the analyses on intra-individual change 
over time (assessed with mixed effect models and generalized estimated equations) showing β / esti-
mate, P-values and standard errors (SE) per assessed item. 
Assessed items Measurement 
in time
β / 
estimate
Standard 
error
99% 
Confidence 
interval of 
estimate
P-value
Feelings of guilt towards children or 
family
T0
T1
T2
T3
T4
T5
0
1.00
-0.58
-0.49
-0.53
1.21
.
0.68
0.40
0.38
0.39
0.49
.
-0.75
-1.60
-1.46
-1.53
-0.06
.
2.75
0.44
0.48
0.47
2.47
.
0.141
0.143
0.195
0.174
0.014
Former psychological problems T0
T1
T2
T3
T4
T5
0
1.80
2.00
2.73
1.82
2.55
.
0.43
0.41
0.45
0.42
0.50
.
0.68
0.94
1.59
0.74
1.26
.
2.91
3.06
3.88
2.90
3.84
.
<0.001
<0.001
<0.001
<0.001
<0.001
Fear about frequent medical 
checkups
T0
T1
T2
T3
T4
T5
0
1.19
1.60
-1.39
1.30
2.06
.
0.46
0.38
0.45
0.38
0.45
.
0.01
0.61
-2.54
0.32
0.91
.
2.37
2.58
-0.24
2.29
3.22
.
0.009
<0.001
0.002
0.001
<0.001
Desire for children T0
T1
T2
T3
T4
T5
0
0.21
2.63
1.36
2.39
2.28
.
0.63
0.50
0.49
0.52
0.55
.
-1.42
1.34
0.10
1.04
0.87
.
1.84
3.93
2.62
3.73
3.69
.
0.738
<0.001
0.006
<0.001
<0.001
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Supporting Information Table S2. Experiences of respondents with endoscopic ultrasound (EUS) and 
magnetic resonance imaging (MRI)
% ‘rather’ / ‘very’
MRI
T1* 
(%)
T2 
(%)
T3 
(%)
T4 
(%)
T5 
(%)
Average 
(%)
How uncomfortable was your experience with MRI? - 14 8 10 6 10%
To what extent do you dread your next MRI? 3 8 5 2 0 4%
EUS 
How uncomfortable was your experience with EUS? - 14 8 7 13 11%
To what extent do you dread your next EUS? 34 9a 7a 5a 6 11%
* T1 questionnaire was send prior to first surveillance investigations but after explanation of study procedures 
by a gastroenterologist
a Significant intra-individual decrease over time (in comparison with first assessment (T1/T2)), non-proportional 
analysis, P <0.01
Supporting Information Table S3. Perceived risk, cancer-related worries, anxiety and depression scores 
T0 T1 T2 T3 T4 T5 Average
Perceived risk of developing PC without surveillance, 
mean (scale 0-100)
34 46 46 42 46 47 44.3
Perceived risk of developing PC with surveillance, 
mean (scale 0-100)
24 28 32 26 32 33 29.4
Cancer Worry Scale score, mean (scale 8-32) 14.4 14.0 13.3 12.4 12.5 12.1 13.0a
HADS-A score, mean (scale 0-21) 5.3 4.6 4.3 4.3 4.4 4.5 4.5
HADS-A score categories:
- Normal level of anxiety (score <8, %)
- Elevated distress (score 8-10, %)
- Significant distress (score >10, %)
69
14
17
81
13
6
84
9
7
75
19
6
80
14
6
78
12
10
79%
14%
7%
HADS-D score, mean (scale 0-21) 2.5 2.4 2.6 2.9 3.2 2.8 2.8
HADS-D score categories:
- Normal level of anxiety (score <8, %)
- Elevated distress (score 8-10, %)
- Significant distress (score >10, %)
91
3
6
90
6
4
93
4
3
92
4
4
87
6
7
90
6
4
91%
5%
5%
a Significant intra-individual decrease over time (in comparison with first assessment (T0)), non-proportional 
analysis, P <0.01
PC, pancreatic cancer; HADS-A, Hospital Anxiety and Depression Scale, 7-item subscale for anxiety; HADS-D, 
Hospital Anxiety and Depression Scale, 7-item subscale for depression
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ABSTRACT
Objectives  It is important to adequately and timely identify individuals with cancer worries 
amongst participants in a pancreatic ductal adenocarcinoma (PDAC) surveillance program, 
because they could benefit from psychosocial support to decrease distress. Therefore, the 
aim of this study was to assess both psychosocial and clinical factors associated with cancer 
worries. 
Methods  High-risk individuals participating in PDAC-surveillance were invited to annually 
complete a cancer worry scale (CWS) questionnaire which was sent after counseling by the 
clinical geneticist (T0), after intake for participation in PDAC-surveillance (T1), and then 
annually after every MRI and endoscopic ultrasonography (EUS) (T2 and further). Analyses 
were performed to identify factors associated with cancer worries in the second year of 
surveillance (T3). 
Results  We found a significant intra-individual decrease in cancer worries (β = -0.84, 
P <0.001), nevertheless, 33% of individuals had a CWS-score ≥14 at T3. We found one 
factor significantly associated with cancer worries at T3: having a family member affected 
by PDAC <50 years of age (β = 0.22, P = 0.03). The detection of a cystic lesion, a shortened 
surveillance interval, or undergoing pancreatic surgery did not lead to more cancer worries 
(P = 0.163, P = 0.33, and P = 0.53, respectively). 
Conclusions  In conclusion, this study identified ‘a family history of PDAC <50 years of 
age’ as the only predictor of cancer worries experienced after 2 years of surveillance in 
individuals at high risk of developing PDAC. This knowledge could help clinicians to timely 
identify individuals ‘at risk’ for high levels of cancer worries who would likely benefit from 
psychosocial support.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease: despite its relatively low inci-
dence of 10-12 new cases per 100,000 persons per year [1-3], PDAC is ranked among the 
top five causes of cancer-related deaths [4, 5]. Its 5-year survival rate has not significantly 
improved over the past decades and is less than 6% [4, 5]. Since survival rates strongly 
depend on the stage of PDAC when detected, there is globally an increasing interest in 
surveillance to detect PDAC or its precursor high-grade dysplastic lesions at an early stage. 
Although screening of the entire population for PDAC is unlikely to be feasible because 
of the lack of a non-invasive, reliable and affordable surveillance tool, surveillance of well-
defined high-risk groups for PDAC might be effective. 
Two specific groups of individuals are considered to be at high risk of developing PDAC: (1) 
mutation carriers of hereditary syndromes that increase the risk of developing PDAC (i.e. 
carriers of mutations in the CDKN2A, BRCA1, BRCA2 or TP53 gene, and individuals with 
Peutz-Jeghers or Lynch syndrome), and (2) individuals without a known gene mutation 
but who have a strong family history of PDAC (familial pancreatic cancer (FPC)). In these 
individuals, the risk of developing PDAC can be up to 75-fold higher than in the general 
population [6-13]. 
Over the past decades, multiple studies into the effectiveness of surveillance for PDAC in 
high-risk individuals have been performed [14-25]. Importantly, however, when assessing 
the effectiveness of a surveillance program, one should also take into account the psy-
chological aspects of repeated participation in such a surveillance program. We previously 
reported that repeated participation in annual surveillance imposed low psychological 
burden on individuals at high risk for PDAC. However, we did find that a third of the 
participants had moderate to high cancer worries [26]. 
As individuals with high levels of cancer worries might benefit from psychosocial support 
to decrease the levels of psychological distress, it could be essential to adequately and 
timely identify these individuals. Therefore, the aim of this study was (1) to evaluate the 
course of cancer worries over a 2-year period of PDAC-surveillance, (2) to identify psycho-
social factors associated with cancer worries, and (3) to assess the impact of pancreatic 
cystic lesion detection, a recommended shortened surveillance interval, and undergoing 
pancreatic surgery on cancer worries in high-risk individuals participating in annual PDAC-
surveillance. 
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METHODS
Participants
All participants of an ongoing Dutch pancreatic cancer surveillance study (FPC-study) were 
invited to participate in a psychological questionnaire study as previously described [26]. 
The FPC-study is an ongoing multicenter prospective study investigating the effectiveness 
of PDAC-surveillance in high-risk individuals. Eligible for inclusion in this study are asymp-
tomatic individuals with an estimated familial or hereditary life-time risk of developing 
PDAC ≥ 10% (see inclusion criteria in Table 1). The minimal age for inclusion between 
2008 and 2013 was 45 years of age (or 30 years in case of Peutz-Jeghers syndrome) or 10 
years younger than the age of the youngest relative with PDAC, whichever age occurred 
first. Since 2013, the minimal age for inclusion is 50 years or 10 years younger than the age 
of the youngest relative with PDAC. Surveillance ends at the age of 75. All potential can-
didates are evaluated by a clinical geneticist prior to inclusion. They are informed that the 
effectiveness of PDAC surveillance in reducing morbidity and mortality is not yet proven. 
Clinical study procedures
The clinical study procedures were previously extensively described [25]. In summary, an-
nual surveillance of the pancreas is performed using endoscopic ultrasonography (EUS), 
carried out by experienced endosonographers, and magnetic resonance imaging (MRI) with 
intravenous administration of gadobutrol. EUS is performed under conscious (midazolam/
fentanyl) or propofol sedation. Some participants undergo surveillance with only MRI or 
EUS (see Table 2) due to contra-indications for either modality (for example claustrophobia, 
pacemaker or discomfort during initial EUS). Follow-up policy is based on the agreement of 
Table 1. Inclusion criteria for the pancreatic cancer surveillance study 
Carriers of CDKN2A gene mutations, regardless of the family history of PDAC
Peutz-Jeghers syndrome patients (diagnosis based on a proven LKB1/STK11 gene mutation or 
clinical signs), regardless of the family history of PDAC
Carriers of gene mutations in BRCA1, BRCA2, TP53, or Mismatch Repair genes with a family history 
of PDAC in ≥ 2 family members
Individuals with ≥ 2 relatives affected by pancreatic cancer who were related in the first degree to 
each other, of which at least one was related in the first-degree to the eligible individual
Individuals with ≥ 3 relatives affected by pancreatic cancer who were related in the first or 
second degree to each other, of which at least one was related in the first-degree to the eligible 
individual
Individuals with ≥ 2 relatives affected by pancreatic cancer who were related in the second degree 
to each other, of which at least one was related in the first-degree to the eligible individual and at 
least one was aged under 50 years at time of diagnosis
PDAC, pancreatic ductal adenocarcinoma
135
7
an expert panel consisting of endosonographists, surgeons, radiologists and pathologists 
and is as follows:
1. Annual surveillance when either no pancreatic abnormalities or cystic lesions < 10 mm 
are detected; 
2. Interval surveillance after 6 months when a novel cystic lesion is detected with a diameter 
of 10-30 mm without worrisome features;
3. Interval surveillance after 3 months when a lesion of unknown significance is detected for 
which there is no unanimous opinion amongst members of the expert panel; 
4. Surgical resection in case of 1. a solid lesion which is considered suspicious for malig-
nancy, 2. a cystic lesion ≥ 30 mm, 3. a cystic lesion with worrisome features (thickened/
enhanced cyst wall and/or mural nodules), or 4. a main branch intraductal papillary 
mucinous neoplasm (IPMN, main pancreatic duct ≥ 10 mm). 
Questionnaire study
All participants of the ongoing PDAC-surveillance study are invited to participate in the 
ongoing prospective multicenter psychological questionnaire study. Participants receive 
a first questionnaire on sociodemographic data after their counseling session with the 
clinical geneticist (T0), a second questionnaire after explanation of the study procedures by 
the gastroenterologist (T1), and then annually after receiving their surveillance results (T2 
and further), see also Figure 1. Because this questionnaire study was added after the first 
inclusion period of the original clinical study protocol, some participants had already had 
their first investigations and therefore started their questionnaires at T2. 
All measurements used in the questionnaires were previously described [26]. We report 
here the results of the cancer-related worries as assessed with the eight-item cancer worry 
scale (CWS) [27, 28]. The items of the CWS are shown in Table 3. The total CWS-score 
ranges from 8 to 32, with higher scores indicating more frequent worries about cancer. 
Figure 1. Overview of both the clinical part of the pancreatic cancer surveillance study and the timing of the 
psychological questionnaires. 
MRI, magnetic resonance imaging; EUS, endoscopic ultrasonography
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There is no clear cut-off point for the CWS-score, nevertheless, a score ≥ 14 could be in-
dicative of moderate to high levels of cancer worries [29]. The Cronbach’s alpha, a measure 
of internal consistency with values > 0.70 being considered acceptable, was high for the 
CWS in the current sample at T3 (0.86, n = 121).  
The Ethical Committee of all participating centers approved the study protocol and the 
study was conducted in accordance with the declaration of Helsinki. All participants gave 
written informed consent prior to the performance of any study-related investigations. 
Statistical analyses
Questionnaires were analyzed using descriptive statistics. Intra-individual change in cancer 
worries over time was assessed with a mixed-effect model (growth curve model) with a 
maximum likelihood estimator and unstructured covariance matrix. Univariate and multi-
variate regression analyses were performed to identify sociodemographic factors from the 
questionnaires T0, T1 and/or T2 that were associated with cancer worries at the second 
year of follow-up (T3). For these analyses, we selected all participants who returned the 
T3 questionnaire as well as at least a T0, T1 or T2 questionnaire. To analyze the impact on 
cancer worries of the detection of a pancreatic cystic lesion, a recommended shortened 
surveillance interval, and undergoing pancreatic surgery, we selected all participants who 
returned the questionnaire in the year of the event (i.e. the detection of a cyst and/or 
an advised shortened surveillance interval and/or undergoing pancreatic surgery; the 
questionnaire was sent after participants had received their surveillance results) and who 
returned the questionnaire 1 year before and/or 1 year after the event. A paired-samples 
T test was performed for these analyses. In all analyses, a P-value < 0.05 was considered 
statistically significant. All analyses were conducted using the Statistical Package for the 
Social Sciences (version 21, SPSS Institute, Chicago, IL). 
RESULTS
Participants’ characteristics
In March 2015, 166 individuals participated in the questionnaire study. Baseline charac-
teristics of all individuals are summarized in Table 2. Mean age of all 166 participants at 
inclusion in the clinical study was 51 years, of whom 47 (28%) were treated for cancer 
(predominantly for melanoma or breast cancer) prior to inclusion in the study. 
Cancer worries
The scores per item on the CWS-questionnaires are shown in Table 3. The mean CWS-score 
was 14 at T0, 14 at T1, 13 at T2, and 12 at T3; the overall average CWS-score was 13. 
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We found a significant intra-individual decrease in the CWS-score over time (β = -0.84, P 
<0.001). Thirty-nine individuals (33%) had a CWS-score ≥ 14 in the second year of follow-
up (T3), this was 51%, 52% and 43% at T0, T1 and T2, respectively. 
Factors associated with cancer worries at the second year of follow-up 
For these sub-analyses, we only included individuals with a T3 assessment, as well as at 
least a T0, T1 or T2 assessment. Of the 166 individuals that participated in the question-
naire study, 117 individuals returned the T3 questionnaire as well as at least a T0, T1 
and/or T2 questionnaire (response 70%). Baseline characteristics for these 117 individuals 
selected for sub-analyses, and for the 49 individuals without the required questionnaires, 
are summarized in Table 2. The subgroup of 117 individuals only differed in comparison to 
the excluded individuals (n = 49) on having children (89% of the included individuals had 
children vs. 65% of excluded individuals, P = 0.04).
Table 3. Scores on the CWS-questionnaire, shown per item per questionnaire
Item 
During the last 7 days:
T0
n = 36
% often/
always 
worried
T1
n = 80
% often/
always 
worried
T2
n = 148
% often/
always 
worried
T3
n = 121
% often/
always 
worried
Average 
(on T0 
to T3)
% often/
always 
worried
How often have you thought about your 
chances of getting cancer (again)?
19 13 10 5 10
Have these thoughts affected your 
mood?
11 5 2 4 4
Have these thoughts interfered with 
your ability to do daily activities?
0 4 1 1 1
How concerned are you about the 
possibility of getting cancer one day?
33 26 26 19 25
How often do you worry about 
developing cancer?
25 11 13 7 12
How much of a problem is this worry? 11 6 5 3 5
How often do you worry about the 
chance of family members developing 
cancer?
28 25 20 12 20
How concerned are you about the 
possibility that you will ever need 
surgery (again)?
14 13 8 5 9
Mean CWS-score (range, SD)
14.4 
(8-26, 4.3)
13.9 
(8-26, 3.8)
13.3 
(8-25, 3.4)
12.2 
(8-25, 3.3)
13.2*
(8-26, 3.6)
* significant (β = -0.84, P <0.001) intra-individual decrease over time (in comparison with first assessment (T0)), 
non-proportional analysis. 
CWS, cancer worry scale; SD, standard deviation
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For the selection of possible predictors of cancer worries in the second year of follow-up 
(T3), we performed univariate regression analyses. Significant predictors were ‘having a 
family member affected by PDAC below the age of 50’ (β = 0.23, P = 0.01), and ‘a 
perceived elevated risk of developing PDAC’ (β = 0.23, P = 0.01). Not predictive were, 
amongst other factors, the number of PDAC-cases in the family and a personal history of 
cancer, see also Table 4. In the next step, the two significant predictors were included in the 
multivariate model, together with age, gender and genetic background. In this multivariate 
analysis (see Table 4), having a family member affected by PDAC below the age of 50 was 
associated with cancer worries in the second year of follow-up (β = 0.22, P = 0.03). Figure 
2 shows the mean CWS-score per questionnaire for all individuals and for individuals with 
and without a family member affected by PDAC <50 years of age. 
Table 4. Univariate and multivariate analysis for factors possibly associated with cancer worries in the 
second year of follow-up (T3)
Factors
N (%) / mean 
(range, SD)
Univariate 
analyses
Multivariate 
analysis
β P-value β P-value
Age at inclusion, mean (range, SD) 51 (19-73, 9.5) -0.142 0.126 0.010 0.924
Female gender 67 (57%) 0.140 0.133 0.119 0.215
Carriership of a gene mutation 57 (49%) 0.172 0.063 0.133 0.183
Number of PDAC cases in the family, mean 
(range, SD)
2 (0-7, 1.2) 0.058 0.538
Having a family member affected by PDAC 
<50 years of age
45 (39%) 0.234 0.016 0.218 0.031
Having children 104 (89%) 0.033 0.723
Being in a relationship 98 (84%) -0.046 0.635
Education at college/university-level 85 (73%) -0.001 0.995
Current or past smoker 50 (43%) 0.140 0.143
Current or past alcohol consumer 81 (69%) -0.031 0.744
Personal history of any type of cancer 35 (30%) 0.048 0.610
Body Mass Index, mean (range, SD) 25.8 (10.0-43.8, 4.6) 0.085 0.233
Perception of moderately to strongly 
elevated risk of developing PDAC 
69 (59%) 0.228 0.013 0.163 0.109
Previous psychological support 17 (15%) 0.181 0.053
Having someone available to confide in 111 (95%) -0.077 0.407
SD, standard deviation; PDAC, pancreatic ductal adenocarcinoma
Bold P-values are considered statistically significant
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Impact of the detection of a pancreatic cystic lesion on cancer worries
In 93 out of all the 166 participants (56%), a pancreatic cystic lesion was detected during 
surveillance. Forty of these 93 individuals (43%) returned the questionnaire the year prior 
to the detection of the cystic lesion (mean CWS-score 13.3, standard deviation (SD) 3.6), 
as well as the questionnaire in the year of the detection of the lesion (mean CWS-score 
12.5, SD 3.7). The difference in mean CWS-score was not statistically significant (95% 
CI for the difference -0.3 to 1.9, P = 0.163). A total of 45 individuals (48%) returned 
the questionnaire in the year of detection (mean CWS-score 11.9, SD 3.5) as well as the 
questionnaire 1 year after detection (mean CWS-score 11.9, SD 3.4). Again, the difference 
in mean CWS-score between the 2 years was not statistically significant (95% CI for the 
difference -1.1 to 1.1, P = 0.97).
Impact of a recommended shortened surveillance interval on cancer 
worries
For 25 out of 166 individuals (15%), a shortened surveillance interval was recommended; 
for 16 individuals an interval of 3 months and for nine individuals an interval of 6 months. 
Six of these 25 individuals (24%) returned the questionnaire in the year prior to the short-
ened surveillance interval (mean CWS-score 14.3, SD 3.8), as well as in the year of the 
shortened surveillance interval (mean CWS-score 15.5, SD 4.7). The difference in mean 
CWS-score of 1.2 points was not significant (95% CI for the difference -3.9 to 1.6, P 
= 0.33). Nine individuals (36%) returned the questionnaire in the year of the shortened 
Figure 2. Mean CWS-scores at different moments in time, shown for all individuals and for individuals 
with and without a family member that was affected by pancreatic cancer under 50 years of age
T0 T1 T2 T3
11
12
13
14
15
16
17
18
All individuals
Individuals with a family member affected by
PDAC <50 years of age
Individuals without a family member affected
by PDAC <50 years of age
Questionnaires
M
ea
n 
CW
S-
sc
or
e
CWS, cancer worry scale; PDAC, pancreatic ductal adenocarcinoma
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surveillance interval (mean CWS-score 14.4, SD 5.2), as well as in the year after (mean 
CWS-score 12.2, SD 4.5). This decrease in mean CWS-score by 2.2 points was also not 
statistically significant (95% CI for the difference -1.0 to 5.4, P = 0.15).
Impact of pancreatic surgery on cancer worries
In 7 out of 166 individuals (4%), pancreatic surgery was performed. Two of these individu-
als returned both the questionnaire from the year prior to surgery (mean CWS-score 10.5, 
SD 3.5), as well as the post-operative questionnaire in the year of surgery (mean CWS-
score 11.0, SD 0.0). The difference in mean CWS-score was not statistically significant (P = 
0.87). Four cases returned both the questionnaire in the year of surgery (mean CWS-score 
14.0, SD 3.5), as well as the questionnaire in the year after surgery (mean CWS-score 11.8, 
SD 3.9). This decrease in score by 2.2 points was not statistically significant (95% CI for the 
difference -7.9 to 12.4, P = 0.53). 
DISCUSSION
In this prospective multicenter study, we assessed the course of cancer worries over a 
2-year period in high-risk individuals participating in annual PDAC-surveillance, assessed 
demographic baseline and psychosocial factors that could be associated with these cancer 
worries, as well as the impact of three clinical events on cancer worries. Independently as-
sociated with cancer worries in the second year of follow-up was having a family member 
that was affected by PDAC below the age of 50.
Because PDAC-surveillance is being performed more and more worldwide, it is key to take 
into account the psychological aspects of repeated participation. Although we previously 
reported a low general psychological burden of annual participation in PDAC-surveillance 
[26], 33% of participants did have cancer-specific worries with a CWS-score ≥ 14. While 
this is not a rigorously tested cut-off point and there are no norm-data on cancer worries 
in the general population, a score ≥ 14 is considered to be indicative of moderate to high 
cancer worries [29]. It is important to adequately and timely identify these individuals with 
cancer worries, because they would likely benefit from psychosocial support to decrease or 
prevent psychological distress. Psychosocial interventions, varying from psycho-education 
and mindfulness-training to cognitive behavioral therapy, have been proven to be effective 
in reducing levels of distress to such levels that patients can perform their daily activities. 
Therefore, this study focused on cancer worries during PDAC-surveillance, more specifi-
cally on the course of cancer worries over time, on predictors of cancer worries, and on 
cancer worries during certain events. To our current knowledge, this is the first study 
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with a prospective design assessing these characteristics of cancer worries in individuals 
at inherited or familial high risk of developing PDAC over time. Although much research 
was done into generalized distress and levels of cancer worries, factors influencing cancer 
worries were hardly studied in populations at inherited high risk of developing other types 
of cancer [28, 30-34]. Sociodemographic and clinical variables found to be significantly as-
sociated with cancer-specific distress for familial adenomatous polyposis (FAP) were lower 
educational level, female gender, diagnosis of FAP (as opposed to being at risk for FAP or 
being a non-carrier), having a personal history of cancer, and having had surgery more 
than 10 years ago [28]. In individuals with Lynch syndrome, however, no difference for age, 
gender, level of education, actual or perceived risk of Lynch syndrome, or a personal history 
of cancer was found [30]. In a Von Hippel-Lindau (VHL) population, factors associated 
with VHL-related worries were diagnosis of, or treatment for, VHL, a high level of social 
constraint, a high perceived risk of developing tumors, and the loss of a close relative due 
to VHL during adolescence [31]. 
As in our previous study [26], individual cancer worries decreased over the 2-year period 
of surveillance in high-risk individuals for PDAC. We identified a perceived elevated risk of 
developing PDAC and having a family member that was affected by PDAC under 50 years 
of age as factors associated with cancer worries in the second year of follow-up, the latter 
being independently associated. Both factors resemble the findings by Lammens et al. [31], 
who described a high perceived risk of developing tumors and the loss of a close relative 
during adolescence as related to cancer-specific worries. 
Surprisingly, a factor not associated with high cancer worries, was a personal history of 
cancer. This factor was previously described as associated with high cancer worries [28], 
and one might expect individuals who already had cancer in the past to be more anxious of 
developing cancer again, especially when being at high risk of this. Educational level was 
also not associated with high cancer worries at the second year of follow-up, in contrast to 
a previous study in FAP-individuals [28].  
We also assessed three clinical events for association with increased cancer worries: the de-
tection of a cystic lesion, a recommended shortened surveillance interval, and undergoing 
pancreatic surgery. For all three events, we did not find a significant change in CWS-score 
for the year prior to the event and/or the year after the event in comparison to the year 
of the event. However, the CWS-score in participants with a recommended shortened 
surveillance interval did differ considerably between that year and the year after the event, 
and so did the CWS-score in the individuals who underwent surgery. This suggests that 
a shortened surveillance interval and pancreatic surgery cause a decrease in CWS-score 
the year after, possibly due to relief at follow-up, however, our sample size for these sub-
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analyses (n = 9 and n = 4) were likely too small to find a statistically significant difference, 
which is also demonstrated by the large 95% confidence interval for the differences in 
CWS-scores. 
This study has several strengths. The prospective design in a large group of individuals at 
high risk of developing pancreatic cancer is unique and of great scientific value. However, 
this study also has some limitations, one of which might be the power for our sub-analyses 
on clinical factors. Therefore, to draw definite conclusions on these factors, a larger study 
sample is needed. Also, because the questionnaire study was added after the first inclusion 
period of the original clinical study protocol, some participants had already had their first 
investigations and therefore started their questionnaires at T2, which resulted in a relatively 
low number of available T0 questionnaires in the analyzed cohort. 
In conclusion, this prospective questionnaire study identified the factor ‘having a family 
member affected by PDAC < 50 years of age’ to be associated with cancer worries in the 
second year of follow-up in individuals at inherited or familial high risk of developing PDAC 
who are participating in annual surveillance. Recognizing this factor can help clinicians 
to timely identify individuals ‘at risk’ of a high level of cancer worries whom would likely 
benefit from psychosocial support to decrease or prevent psychological distress. 
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SUMMARY AND GENERAL DISCUSSION
Pancreatic cancer remains one of the most fatal human malignancies. Despite improve-
ments in surgical techniques and (neo)adjuvant therapies, survival rates have not improved 
during the last decades. Survival rates are strongly dependent on the stage of pancreatic 
cancer. These poor survival rates are at least partly due to the late onset of symptoms, lead-
ing to only 8-27% of all patients to present with localized curable disease. Because of the 
poor prognosis once pancreatic cancer has become symptomatic, there is great interest in 
the prevention of pancreatic cancer. Primary prevention strategies, such as lifestyle changes 
to reduce the number of risk factors (e.g. smoking, excessive alcohol consumption, obesity 
and dietary factors), are difficult for most people to implement and adhere to. Second-
ary prevention strategies (the diagnosis and treatment of advanced precursor lesions or 
early stage of pancreatic cancer before it causes significant morbidity), however, might 
contribute to the prevention of pancreatic cancer and hence improvement of pancreatic 
cancer survival. Currently, several studies are being performed to assess the feasibility of a 
pancreatic cancer surveillance program. Screening of the general population is not feasible 
as we currently lack a simple, reliable and inexpensive screening tool. However, evidence 
is starting to accumulate that screening might be worthwhile when offered to individuals 
at high risk of developing pancreatic cancer. High-risk individuals include mutation carriers 
of pancreatic cancer-prone gene mutations (e.g. CDKN2A, BRCA1, BRCA2, STK11/LKB1) 
and relatives of patients with familial pancreatic cancer. The risk of developing pancreatic 
cancer within these well-defined populations of high-risk individuals is estimated to be 
at least 10-fold increased compared to the general population and exceeds 76-fold in 
selected cases. This thesis reported on different aspects of such pancreatic cancer surveil-
lance programs. 
Part one of this thesis focused on the clinical aspects of surveillance. 
Both endoscopic ultrasonography (EUS) and magnetic resonance imaging (MRI) are fre-
quently used as imaging modality in pancreatic cancer surveillance. However, hardly any 
study compared the diagnostic yields of both modalities in a blinded fashion and thus it is 
unclear whether one of both modalities would suffice or if both tests are complimentary. 
Therefore, in chapter 2, we performed a multicenter comparative blinded analysis on 
the yield of both EUS and MRI. We performed a blinded multicenter study in 139 Dutch 
high-risk individuals undergoing first-time screening of the pancreas. Participating gastro-
enterologists and radiologists were blinded to the baseline results of either EUS or MRI 
imaging. To compare both imaging test results, a percentage agreement was calculated 
for the detection and location of lesions, and a Spearman’s rho correlation coefficient was 
calculated for the size of lesions.
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We revealed that EUS and/or MRI detected clinically relevant pancreatic lesions in 6% of 
participants of surveillance (in 9 out of 139 high-risk individuals). Eleven clinically relevant 
lesions were detected: two solid lesions and 9 cystic lesions ≥10 mm in size. Of all 11 
clinically relevant lesions, six (55%) were detected by both modalities. EUS detected a total 
of 8 (73%) and MRI detected a total of 9 (82%) clinically relevant lesions. Both solid lesions 
were detected by EUS only and proved to be a stage I pancreatic cancer and a multifocal 
PanIN-2. Of the 9 cysts ≥10 mm, six were detected by both imaging techniques and three 
were detected by MRI only. The agreement between EUS and MRI for the detection of 
clinically relevant lesions was only 55%. However, there was a perfect agreement between 
EUS and MRI for location of clinically relevant lesions and a substantial to almost perfect 
agreement between EUS and MRI on the size of clinically relevant lesions (Spearman’s rho 
correlation coefficient of 0.638). This led us to conclude that both imaging modalities 
were complementary rather than interchangeable: contrary to EUS, MRI was found to be 
very sensitive for the detection of cystic lesions of any size, MRI however might have some 
important limitations with regard to the timely detection of solid lesions. Therefore, for 
future screening and surveillance we will continue to use both imaging modalities. 
Frequent high-resolution imaging of the pancreas reveals frequent detection of cystic le-
sions, as also shown in chapter 2. Studies on pancreatic cancer surveillance show cystic 
lesions of the pancreas to be present in up to 42% of high-risk individuals, whereas the 
prevalence of pancreatic cysts in the general population is estimated to be only 0-10% 
depending on age. However, it is still unclear whether the prevalence and growth char-
acteristics of cystic lesions are equal within the two distinct high-risk groups (mutation 
carriers versus individuals with a strong family history of pancreatic cancer (FPC individu-
als)). Therefore, in chapter 3, we evaluated the prevalence and progression of these cystic 
pancreatic lesions in the two distinct high-risk groups for developing pancreatic cancer. 
We extracted data from our ongoing pancreatic cancer surveillance study on the detected 
cystic lesions at diagnosis and follow-up. Cystic lesions were highly prevalent, a total of 
100 (54%) of the 186 individuals included had at least one pancreatic cystic lesion. Cystic 
lesions ≥10 mm in size were more prevalent in FPC individuals (in 14 of 88 FPC individuals, 
16%) than in mutation carriers (5 of 98 mutation carriers, 5%), even after adjusting our 
analysis for the statistically significant older age of the FPC individuals (P=0.045). Only 7 le-
sions showed progression during follow-up; 4 lesions grew ≥4 mm and 3 lesions developed 
worrisome features. Only 1 of these lesions that progressed was in a FPC individual, all 6 
other progressed lesions were detected in mutation carriers. Two of these 7 lesions that 
progressed were found to be pancreatic cancer, both in mutation carriers. 
The higher prevalence of cystic lesions in FPC individuals is unexpected. Because of the 
presumed autosomal dominant inheritance pattern observed in FPC families, half of the 
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FPC individuals probably do not carry a gene mutation and will therefore also not be at 
increased risk of developing pancreatic cancer. This is in contrast to our proven mutation 
carriers in whom an increased risk of pancreatic cancer was confirmed by genetic testing. 
Therefore, the higher prevalence of cystic lesions in FPC individuals might be indicative of 
a difference in pathophysiology or in molecular subtypes of pancreatic cancer between the 
2 high-risk groups. An even more important observation, however, is the fact that almost 
no progression of cystic lesions was seen in FPC individuals (no single pancreatic cancer 
developed within the FPC cohort), whereas lesions in mutation carriers did progress in 
a significant proportion of individuals (pancreatic cancer incidence 2%). This difference 
in progression between the 2 groups eventually might have important implications for 
surveillance strategies, such as applying different strategies with shorter or longer surveil-
lance intervals between groups which would not only tailor the intensity and burden of 
surveillance according to the actual risk, but also facilitates a cost-effective utilization of 
limited and costly health care resources. 
Except from the frequent detection of pancreatic cystic lesions during pancreatic cancer 
surveillance, as shown in chapter 3, features of chronic pancreatitis are also frequently 
detected by EUS. The clinical significance of these features of chronic pancreatitis in 
asymptomatic individuals is still unclear, but research did suggest that these features 
might be related to emerging PanIN and IPMN lesions, both possible precursor lesions to 
pancreatic cancer. Therefore, in chapter 4, we focused our research on these features of 
chronic pancreatitis which we longitudinally assessed. We included all individuals that were 
participating in pancreatic cancer surveillance in the Erasmus University Medical Center 
Rotterdam for whom two EUS videos were available 3 years apart (2012 and 2015). Two 
highly experienced endosonographers reassessed the anonymized videos for features 
of chronic pancreatitis separately, after which a consensus meeting was held to discuss 
individuals in whom there was a difference in scored features. Forty-two videos from 21 
individuals were reviewed. 
Review of the EUS videos showed features of chronic pancreatitis to be highly prevalent: 
86% (in 2012) and 81% (in 2015) of individuals had at least one feature of chronic pan-
creatitis detected by EUS. This prevalence is much higher than described in a non-high-risk 
cohort (17%). This causes the alleged association between (progression) of specific EUS 
features and presence of PanIN or IPMN lesions to bear particular interest. We performed 
interobserver agreement analyses, which showed an almost perfect agreement at 83%. 
We also performed univariate and multivariate analyses regarding possible risk factors 
associated with the detection of a mean of ≥4 features of chronic pancreatitis. Univariate 
analysis identified ‘age of the youngest relative affected by pancreatic cancer’ as the only 
risk factor (P=0.002), but it was not sustained after multivariate analysis. We also assessed 
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intra-individual change in the detected features of chronic pancreatitis over time. Except for 
hyperechoic foci without shadowing, which decreased intra-individually (β=-1.6, P=0.006), 
the features did not change in the 3 years of follow-up. To our knowledge, this is the first 
study to assess intra-individual change over time in detected features of chronic pancre-
atitis. Although the features did not change in the 3 years of follow-up, we must keep in 
mind that the development and progression of precursor lesions into pancreatic cancer 
may take multiple years. Longer follow-up and, if available, pathological examination of 
pancreatic resection specimens will be essential to understanding the relationship between 
these features of chronic pancreatitis and development of malignancy, and whether detec-
tion of these features bears clinical relevance, for example, in setting the indication for 
resection or serving as a criterion of influence in determining the screening interval.  
Pancreatic cancer surveillance will yield highly suspicious lesions for which surgery is per-
formed, even in the absence of confirmatory cytology or histology. Since little is known 
about the surgical pathology findings of high-risk individuals who have undergone surgery, 
in chapter 5, we focused our research on the diagnostic yield and outcomes of high-risk 
individuals who underwent surgical resection or progressed to invasive cancer while par-
ticipating in pancreatic cancer surveillance. We used data from 11 prospective surveillance 
programs across the world (United States of America, The Netherlands, Italy and Israel), 
using the CAncer of the Pancreas Screening (CAPS) collaboration which was formed in 
2010 to help organize global research on pancreatic cancer surveillance. We gathered 
data of a total of 76 high-risk individuals of whom 71 underwent surgery and of whom 5 
were diagnosed with advanced irresectable disease. High-risk neoplastic lesions (defined 
as PanIN-3 lesions, branch-duct IPMNs with high-grade dysplasia, main-duct IPMNs and 
pancreatic cancers) were present in 32 (45%) of the 71 resection specimens. We found 
four pre-operative factors to be associated with high-risk neoplastic lesions or pancreatic 
cancer: age ≥ 65 at the time of surgery, female gender, carriage of a mutation in a known 
pancreatic cancer susceptibility gene, and location of a lesion in the head/uncinate region 
of the pancreas. Survival between individuals with no or low-risk neoplastic lesions versus 
individuals with high-risk neoplastic lesions did not differ significantly. Survival worsened 
with advancing stage of pancreatic cancer. This result support the intent and pursuit of 
pancreatic cancer surveillance programs to detect and resect advanced neoplastic lesions 
before they have developed into pancreatic cancer. While all screening programs carry 
the risk of overtreatment, our results suggest that surveillance of high-risk individuals 
leads to the treatment of an acceptable mix of lesions. More research is needed to better 
understand the risk factors for individuals at high risk of developing pancreatic cancer, and 
importantly to improve selection of individuals for surgery. Collaborating internationally 
in large worldwide prospective studies is of high importance due to the small number of 
interventions at any individual center. 
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Part two of this thesis focused on the psychosocial aspects of surveillance. 
When assessing the successfulness of a surveillance program, importantly, we should not 
only focus on clinical results, but also on the psychological aspects of repeated participa-
tion in such a program because it will have an important effect on the participation rate 
and adherence to surveillance. As surveillance entails long-term participation and repeated 
exposure to investigations, longer follow-up studies are required. There were no prospec-
tive studies with more than 12 months of follow-up assessing the feasibility of pancreatic 
cancer surveillance from a psychological point of view. Therefore, in chapter 6, we ana-
lyzed data from our ongoing prospective multicenter psychological questionnaire study in 
which participants were, at that date, followed with questionnaires for at least 3 years. 
Participants received a first questionnaire on background data after having undergone 
counseling by the clinical geneticist, a second questionnaire after having received the 
explanation of study procedures by the gastroenterologist, and thereafter annually after 
having received their surveillance results. Of the 152 individuals who have been participat-
ing in pancreatic cancer surveillance in the our study since its start in 2008, 140 individuals 
(92%) returned one or multiple completed questionnaires. In total, 477 questionnaires 
were received and analyzed. The most frequently reported motivation for participating 
in pancreatic cancer surveillance was that cancer might be detected early (checked in an 
average of 98% of all instances). For as much as 87% of respondents, the advantages 
of surveillance outweigh the disadvantages, and the majority of respondents (79%) feel 
reassured after their follow-up visit. Only a minority of respondents are nervous before 
their follow-up visit or dread the visit (14% and 13%, respectively). Both MRI and EUS are 
experienced as uncomfortable by only the minority of respondents (10% and 11%, respec-
tively). Only 3% of respondents dread their first MRI versus 34% of respondents dreading 
their first EUS. However, once experienced, the percentage of respondents dreading their 
next EUS dropped significantly (p <0.001) to the same level as that of the MRI (6–9% and 
0–8%, respectively). Few respondents experience worries about cancer, and the mean level 
of worries decreases even further
each year of participation. The percentage of individuals with clinical relevant levels of 
anxiety and depression is low and stable over a 3-year period. Thus, this study shows that 
pancreatic cancer surveillance is well feasible from a psychological point of view, as the 
psychological burden of participation in a pancreatic cancer surveillance program is low. 
Although we reported in chapter 6 that repeated participation in annual surveillance im-
posed low psychological burden, we did find that a third of the participants had moderate 
to high cancer worries. As individuals with high levels of cancer worries might benefit 
from psychosocial support, it could be essential to adequately and timely identify the 
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individuals with high cancer worries. Therefore, in chapter 7, we further investigated 
cancer worries using the cancer-worry-scale questionnaire. More specifically, we focused 
on the course of cancer worries over time, on predictors of cancers worries, and on cancer 
worries during certain events. We analyzed questionnaires of 166 participants. The mean 
cancer-worry-scale score was quite low at 14, which decreased intra-individually over the 
two year course of time. The detection of a pancreatic cystic lesion during surveillance did 
not impact on cancer worries significantly. There was a trend towards more cancer worries 
when a shortened surveillance interval was recommended and when surgery was recom-
mended, however, the difference was not statistically significant which is probably due to 
small sample sizes. Multivariate analysis showed that having a family member affected by 
pancreatic cancer below the age of 50 was associated with cancer worries in the second 
year of follow-up. Recognizing this factor can help clinicians to timely identify individuals 
´at risk´ of a high level of cancer worries whom would likely benefit from psychosocial 
support to decrease or prevent psychological distress. 
Future perspectives
The decisive question is whether screening and surveillance programmes ultimately improve 
the overall survival rate of individuals at high risk for the development of pancreatic cancer. 
Based on present studies, it is not possible to draw a definite conclusion about the (po-
tential) merits of surveillance to prevent pancreatic cancer death. To definitely answer this 
question more research is required with careful long-term follow-up of affected individuals 
within well-defined research programmes. Pooling of data from various (international) 
cohorts will be needed to acquire sufficient numbers for meaningful statistical analysis and 
accurate estimates of risk reduction and survival benefit. 
Future research should not only focus on the use of imaging modalities, but also on the 
application of biomarkers. Numerous efforts have been undertaken in the last years to 
identify biomarkers that are reliable in diagnosing pancreatic cancer. At present, biomark-
ers have a limited role in diagnosing early stage pancreatic cancer, partly due to the low 
specificity and sensitivity of the currently available markers. Combining markers, or iden-
tifying (new) specific biomarkers from bodily secretions such as pancreatic juice obtained 
during endoscopic ultrasonography should be further researched. Such quest should not 
only focus on identifying (early) pancreatic cancer, but also on the detection of precursor 
lesion such as high-grade dysplastic PanIN or high-grade dysplastic IPMN as these lesions 
represent the ideal target for surgical resection. Sequential collection of pancreatic juice 
during the annual EUS investigations and following biomarker expression over time seems 
promising. 
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Future research should also be directed towards a better understanding of the risk of 
individuals on developing pancreatic cancer, especially in the individuals in which there 
is a strong family history of pancreatic cancer but no gene mutation was found. Whole 
genome sequencing might be able to detect additional pancreatic cancer-prone gene 
mutations in these individuals which could lead to a better surveillance strategy according 
to the actual risk, and thus could facilitate a better and more cost-effective utilization of 
limited health care resources. 

Chapter 9
Samenvatting en discussie
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SAMENVATTING EN DISCUSSIE
Pancreascarcinoom blijft één van de dodelijkste vormen van kanker. Ondanks verbeteringen 
in chirurgische technieken en (neo)adjuvante behandelingen is de overleving van pancreas-
carcinoom de laatste decennia nauwelijks verbeterd. De overleving is sterk afhankelijk van 
het stadium van pancreascarcinoom ten tijde van diagnose. De slechte overleving wordt 
dan ook deels verklaard door het laat ontstaan van symptomen waardoor slechts 8-27% 
van de patiënten gediagnosticeerd wordt in een stadium met beperkte lokale ziekte waar-
bij er nog curatieve opties bestaan. Door de slechte prognose zodra pancreascarcinoom 
eenmaal symptomatisch is, is er veel interesse in de preventie van pancreascarcinoom. Pri-
maire preventie strategieën, zoals verandering van leefstijl om het aantal risicofactoren te 
verminderen (bv roken, excessief alcoholgebruik, obesitas en dieetfactoren), blijkt voor veel 
mensen lastig te implementeren en ook vol te houden. Secundaire preventie strategieën 
(de diagnose en behandeling van gevorderde voorloperstadia of een vroeg stadium van 
pancreascarcinoom voordat het significante morbiditeit geeft) kunnen wel bijdragen aan 
de preventie van pancreascarcinoom en daarmee de overleving van pancreascarcinoom. 
Onderzoek van de gehele populatie zal echter niet haalbaar zijn gezien het gebrek aan een 
gemakkelijke, betrouwbare en betaalbare diagnostische test. Echter, er begint zich steeds 
meer bewijs op te bouwen dat surveillance wel zinvol kan zijn wanneer het aangeboden 
wordt aan individuen met een hoog risico op het ontwikkelen van pancreascarcinoom, 
zoals dragers van een mutatie in een gen dat het risico op pancreascarcinoom verhoogd en 
verwanten van patiënten met een familiair pancreascarcinoom. Hoofdstuk 1 gaat dieper 
in op de verschillende risicogroepen, op de mogelijke testen die te gebruiken zijn voor 
surveillance en de doelen van surveillance. Daarna is dit proefschrift opgedeeld in twee 
delen. 
Deel één van dit proefschrift richt zich op verschillende klinische aspecten van surveillance. 
Momenteel worden endo-echografie (EUS) en MRI frequent gebruikt als beeldvormende 
technieken voor surveillance op pancreascarcinoom. Echter, er zijn nauwelijks geblindeerde 
vergelijkende studies beschikbaar welke de twee technieken met elkaar vergelijken ten 
aanzien van hun geschiktheid om te gebruiken in surveillance. In hoofdstuk 2 worden de 
resultaten beschreven van het geblindeerd en vergelijkend onderzoek tussen EUS en MRI 
in 139 individuen met een verhoogd risico op het ontwikkelen van pancreascarcinoom. De 
deelnemers ondergingen zowel een EUS als een MRI waarbij zowel de endo-echografist als 
de radioloog werden geblindeerd voor de uitslag van de andere beeldvormende techniek, 
waarna de uitslag met elkaar werd vergeleken. De overeenkomst in de detectie van klinisch 
relevante laesies was slechts 55%. Daarbij bleek de MRI erg gevoelig voor het aantonen van 
pancreascystes, echter, werden twee solide laesies, waarvan één een pancreascarcinoom 
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en de ander een PanIN-2 laesie, enkel door de EUS gedetecteerd. Hieruit is te concluderen 
dat beide technieken elkaar aanvullen, vandaar dat ook voor toekomstige surveillance 
beide beeldvormende technieken gebruikt zullen blijven worden. 
Frequente hoog-resolutie beeldvorming van het pancreas laat frequente detectie van cys-
teuze laesies zien, zoals ook in hoofdstuk 2 beschreven werd, met een veel hogere inciden-
tie in hoog-risico individuen dan in de algemene bevolking. Echter, het is nog onduidelijk 
of de prevalentie en de groeikarakteristieken van deze cysteuze laesies vergelijkbaar zijn 
in de twee risicogroepen (mutatiedragers versus individuen met een familiaire belasting 
(FPC individuen)). Daarom hebben we dit in hoofdstuk 3 verder onderzocht. Er bleek een 
hoge prevalentie van cysteuze laesies: 54% van de 186 deelnemers had een pancreascyste. 
Cystes ≥10 mm waren statistisch significant prevalenter in FPC individuen dan in mutatie-
dragers (16 versus 5%). Slechts 7 laesies toonden progressie: 4 laesies groeiden ≥4mm en 
3 laesies ontwikkelden ‘worrisome features’. Slechts 1 van deze 7 laesies werd gevonden 
in een FPC individu, alle andere 6 laesies die progressie vertoonden werden gevonden 
in mutatiedragers, waarvan 2 laesies pancreascarcinoom bleken te betreffen. Er zijn dus 
meer cystes in de FPC individuen echter met nauwelijks progressie, terwijl de cystes in 
mutatiedragers frequenter progressie vertoonden. Dit verschil tussen de beide risicogro-
epen kan belangrijke implicaties hebben voor de surveillance strategie, zoals bijvoorbeeld 
het toepassen van verschillende strategieën met kortere of langere surveillance intervallen 
afhankelijk van het daadwerkelijke risico op ontaarding in maligniteit. 
Naast de frequente detectie van pancreascysten worden tevens frequent tekenen van 
chronische pancreatitis beschreven tijdens de EUS. Ook hiervan is nog onduidelijk wat de 
betekenis is in deze asymptomatische individuen, echter in de literatuur is eerder gesugger-
eerd dat deze tekenen gerelateerd kunnen zijn aan ontwikkelende PanIN en IPMN laesies, 
beiden mogelijke voorlopers van pancreascarcinoom. Daarom hebben we in hoofdstuk 
4 deze kenmerken van chronische pancreatitis verder onderzocht. Twee ervaren endo-
echografisten hebben de 42 opgenomen video’s van de EUS-onderzoeken in het Erasmus 
MC van 2012 en 2015 beoordeeld op kenmerken van chronische pancreatitis. Kenmerken 
van chronische pancreatitis bleken zeer frequent aanwezig (in 81-86% van de individuen) 
waarbij de interobserver agreement goed was (83%). Er was geen progressie van tekenen 
van chronische pancreatitis over de 3 jaar aan follow-up. Langere follow-up en, indien 
beschikbaar, resectiepreparaten van het pancreas zijn essentieel om verdere duidelijkheid 
te verkrijgen over de klinische relevantie van de bevinding van tekenen van chronische 
pancreatitis. 
Surveillance van het pancreas brengt ook voor maligniteit verdachte laesies aan het licht 
waarvoor resectie wordt verricht. Er is echter nog weinig bekend over de uitkomsten na 
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chirurgie en de pathologische bevindingen in het resectiepreparaat in deze groep indi-
viduen. In hoofdstuk 5 wordt er verder ingegaan op de resultaten van 76 hoog-risico 
individuen die werden geopereerd vanwege een voor maligniteit verdachte afwijking 
(n=71) of werden gediagnosticeerd met gemetastaseerd pancreascarcinoom (n=5) tijdens 
deelname aan surveillance. De resultaten van deze individuen werden verzameld via het 
CAncer of the Pancreas Screening (CAPS) samenwerkingsverband welke in 2010 werd 
opgericht om pancreassurveillance wereldwijd te coördineren. Hoog-risico neoplastische 
laesies (gedefinieerd als PanIN-3 laesies, branch-duct IPMNs met hooggradige dysplasie, 
main-duct IPMNs en pancreascarcinoom) bleken aanwezig in 32 (45%) van de 71 
resectiepreparaten. Vier preoperatieve factoren waren gerelateerd aan deze hoog-risico 
neoplastische laesies, namelijk leeftijd ≥65 jaar ten tijde van chirurgie, vrouwelijk geslacht, 
mutatiedragerschap en locatie van de laesie in de kop/uncinatus van het pancreas. De 
overleving van individuen met hoog-risico neoplastische laesies verschilde niet van degenen 
zonder laesies of met laag-risico neoplastische laesies. De overleving verslechterde wel met 
vorderend stadium van pancreascarcinoom. Deze resultaten ondersteunen het streven naar 
detectie van voorlopers van pancreascarcinoom middels surveillance. 
Deel twee van dit proefschrift richt zich op de psychosociale aspecten van surveillance. 
Wanneer de haalbaarheid van een surveillance programma wordt beoordeeld, moet er niet 
alleen op de klinische aspecten en resultaten gelet worden, maar is ook de psychologische 
belasting van deelname aan surveillance erg belangrijk aangezien dit de deelname en 
trouw aan surveillance zal beïnvloeden. In hoofdstuk 6 worden de resultaten van de 
psychosociale vragenlijststudie beschreven waarin op dat moment 3 jaar aan follow-up 
vragenlijsten beschikbaar was. Deelnemers kregen een vragenlijst na hun bezoek aan de 
klinisch geneticus, na hun bezoek aan de MDL-arts met uitleg over deelname aan pancre-
assurveillance in studieverband en daarna elk jaar na de jaarlijkse onderzoeken met EUS 
en MRI. De deelname aan de vragenlijststudie was erg hoog (92%). Voor maar liefst 87% 
van de participanten wogen de voordelen van surveillance op tegen de nadelen en de 
meerderheid (79%) van de deelnemers voelde zich elk jaar gerustgesteld na het follow-up 
bezoek. Een klein deel van de respondenten (13%) zag op tegen de jaarlijkse onderzoeken 
en slechts een klein deel ervoer de MRI en EUS als oncomfortabel (respectievelijk 10 en 
11% van de deelnemers). Er waren lage scores met betrekking tot zorgen omtrent kanker 
en met betrekking tot depressiviteit en angst. Deze resultaten tonen dat surveillance van 
het pancreas vanuit psychosociaal oogpunt haalbaar lijkt. 
Toch viel op dat enkele individuen vrij veel zorgen omtrent kanker hadden. Dit wordt in 
hoofdstuk 7 verder onderzocht aangezien deze individuen baat zouden kunnen hebben 
bij psychosociale begeleiding. De cancer-worry scale vragenlijst werd geanalyseerd, waarbij 
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de gemiddelde score laag was en er sprake was van een intra-individuele daling over een 
tijd van 2 jaar aan follow-up. Daarbij leek er sprake te zijn van meer zorgen wanneer er 
een verkort surveillance interval werd geadviseerd en ook wanneer er een operatie werd 
geadviseerd, echter, de aantallen waren te klein om hier een statistisch significant verschil 
in aan te tonen. Multivariate analyse toonde wel dat de respondenten met een familielid bij 
wie op een leeftijd jonger dan 50 jaar pancreascarcinoom was vastgesteld hogere zorgen 
omtrent kanker hadden. Met name deze deelnemers zouden baat kunnen hebben bij 
psychosociale begeleiding. 
In hoofdstuk 8 worden de belangrijkste bevindingen uit dit proefschrift samengevat en 
aanbevelingen voor toekomstig onderzoek beschreven. 
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ABBREVIATIONS
5-FU 5-fluorouracil 
APC Adenomatous polyposis coli
ATM Ataxia telangiectasia mutated
BD-IPMN Branch-duct intraductal papillary mucinous neoplasm
BMI Body mass index
CA 19-9 Cancer antigen 19-9
CAPS Cancer of the pancreas screening
CEA Carcino-embryonal antigen
CI Confidence interval
CMM Cutaneous malignant melanoma 
CP Chronic pancreatitis
CT Computed tomography
CWS Cancer worry scale
ERCP Endoscopic retrograde cholangiopancreaticography
EUS Endoscopic ultrasonography
EUS-FNA Endoscopic ultrasonography-guided fine needle aspiration
F Female
FAMMM Familial atypical multiple mole melanoma 
FAP Familial adenomatous polyposis
FDG-PET 18F-fluorodeoxyglucose positron emission tomography
FDR First-degree relative
FPC Familial pancreatic cancer
FU Follow-up
GI Gastrointestinal
HADS Hospital anxiety and depression scale
HBOC Hereditary breast and ovarian cancer 
HP Hereditary pancreatitis
HRI High-risk individual
HRN High-risk neoplastic precursor lesion
IPMN Intraductal papillary mucinous neoplasm
LAT Living apart together
M Male
MB-IPMN Main-branch intraducatl papillary mucinous neoplasm
MCN Mucinous cystic neoplasm
MDCT Multi detector computed tomography
MD-IPMN Main-duct intraductal papillary mucinous neoplasm
MMR Mismatch repair genes
Mo Month
MPD Main pancreatic duct
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MRCP Magnetic resonance cholangiopancreatography
MRI Magnetic resonance imaging
N/A Not applicable
No Number
OR Odds ratio
PanIN Pancreatic intraepithelial neoplasia
PanNET Pancreatic neuroendocrine tumor
PC Pancreatic cancer
PDAC Pancreatic ductal adenocarcinoma
PET Positron emission tomography
PJS Peutz-Jeghers syndrome
RR Relative risk
SB-IPMN Side-branch intraductal papillary mucinous neoplasm
SDR Second-degree relative
SE Standard error
SIR Standardized incidence ratio
SPSS Statistical package for the social sciences
VHL Von Hippel-Lindau
y Year
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